# PeptideScanner evidence objects: Octreotide

Every published version of the records placed with Octreotide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/octreotide.json. Selected public evidence only; not medical advice.

- Objects: 163
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00002779-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00002779

> PeptideScanner retained ClinicalTrials.gov record NCT00002779 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-15, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00002779-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-12-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00002779-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00002779-octreotide-v1
- Content SHA-256: `494a4a6cf20588f11399a74d5f6126a3c74b9149e4883f699d606a28c452b3a6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00002779 ([`ctg-observation-nct00002779-2016-12-15-ddf6fc5b7b99`](#source-ctg-observation-nct00002779-2016-12-15-ddf6fc5b7b99))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00002779 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-15, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00002779-2016-12-15-ddf6fc5b7b99`](#source-ctg-observation-nct00002779-2016-12-15-ddf6fc5b7b99))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00002779 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-15, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00002779-2016-12-15-ddf6fc5b7b99`](#source-ctg-observation-nct00002779-2016-12-15-ddf6fc5b7b99))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00002779-2016-12-15-ddf6fc5b7b99`](#source-ctg-observation-nct00002779-2016-12-15-ddf6fc5b7b99))

### Sources

<a id="source-ctg-observation-nct00002779-2016-12-15-ddf6fc5b7b99"></a>
- **ClinicalTrials.gov record NCT00002779 · retained source version 2016-12-15:ddf6fc5b7b99e2264de139646f8cadd166ef434779297b834466287293b46acc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00002779) (`ctg-observation-nct00002779-2016-12-15-ddf6fc5b7b99`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00002779." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00002779-octreotide-v1 SHA-256: 494a4a6cf20588f11399a74d5f6126a3c74b9149e4883f699d606a28c452b3a6.

---

<a id="clinicaltrials-gov-nct00002864-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00002864

> PeptideScanner retained ClinicalTrials.gov record NCT00002864 at 2026-07-30T20:29:13.581Z. Its registry update date was 2020-04-01, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00002864-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-04-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00002864-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00002864-octreotide-v1
- Content SHA-256: `c3f1917152222d685a926af0b0ebfa5fb94f141e439d8b9b48602766a84d5081`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00002864 ([`ctg-observation-nct00002864-2020-04-01-8c17ee9695be`](#source-ctg-observation-nct00002864-2020-04-01-8c17ee9695be))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00002864 at 2026-07-30T20:29:13.581Z. Its registry update date was 2020-04-01, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00002864-2020-04-01-8c17ee9695be`](#source-ctg-observation-nct00002864-2020-04-01-8c17ee9695be))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00002864 at 2026-07-30T20:29:13.581Z. Its registry update date was 2020-04-01, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00002864-2020-04-01-8c17ee9695be`](#source-ctg-observation-nct00002864-2020-04-01-8c17ee9695be))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00002864-2020-04-01-8c17ee9695be`](#source-ctg-observation-nct00002864-2020-04-01-8c17ee9695be))

### Sources

<a id="source-ctg-observation-nct00002864-2020-04-01-8c17ee9695be"></a>
- **ClinicalTrials.gov record NCT00002864 · retained source version 2020-04-01:8c17ee9695be9abed88361f6a5a757c76d9806e0e97f59949158e1b9093308b0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00002864) (`ctg-observation-nct00002864-2020-04-01-8c17ee9695be`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00002864." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00002864-octreotide-v1 SHA-256: c3f1917152222d685a926af0b0ebfa5fb94f141e439d8b9b48602766a84d5081.

---

<a id="clinicaltrials-gov-nct00003057-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00003057

> PeptideScanner retained ClinicalTrials.gov record NCT00003057 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-18, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00003057-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-06-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00003057-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00003057-octreotide-v1
- Content SHA-256: `e2a65a3db8889af186b19b06caefe05f9d3836b4e73b001b243a0114c9be17ee`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00003057 ([`ctg-observation-nct00003057-2023-06-18-ea33f85274d7`](#source-ctg-observation-nct00003057-2023-06-18-ea33f85274d7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00003057 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-18, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00003057-2023-06-18-ea33f85274d7`](#source-ctg-observation-nct00003057-2023-06-18-ea33f85274d7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00003057 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-18, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00003057-2023-06-18-ea33f85274d7`](#source-ctg-observation-nct00003057-2023-06-18-ea33f85274d7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00003057-2023-06-18-ea33f85274d7`](#source-ctg-observation-nct00003057-2023-06-18-ea33f85274d7))

### Sources

<a id="source-ctg-observation-nct00003057-2023-06-18-ea33f85274d7"></a>
- **ClinicalTrials.gov record NCT00003057 · retained source version 2023-06-18:ea33f85274d7ba412a99711651a58ffa6fcb2e8c4dffa508a5453a0e993caeba** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00003057) (`ctg-observation-nct00003057-2023-06-18-ea33f85274d7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00003057." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00003057-octreotide-v1 SHA-256: e2a65a3db8889af186b19b06caefe05f9d3836b4e73b001b243a0114c9be17ee.

---

<a id="clinicaltrials-gov-nct00003283-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00003283

> PeptideScanner retained ClinicalTrials.gov record NCT00003283 at 2026-07-30T19:11:49.727Z. Its registry update date was 2023-06-15, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00003283-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-06-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00003283-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00003283-octreotide-v1
- Content SHA-256: `71d4e4efd2842f83c54d3dd1736a6b94f94bfb363a664f15620bf12ec94f37e4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00003283 ([`ctg-observation-nct00003283-2023-06-15-4f886c37d8a4`](#source-ctg-observation-nct00003283-2023-06-15-4f886c37d8a4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00003283 at 2026-07-30T19:11:49.727Z. Its registry update date was 2023-06-15, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00003283-2023-06-15-4f886c37d8a4`](#source-ctg-observation-nct00003283-2023-06-15-4f886c37d8a4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00003283 at 2026-07-30T19:11:49.727Z. Its registry update date was 2023-06-15, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00003283-2023-06-15-4f886c37d8a4`](#source-ctg-observation-nct00003283-2023-06-15-4f886c37d8a4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00003283-2023-06-15-4f886c37d8a4`](#source-ctg-observation-nct00003283-2023-06-15-4f886c37d8a4))

### Sources

<a id="source-ctg-observation-nct00003283-2023-06-15-4f886c37d8a4"></a>
- **ClinicalTrials.gov record NCT00003283 · retained source version 2023-06-15:4f886c37d8a4659631070475e1c154ed22d9a30611f571d585c87e710ae16079** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00003283) (`ctg-observation-nct00003283-2023-06-15-4f886c37d8a4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00003283." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00003283-octreotide-v1 SHA-256: 71d4e4efd2842f83c54d3dd1736a6b94f94bfb363a664f15620bf12ec94f37e4.

---

<a id="clinicaltrials-gov-nct00004327-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00004327

> PeptideScanner retained ClinicalTrials.gov record NCT00004327 at 2026-07-30T22:50:58.187Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00004327-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2005-06-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00004327-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00004327-octreotide-v1
- Content SHA-256: `4697b862575071374188ef876c519c6cc05911e8b10ab289de8bc736d208c3ce`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00004327 ([`ctg-observation-nct00004327-2005-06-24-49110561697a`](#source-ctg-observation-nct00004327-2005-06-24-49110561697a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00004327 at 2026-07-30T22:50:58.187Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00004327-2005-06-24-49110561697a`](#source-ctg-observation-nct00004327-2005-06-24-49110561697a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00004327 at 2026-07-30T22:50:58.187Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00004327-2005-06-24-49110561697a`](#source-ctg-observation-nct00004327-2005-06-24-49110561697a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00004327-2005-06-24-49110561697a`](#source-ctg-observation-nct00004327-2005-06-24-49110561697a))

### Sources

<a id="source-ctg-observation-nct00004327-2005-06-24-49110561697a"></a>
- **ClinicalTrials.gov record NCT00004327 · retained source version 2005-06-24:49110561697acd553d8a40e0dda258217c8906dd8e2de6795616a4de46023065** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00004327) (`ctg-observation-nct00004327-2005-06-24-49110561697a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00004327." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00004327-octreotide-v1 SHA-256: 4697b862575071374188ef876c519c6cc05911e8b10ab289de8bc736d208c3ce.

---

<a id="clinicaltrials-gov-nct00004895-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00004895

> PeptideScanner retained ClinicalTrials.gov record NCT00004895 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-06, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00004895-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-06-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00004895-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00004895-octreotide-v1
- Content SHA-256: `0847b93fdfab07824d9b6d793eb1c9bbab6f88f2cdc6ac24c3923f0e8122be4a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00004895 ([`ctg-observation-nct00004895-2012-06-06-bbca90eba762`](#source-ctg-observation-nct00004895-2012-06-06-bbca90eba762))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00004895 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-06, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00004895-2012-06-06-bbca90eba762`](#source-ctg-observation-nct00004895-2012-06-06-bbca90eba762))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00004895 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-06, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00004895-2012-06-06-bbca90eba762`](#source-ctg-observation-nct00004895-2012-06-06-bbca90eba762))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00004895-2012-06-06-bbca90eba762`](#source-ctg-observation-nct00004895-2012-06-06-bbca90eba762))

### Sources

<a id="source-ctg-observation-nct00004895-2012-06-06-bbca90eba762"></a>
- **ClinicalTrials.gov record NCT00004895 · retained source version 2012-06-06:bbca90eba762dd8837da3b4c03a317191b70bba682e68ed3408e26000e9257ee** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00004895) (`ctg-observation-nct00004895-2012-06-06-bbca90eba762`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00004895." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00004895-octreotide-v1 SHA-256: 0847b93fdfab07824d9b6d793eb1c9bbab6f88f2cdc6ac24c3923f0e8122be4a.

---

<a id="clinicaltrials-gov-nct00005906-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00005906

> PeptideScanner retained ClinicalTrials.gov record NCT00005906 at 2026-07-30T22:25:23.111Z. Its registry update date was 2010-04-30, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00005906-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2010-04-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00005906-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00005906-octreotide-v1
- Content SHA-256: `d522b6e2d8d9772ac0ca4cac815ba744b9a0ebc1ff46c2a6de2a902fc48dbf84`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00005906 ([`ctg-observation-nct00005906-2010-04-30-3acd36014f9b`](#source-ctg-observation-nct00005906-2010-04-30-3acd36014f9b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00005906 at 2026-07-30T22:25:23.111Z. Its registry update date was 2010-04-30, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00005906-2010-04-30-3acd36014f9b`](#source-ctg-observation-nct00005906-2010-04-30-3acd36014f9b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00005906 at 2026-07-30T22:25:23.111Z. Its registry update date was 2010-04-30, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00005906-2010-04-30-3acd36014f9b`](#source-ctg-observation-nct00005906-2010-04-30-3acd36014f9b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00005906-2010-04-30-3acd36014f9b`](#source-ctg-observation-nct00005906-2010-04-30-3acd36014f9b))

### Sources

<a id="source-ctg-observation-nct00005906-2010-04-30-3acd36014f9b"></a>
- **ClinicalTrials.gov record NCT00005906 · retained source version 2010-04-30:3acd36014f9b02c60148ffb4a9014d6334bc991be097e6fce5d42148d8a6e802** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00005906) (`ctg-observation-nct00005906-2010-04-30-3acd36014f9b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00005906." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00005906-octreotide-v1 SHA-256: d522b6e2d8d9772ac0ca4cac815ba744b9a0ebc1ff46c2a6de2a902fc48dbf84.

---

<a id="clinicaltrials-gov-nct00008073-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00008073

> PeptideScanner retained ClinicalTrials.gov record NCT00008073 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-12-19, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00008073-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-12-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00008073-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00008073-octreotide-v1
- Content SHA-256: `6201d2ed9dd24e65467fdb95e8a44f5849b8e056297c8b7bc8a5e7b41749a31e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00008073 ([`ctg-observation-nct00008073-2013-12-19-e6df5acfa3d1`](#source-ctg-observation-nct00008073-2013-12-19-e6df5acfa3d1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00008073 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-12-19, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00008073-2013-12-19-e6df5acfa3d1`](#source-ctg-observation-nct00008073-2013-12-19-e6df5acfa3d1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00008073 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-12-19, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00008073-2013-12-19-e6df5acfa3d1`](#source-ctg-observation-nct00008073-2013-12-19-e6df5acfa3d1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00008073-2013-12-19-e6df5acfa3d1`](#source-ctg-observation-nct00008073-2013-12-19-e6df5acfa3d1))

### Sources

<a id="source-ctg-observation-nct00008073-2013-12-19-e6df5acfa3d1"></a>
- **ClinicalTrials.gov record NCT00008073 · retained source version 2013-12-19:e6df5acfa3d1444956869d3d4636cafc9d1549d2555ab2745a2990100e34e5f2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00008073) (`ctg-observation-nct00008073-2013-12-19-e6df5acfa3d1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00008073." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00008073-octreotide-v1 SHA-256: 6201d2ed9dd24e65467fdb95e8a44f5849b8e056297c8b7bc8a5e7b41749a31e.

---

<a id="clinicaltrials-gov-nct00033605-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00033605

> PeptideScanner retained ClinicalTrials.gov record NCT00033605 at 2026-07-30T21:36:16.907Z. Its registry update date was 2016-07-13, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00033605-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-07-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00033605-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00033605-octreotide-v1
- Content SHA-256: `4f8a8236aff58bac2d11903735dae5eac4301c450ae87cd25d0b08c4b4d556c4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00033605 ([`ctg-observation-nct00033605-2016-07-13-157e73ea5736`](#source-ctg-observation-nct00033605-2016-07-13-157e73ea5736))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00033605 at 2026-07-30T21:36:16.907Z. Its registry update date was 2016-07-13, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00033605-2016-07-13-157e73ea5736`](#source-ctg-observation-nct00033605-2016-07-13-157e73ea5736))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00033605 at 2026-07-30T21:36:16.907Z. Its registry update date was 2016-07-13, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00033605-2016-07-13-157e73ea5736`](#source-ctg-observation-nct00033605-2016-07-13-157e73ea5736))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00033605-2016-07-13-157e73ea5736`](#source-ctg-observation-nct00033605-2016-07-13-157e73ea5736))

### Sources

<a id="source-ctg-observation-nct00033605-2016-07-13-157e73ea5736"></a>
- **ClinicalTrials.gov record NCT00033605 · retained source version 2016-07-13:157e73ea57367db0fb097171d0cb0a2cb16ce6bde79d3a444aa79129db2d4559** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00033605) (`ctg-observation-nct00033605-2016-07-13-157e73ea5736`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00033605." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00033605-octreotide-v1 SHA-256: 4f8a8236aff58bac2d11903735dae5eac4301c450ae87cd25d0b08c4b4d556c4.

---

<a id="clinicaltrials-gov-nct00171613-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00171613

> PeptideScanner retained ClinicalTrials.gov record NCT00171613 at 2026-07-30T22:14:20.909Z. Its registry update date was 2012-04-30, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00171613-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-04-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00171613-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00171613-octreotide-v1
- Content SHA-256: `4f72f6ca063618870dff3b29a45a7a3803a1f7e4bb3fa78ec14c80f7fe23703a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00171613 ([`ctg-observation-nct00171613-2012-04-30-55b775ca5b74`](#source-ctg-observation-nct00171613-2012-04-30-55b775ca5b74))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00171613 at 2026-07-30T22:14:20.909Z. Its registry update date was 2012-04-30, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00171613-2012-04-30-55b775ca5b74`](#source-ctg-observation-nct00171613-2012-04-30-55b775ca5b74))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00171613 at 2026-07-30T22:14:20.909Z. Its registry update date was 2012-04-30, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00171613-2012-04-30-55b775ca5b74`](#source-ctg-observation-nct00171613-2012-04-30-55b775ca5b74))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00171613-2012-04-30-55b775ca5b74`](#source-ctg-observation-nct00171613-2012-04-30-55b775ca5b74))

### Sources

<a id="source-ctg-observation-nct00171613-2012-04-30-55b775ca5b74"></a>
- **ClinicalTrials.gov record NCT00171613 · retained source version 2012-04-30:55b775ca5b74ec7dbd2dd92543ec65d11d3cda85728dff7cff49c985dedffa08** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00171613) (`ctg-observation-nct00171613-2012-04-30-55b775ca5b74`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00171613." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00171613-octreotide-v1 SHA-256: 4f72f6ca063618870dff3b29a45a7a3803a1f7e4bb3fa78ec14c80f7fe23703a.

---

<a id="clinicaltrials-gov-nct00171886-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00171886

> PeptideScanner retained ClinicalTrials.gov record NCT00171886 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-02-24, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00171886-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-02-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00171886-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00171886-octreotide-v1
- Content SHA-256: `1faed06a8dffb0d16b8b81bd6d9f820b13bfd253051e831b778824fbb0003cc9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00171886 ([`ctg-observation-nct00171886-2017-02-24-f455d2431e15`](#source-ctg-observation-nct00171886-2017-02-24-f455d2431e15))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00171886 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-02-24, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00171886-2017-02-24-f455d2431e15`](#source-ctg-observation-nct00171886-2017-02-24-f455d2431e15))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00171886 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-02-24, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00171886-2017-02-24-f455d2431e15`](#source-ctg-observation-nct00171886-2017-02-24-f455d2431e15))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00171886-2017-02-24-f455d2431e15`](#source-ctg-observation-nct00171886-2017-02-24-f455d2431e15))

### Sources

<a id="source-ctg-observation-nct00171886-2017-02-24-f455d2431e15"></a>
- **ClinicalTrials.gov record NCT00171886 · retained source version 2017-02-24:f455d2431e15bb8bf0466e42a52561262ba165dec390d46c306ed3105182eb66** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00171886) (`ctg-observation-nct00171886-2017-02-24-f455d2431e15`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00171886." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00171886-octreotide-v1 SHA-256: 1faed06a8dffb0d16b8b81bd6d9f820b13bfd253051e831b778824fbb0003cc9.

---

<a id="clinicaltrials-gov-nct00182754-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00182754

> PeptideScanner retained ClinicalTrials.gov record NCT00182754 at 2026-07-30T21:24:24.234Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00182754-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00182754-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00182754-octreotide-v1
- Content SHA-256: `84dfcb64d1e0a1ce9f04635f2074d250a76a041153285dea2a60915a6b762d62`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00182754 ([`ctg-observation-nct00182754-2017-04-11-c5fd6226531c`](#source-ctg-observation-nct00182754-2017-04-11-c5fd6226531c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00182754 at 2026-07-30T21:24:24.234Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00182754-2017-04-11-c5fd6226531c`](#source-ctg-observation-nct00182754-2017-04-11-c5fd6226531c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00182754 at 2026-07-30T21:24:24.234Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00182754-2017-04-11-c5fd6226531c`](#source-ctg-observation-nct00182754-2017-04-11-c5fd6226531c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00182754-2017-04-11-c5fd6226531c`](#source-ctg-observation-nct00182754-2017-04-11-c5fd6226531c))

### Sources

<a id="source-ctg-observation-nct00182754-2017-04-11-c5fd6226531c"></a>
- **ClinicalTrials.gov record NCT00182754 · retained source version 2017-04-11:c5fd6226531c05c8c65a889e472068c7ac5ecb8784355be726d30f5363476163** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00182754) (`ctg-observation-nct00182754-2017-04-11-c5fd6226531c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00182754." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00182754-octreotide-v1 SHA-256: 84dfcb64d1e0a1ce9f04635f2074d250a76a041153285dea2a60915a6b762d62.

---

<a id="clinicaltrials-gov-nct00223691-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00223691

> PeptideScanner retained ClinicalTrials.gov record NCT00223691 at 2026-07-30T21:25:36.812Z. Its registry update date was 2017-01-18, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00223691-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-01-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00223691-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00223691-octreotide-v1
- Content SHA-256: `3354694845d33514e05bb883e2f34cf2f3ddcfb5b5dab8914a17c2be3d5762dd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00223691 ([`ctg-observation-nct00223691-2017-01-18-f7a14d5e3206`](#source-ctg-observation-nct00223691-2017-01-18-f7a14d5e3206))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00223691 at 2026-07-30T21:25:36.812Z. Its registry update date was 2017-01-18, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00223691-2017-01-18-f7a14d5e3206`](#source-ctg-observation-nct00223691-2017-01-18-f7a14d5e3206))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00223691 at 2026-07-30T21:25:36.812Z. Its registry update date was 2017-01-18, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00223691-2017-01-18-f7a14d5e3206`](#source-ctg-observation-nct00223691-2017-01-18-f7a14d5e3206))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00223691-2017-01-18-f7a14d5e3206`](#source-ctg-observation-nct00223691-2017-01-18-f7a14d5e3206))

### Sources

<a id="source-ctg-observation-nct00223691-2017-01-18-f7a14d5e3206"></a>
- **ClinicalTrials.gov record NCT00223691 · retained source version 2017-01-18:f7a14d5e3206c5ba82ae65adda4cfc41fb9e47113b21b2625fbb15809cf14e91** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00223691) (`ctg-observation-nct00223691-2017-01-18-f7a14d5e3206`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00223691." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00223691-octreotide-v1 SHA-256: 3354694845d33514e05bb883e2f34cf2f3ddcfb5b5dab8914a17c2be3d5762dd.

---

<a id="clinicaltrials-gov-nct00226967-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00226967

> PeptideScanner retained ClinicalTrials.gov record NCT00226967 at 2026-07-30T20:33:20.622Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00226967-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00226967-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00226967-octreotide-v1
- Content SHA-256: `6854951b950a666e274a8595d1399361a41b01dba4e6b5114fee90b44942a92c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00226967 ([`ctg-observation-nct00226967-2020-01-27-2fa0cadb1709`](#source-ctg-observation-nct00226967-2020-01-27-2fa0cadb1709))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00226967 at 2026-07-30T20:33:20.622Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00226967-2020-01-27-2fa0cadb1709`](#source-ctg-observation-nct00226967-2020-01-27-2fa0cadb1709))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00226967 at 2026-07-30T20:33:20.622Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00226967-2020-01-27-2fa0cadb1709`](#source-ctg-observation-nct00226967-2020-01-27-2fa0cadb1709))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00226967-2020-01-27-2fa0cadb1709`](#source-ctg-observation-nct00226967-2020-01-27-2fa0cadb1709))

### Sources

<a id="source-ctg-observation-nct00226967-2020-01-27-2fa0cadb1709"></a>
- **ClinicalTrials.gov record NCT00226967 · retained source version 2020-01-27:2fa0cadb17091233799e192cb06f2dc03d04445525ebf126b34e7033954d4884** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00226967) (`ctg-observation-nct00226967-2020-01-27-2fa0cadb1709`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00226967." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00226967-octreotide-v1 SHA-256: 6854951b950a666e274a8595d1399361a41b01dba4e6b5114fee90b44942a92c.

---

<a id="clinicaltrials-gov-nct00241020-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00241020

> PeptideScanner retained ClinicalTrials.gov record NCT00241020 at 2026-07-30T21:37:20.823Z. Its registry update date was 2016-04-12, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00241020-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-04-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00241020-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00241020-octreotide-v1
- Content SHA-256: `dd55684c2a532a61150d1edd61916f993212d8e906905b280b8174bcc632199b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00241020 ([`ctg-observation-nct00241020-2016-04-12-2ff69f093abb`](#source-ctg-observation-nct00241020-2016-04-12-2ff69f093abb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00241020 at 2026-07-30T21:37:20.823Z. Its registry update date was 2016-04-12, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00241020-2016-04-12-2ff69f093abb`](#source-ctg-observation-nct00241020-2016-04-12-2ff69f093abb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00241020 at 2026-07-30T21:37:20.823Z. Its registry update date was 2016-04-12, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00241020-2016-04-12-2ff69f093abb`](#source-ctg-observation-nct00241020-2016-04-12-2ff69f093abb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00241020-2016-04-12-2ff69f093abb`](#source-ctg-observation-nct00241020-2016-04-12-2ff69f093abb))

### Sources

<a id="source-ctg-observation-nct00241020-2016-04-12-2ff69f093abb"></a>
- **ClinicalTrials.gov record NCT00241020 · retained source version 2016-04-12:2ff69f093abb46531bbbf83993eb6dd7197b05aeee9ebe93bf78ab391a439c56** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00241020) (`ctg-observation-nct00241020-2016-04-12-2ff69f093abb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00241020." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00241020-octreotide-v1 SHA-256: dd55684c2a532a61150d1edd61916f993212d8e906905b280b8174bcc632199b.

---

<a id="clinicaltrials-gov-nct00257426-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00257426

> PeptideScanner retained ClinicalTrials.gov record NCT00257426 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00257426-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-02-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00257426-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00257426-octreotide-v1
- Content SHA-256: `55f551ce02ea97d9660b51b7d68ce083853472aebdaf55c1cb1d1eca14d65466`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00257426 ([`ctg-observation-nct00257426-2012-02-14-07a845b679ed`](#source-ctg-observation-nct00257426-2012-02-14-07a845b679ed))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00257426 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00257426-2012-02-14-07a845b679ed`](#source-ctg-observation-nct00257426-2012-02-14-07a845b679ed))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00257426 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00257426-2012-02-14-07a845b679ed`](#source-ctg-observation-nct00257426-2012-02-14-07a845b679ed))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00257426-2012-02-14-07a845b679ed`](#source-ctg-observation-nct00257426-2012-02-14-07a845b679ed))

### Sources

<a id="source-ctg-observation-nct00257426-2012-02-14-07a845b679ed"></a>
- **ClinicalTrials.gov record NCT00257426 · retained source version 2012-02-14:07a845b679eda1e47dc4a8019cba45ccf95cba02c3c9687394e804354c87e23b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00257426) (`ctg-observation-nct00257426-2012-02-14-07a845b679ed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00257426." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00257426-octreotide-v1 SHA-256: 55f551ce02ea97d9660b51b7d68ce083853472aebdaf55c1cb1d1eca14d65466.

---

<a id="clinicaltrials-gov-nct00262470-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00262470

> PeptideScanner retained ClinicalTrials.gov record NCT00262470 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-08, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00262470-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-10-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00262470-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00262470-octreotide-v1
- Content SHA-256: `f61a860d29b538455314723d3bdc3e332d155ce83e1463a45c11008f0c47ebf8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00262470 ([`ctg-observation-nct00262470-2025-10-08-96be89f835d6`](#source-ctg-observation-nct00262470-2025-10-08-96be89f835d6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00262470 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-08, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00262470-2025-10-08-96be89f835d6`](#source-ctg-observation-nct00262470-2025-10-08-96be89f835d6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00262470 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-08, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00262470-2025-10-08-96be89f835d6`](#source-ctg-observation-nct00262470-2025-10-08-96be89f835d6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00262470-2025-10-08-96be89f835d6`](#source-ctg-observation-nct00262470-2025-10-08-96be89f835d6))

### Sources

<a id="source-ctg-observation-nct00262470-2025-10-08-96be89f835d6"></a>
- **ClinicalTrials.gov record NCT00262470 · retained source version 2025-10-08:96be89f835d602e7b6f53e9ff71eef47e7fae7335a1abe53fe0af59b369c1707** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00262470) (`ctg-observation-nct00262470-2025-10-08-96be89f835d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00262470." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00262470-octreotide-v1 SHA-256: f61a860d29b538455314723d3bdc3e332d155ce83e1463a45c11008f0c47ebf8.

---

<a id="clinicaltrials-gov-nct00332969-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00332969

> PeptideScanner retained ClinicalTrials.gov record NCT00332969 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-03-31, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00332969-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-03-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00332969-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00332969-octreotide-v1
- Content SHA-256: `a6135b856ec1db0f2e0a064ae4edd303b4a053a4119d6a341ea86cb323176ec5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00332969 ([`ctg-observation-nct00332969-2017-03-31-9259e70117a7`](#source-ctg-observation-nct00332969-2017-03-31-9259e70117a7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00332969 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-03-31, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00332969-2017-03-31-9259e70117a7`](#source-ctg-observation-nct00332969-2017-03-31-9259e70117a7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00332969 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-03-31, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00332969-2017-03-31-9259e70117a7`](#source-ctg-observation-nct00332969-2017-03-31-9259e70117a7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00332969-2017-03-31-9259e70117a7`](#source-ctg-observation-nct00332969-2017-03-31-9259e70117a7))

### Sources

<a id="source-ctg-observation-nct00332969-2017-03-31-9259e70117a7"></a>
- **ClinicalTrials.gov record NCT00332969 · retained source version 2017-03-31:9259e70117a73073380c4323b259b4807ea126dca44f78d52017b09d929af30f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00332969) (`ctg-observation-nct00332969-2017-03-31-9259e70117a7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00332969." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00332969-octreotide-v1 SHA-256: a6135b856ec1db0f2e0a064ae4edd303b4a053a4119d6a341ea86cb323176ec5.

---

<a id="clinicaltrials-gov-nct00412061-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00412061

> PeptideScanner retained ClinicalTrials.gov record NCT00412061 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-11-21, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00412061-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00412061-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00412061-octreotide-v1
- Content SHA-256: `957385cbea9b58fccf61956a36e6327c295f1e43106640d6f4158d5126953df1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00412061 ([`ctg-observation-nct00412061-2014-11-21-4f24aabb271a`](#source-ctg-observation-nct00412061-2014-11-21-4f24aabb271a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00412061 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-11-21, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00412061-2014-11-21-4f24aabb271a`](#source-ctg-observation-nct00412061-2014-11-21-4f24aabb271a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00412061 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-11-21, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00412061-2014-11-21-4f24aabb271a`](#source-ctg-observation-nct00412061-2014-11-21-4f24aabb271a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00412061-2014-11-21-4f24aabb271a`](#source-ctg-observation-nct00412061-2014-11-21-4f24aabb271a))

### Sources

<a id="source-ctg-observation-nct00412061-2014-11-21-4f24aabb271a"></a>
- **ClinicalTrials.gov record NCT00412061 · retained source version 2014-11-21:4f24aabb271ad31687903fd11deaf04885b85d3840aca0d499a1deeb41f5a488** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00412061) (`ctg-observation-nct00412061-2014-11-21-4f24aabb271a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00412061." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00412061-octreotide-v1 SHA-256: 957385cbea9b58fccf61956a36e6327c295f1e43106640d6f4158d5126953df1.

---

<a id="clinicaltrials-gov-nct00426153-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00426153

> PeptideScanner retained ClinicalTrials.gov record NCT00426153 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-11-21, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00426153-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00426153-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00426153-octreotide-v1
- Content SHA-256: `27d76f290edc1b33a34a3c92eb2a8c150d30c73a5aefd1d8b5e09885b1744a71`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00426153 ([`ctg-observation-nct00426153-2012-11-21-c8c663655d0d`](#source-ctg-observation-nct00426153-2012-11-21-c8c663655d0d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00426153 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-11-21, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00426153-2012-11-21-c8c663655d0d`](#source-ctg-observation-nct00426153-2012-11-21-c8c663655d0d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00426153 at 2026-07-30T22:14:20.912Z. Its registry update date was 2012-11-21, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00426153-2012-11-21-c8c663655d0d`](#source-ctg-observation-nct00426153-2012-11-21-c8c663655d0d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00426153-2012-11-21-c8c663655d0d`](#source-ctg-observation-nct00426153-2012-11-21-c8c663655d0d))

### Sources

<a id="source-ctg-observation-nct00426153-2012-11-21-c8c663655d0d"></a>
- **ClinicalTrials.gov record NCT00426153 · retained source version 2012-11-21:c8c663655d0dbb5ec0469fa0e08bc87f85306014285df510df26c8fad5ebcbba** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00426153) (`ctg-observation-nct00426153-2012-11-21-c8c663655d0d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00426153." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00426153-octreotide-v1 SHA-256: 27d76f290edc1b33a34a3c92eb2a8c150d30c73a5aefd1d8b5e09885b1744a71.

---

<a id="clinicaltrials-gov-nct00427349-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00427349

> PeptideScanner retained ClinicalTrials.gov record NCT00427349 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-05, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00427349-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00427349-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00427349-octreotide-v1
- Content SHA-256: `d8fe30a684726da10fe3612bf6d9c17f1ba03efea766a08206eaa52153ab3c06`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00427349 ([`ctg-observation-nct00427349-2023-07-05-226b17a41d37`](#source-ctg-observation-nct00427349-2023-07-05-226b17a41d37))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00427349 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00427349-2023-07-05-226b17a41d37`](#source-ctg-observation-nct00427349-2023-07-05-226b17a41d37))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00427349 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00427349-2023-07-05-226b17a41d37`](#source-ctg-observation-nct00427349-2023-07-05-226b17a41d37))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00427349-2023-07-05-226b17a41d37`](#source-ctg-observation-nct00427349-2023-07-05-226b17a41d37))

### Sources

<a id="source-ctg-observation-nct00427349-2023-07-05-226b17a41d37"></a>
- **ClinicalTrials.gov record NCT00427349 · retained source version 2023-07-05:226b17a41d3718e8a7bfe902342164445ab4e9f6ef4a09ccdf44b8d2a224a1f3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00427349) (`ctg-observation-nct00427349-2023-07-05-226b17a41d37`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00427349." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00427349-octreotide-v1 SHA-256: d8fe30a684726da10fe3612bf6d9c17f1ba03efea766a08206eaa52153ab3c06.

---

<a id="clinicaltrials-gov-nct00463983-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00463983

> PeptideScanner retained ClinicalTrials.gov record NCT00463983 at 2026-07-30T18:30:10.977Z. Its registry update date was 2025-03-05, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00463983-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-03-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00463983-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00463983-octreotide-v1
- Content SHA-256: `8fe4634bfae81e4fb319c25b47f2e315cb8a40a5140b5736f89a33c87b0973c6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00463983 ([`ctg-observation-nct00463983-2025-03-05-a92b6860a3b4`](#source-ctg-observation-nct00463983-2025-03-05-a92b6860a3b4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00463983 at 2026-07-30T18:30:10.977Z. Its registry update date was 2025-03-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00463983-2025-03-05-a92b6860a3b4`](#source-ctg-observation-nct00463983-2025-03-05-a92b6860a3b4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00463983 at 2026-07-30T18:30:10.977Z. Its registry update date was 2025-03-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00463983-2025-03-05-a92b6860a3b4`](#source-ctg-observation-nct00463983-2025-03-05-a92b6860a3b4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00463983-2025-03-05-a92b6860a3b4`](#source-ctg-observation-nct00463983-2025-03-05-a92b6860a3b4))

### Sources

<a id="source-ctg-observation-nct00463983-2025-03-05-a92b6860a3b4"></a>
- **ClinicalTrials.gov record NCT00463983 · retained source version 2025-03-05:a92b6860a3b4dda7b59ede9c30a08e08a9302bbe602fbcf6ba819131fe2f1ac8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00463983) (`ctg-observation-nct00463983-2025-03-05-a92b6860a3b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00463983." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00463983-octreotide-v1 SHA-256: 8fe4634bfae81e4fb319c25b47f2e315cb8a40a5140b5736f89a33c87b0973c6.

---

<a id="clinicaltrials-gov-nct00521300-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00521300

> PeptideScanner retained ClinicalTrials.gov record NCT00521300 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-06-02, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00521300-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-06-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00521300-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00521300-octreotide-v1
- Content SHA-256: `5d52bde9eb66b6fbd2a65c7d0fdcae287fcdfdc106e9ad48c0e9b5eb2f2eca70`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00521300 ([`ctg-observation-nct00521300-2014-06-02-a4fde4903407`](#source-ctg-observation-nct00521300-2014-06-02-a4fde4903407))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00521300 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-06-02, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00521300-2014-06-02-a4fde4903407`](#source-ctg-observation-nct00521300-2014-06-02-a4fde4903407))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00521300 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-06-02, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00521300-2014-06-02-a4fde4903407`](#source-ctg-observation-nct00521300-2014-06-02-a4fde4903407))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00521300-2014-06-02-a4fde4903407`](#source-ctg-observation-nct00521300-2014-06-02-a4fde4903407))

### Sources

<a id="source-ctg-observation-nct00521300-2014-06-02-a4fde4903407"></a>
- **ClinicalTrials.gov record NCT00521300 · retained source version 2014-06-02:a4fde49034078f0855e92a69c079a8010211d9c5761c51a47d74f782dc53c9b8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00521300) (`ctg-observation-nct00521300-2014-06-02-a4fde4903407`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00521300." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00521300-octreotide-v1 SHA-256: 5d52bde9eb66b6fbd2a65c7d0fdcae287fcdfdc106e9ad48c0e9b5eb2f2eca70.

---

<a id="clinicaltrials-gov-nct00534677-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00534677

> PeptideScanner retained ClinicalTrials.gov record NCT00534677 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-12-05, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00534677-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2007-12-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00534677-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00534677-octreotide-v1
- Content SHA-256: `a519d3c4a7e6b16e6ec3f5165ac937408dc0bd3ebf1a88bf2d65c8e27e2eeaf8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00534677 ([`ctg-observation-nct00534677-2007-12-05-1216ca069279`](#source-ctg-observation-nct00534677-2007-12-05-1216ca069279))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00534677 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-12-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00534677-2007-12-05-1216ca069279`](#source-ctg-observation-nct00534677-2007-12-05-1216ca069279))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00534677 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-12-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00534677-2007-12-05-1216ca069279`](#source-ctg-observation-nct00534677-2007-12-05-1216ca069279))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00534677-2007-12-05-1216ca069279`](#source-ctg-observation-nct00534677-2007-12-05-1216ca069279))

### Sources

<a id="source-ctg-observation-nct00534677-2007-12-05-1216ca069279"></a>
- **ClinicalTrials.gov record NCT00534677 · retained source version 2007-12-05:1216ca0692798e30d6431a10adf04912e3ddd66ee804041a0e22175fb0593f21** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00534677) (`ctg-observation-nct00534677-2007-12-05-1216ca069279`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00534677." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00534677-octreotide-v1 SHA-256: a519d3c4a7e6b16e6ec3f5165ac937408dc0bd3ebf1a88bf2d65c8e27e2eeaf8.

---

<a id="clinicaltrials-gov-nct00569127-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00569127

> PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-08-10T18:10:03.946Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00569127-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00569127-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00569127-octreotide-v1
- Content SHA-256: `3ba282baf53c1e443dbdfc7424ebb142ef4977dedd4b9cadeaa2ff7f1e6ebbc9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00569127 ([`ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6`](#source-ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-08-10T18:10:03.946Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6`](#source-ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-08-10T18:10:03.946Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6`](#source-ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6`](#source-ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6))

### Sources

<a id="source-ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6"></a>
- **ClinicalTrials.gov record NCT00569127 · retained source version 2026-07-29:dcf52ae95ff64e3f9136017a8f2d1a97163ca52300afb3c8aec7c3bce7d3b9f8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00569127) (`ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00569127." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00569127-octreotide-v1 SHA-256: 3ba282baf53c1e443dbdfc7424ebb142ef4977dedd4b9cadeaa2ff7f1e6ebbc9.

---

<a id="clinicaltrials-gov-nct00569127-octreotide-v2"></a>

## ClinicalTrials.gov record NCT00569127

> PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00569127-octreotide:v2`
- Evidence domain: Clinical trials
- Date in source: 2026-11-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00569127-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00569127-octreotide-v2
- Content SHA-256: `6f9b0aa8796460563191e118932548338e8999dffb50f74ac61aefab4ebf9893`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00569127 ([`ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2`](#source-ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2`](#source-ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2`](#source-ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2`](#source-ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2))

### Sources

<a id="source-ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2"></a>
- **ClinicalTrials.gov record NCT00569127 · retained source version 2026-11-13:045f08ac34ffafa2740d88dc6dd0b433022b2451d93ff246e833f85b7d198224** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00569127) (`ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2`)

### Correction lineage

updated on 2026-11-15: ClinicalTrials.gov posted a newer version of NCT00569127, with a registry update date of 2026-11-13. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2`](#source-ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2)

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00569127." Version 2, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00569127-octreotide-v2 SHA-256: 6f9b0aa8796460563191e118932548338e8999dffb50f74ac61aefab4ebf9893.

---

<a id="clinicaltrials-gov-nct00600886-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00600886

> PeptideScanner retained ClinicalTrials.gov record NCT00600886 at 2026-07-30T21:23:14.761Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00600886-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-07-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00600886-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00600886-octreotide-v1
- Content SHA-256: `09737b7d912f50687abac5d681c2791e2f287056ca9e578f686d8f0008651527`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00600886 ([`ctg-observation-nct00600886-2017-07-02-7a6f5ff7bdcd`](#source-ctg-observation-nct00600886-2017-07-02-7a6f5ff7bdcd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00600886 at 2026-07-30T21:23:14.761Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00600886-2017-07-02-7a6f5ff7bdcd`](#source-ctg-observation-nct00600886-2017-07-02-7a6f5ff7bdcd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00600886 at 2026-07-30T21:23:14.761Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00600886-2017-07-02-7a6f5ff7bdcd`](#source-ctg-observation-nct00600886-2017-07-02-7a6f5ff7bdcd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00600886-2017-07-02-7a6f5ff7bdcd`](#source-ctg-observation-nct00600886-2017-07-02-7a6f5ff7bdcd))

### Sources

<a id="source-ctg-observation-nct00600886-2017-07-02-7a6f5ff7bdcd"></a>
- **ClinicalTrials.gov record NCT00600886 · retained source version 2017-07-02:7a6f5ff7bdcd33cdf5b1a21fb1e5de996a4ef8f68efce26bd3339490a08d7946** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00600886) (`ctg-observation-nct00600886-2017-07-02-7a6f5ff7bdcd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00600886." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00600886-octreotide-v1 SHA-256: 09737b7d912f50687abac5d681c2791e2f287056ca9e578f686d8f0008651527.

---

<a id="clinicaltrials-gov-nct00690430-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00690430

> PeptideScanner retained ClinicalTrials.gov record NCT00690430 at 2026-07-30T21:55:56.629Z. Its registry update date was 2013-07-30, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00690430-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-07-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00690430-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00690430-octreotide-v1
- Content SHA-256: `c3218898ed0568e4bbf0406090a57b46dac4b7e4c4c12a2b8f0c86cc394caa6a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00690430 ([`ctg-observation-nct00690430-2013-07-30-41c579b82949`](#source-ctg-observation-nct00690430-2013-07-30-41c579b82949))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00690430 at 2026-07-30T21:55:56.629Z. Its registry update date was 2013-07-30, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00690430-2013-07-30-41c579b82949`](#source-ctg-observation-nct00690430-2013-07-30-41c579b82949))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00690430 at 2026-07-30T21:55:56.629Z. Its registry update date was 2013-07-30, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00690430-2013-07-30-41c579b82949`](#source-ctg-observation-nct00690430-2013-07-30-41c579b82949))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00690430-2013-07-30-41c579b82949`](#source-ctg-observation-nct00690430-2013-07-30-41c579b82949))

### Sources

<a id="source-ctg-observation-nct00690430-2013-07-30-41c579b82949"></a>
- **ClinicalTrials.gov record NCT00690430 · retained source version 2013-07-30:41c579b82949e435c460699751e0ad484b51a210f92d211379a2928ab547a226** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00690430) (`ctg-observation-nct00690430-2013-07-30-41c579b82949`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00690430." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00690430-octreotide-v1 SHA-256: c3218898ed0568e4bbf0406090a57b46dac4b7e4c4c12a2b8f0c86cc394caa6a.

---

<a id="clinicaltrials-gov-nct00966355-octreotide-v1"></a>

## ClinicalTrials.gov record NCT00966355

> PeptideScanner retained ClinicalTrials.gov record NCT00966355 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-03-19, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct00966355-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-03-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00966355-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00966355-octreotide-v1
- Content SHA-256: `9b3b0ee5970b5030d5ebab847db7d6560de81fdd286c80d0c2465cde742d0b75`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00966355 ([`ctg-observation-nct00966355-2018-03-19-e3e8f7652cdd`](#source-ctg-observation-nct00966355-2018-03-19-e3e8f7652cdd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00966355 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-03-19, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00966355-2018-03-19-e3e8f7652cdd`](#source-ctg-observation-nct00966355-2018-03-19-e3e8f7652cdd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00966355 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-03-19, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct00966355-2018-03-19-e3e8f7652cdd`](#source-ctg-observation-nct00966355-2018-03-19-e3e8f7652cdd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00966355-2018-03-19-e3e8f7652cdd`](#source-ctg-observation-nct00966355-2018-03-19-e3e8f7652cdd))

### Sources

<a id="source-ctg-observation-nct00966355-2018-03-19-e3e8f7652cdd"></a>
- **ClinicalTrials.gov record NCT00966355 · retained source version 2018-03-19:e3e8f7652cdd991392e1a8f5ca4cec656d619875cf52f00b4856a63622363d5d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00966355) (`ctg-observation-nct00966355-2018-03-19-e3e8f7652cdd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00966355." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct00966355-octreotide-v1 SHA-256: 9b3b0ee5970b5030d5ebab847db7d6560de81fdd286c80d0c2465cde742d0b75.

---

<a id="clinicaltrials-gov-nct01121939-octreotide-v1"></a>

## ClinicalTrials.gov record NCT01121939

> PeptideScanner retained ClinicalTrials.gov record NCT01121939 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-02-05, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct01121939-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-02-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01121939-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01121939-octreotide-v1
- Content SHA-256: `02a7a4a5464dd351aa0076b48a021751b0a946e2b76dead6fa186a8eb90a7cd3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01121939 ([`ctg-observation-nct01121939-2016-02-05-71f0eb4a1f21`](#source-ctg-observation-nct01121939-2016-02-05-71f0eb4a1f21))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01121939 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-02-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01121939-2016-02-05-71f0eb4a1f21`](#source-ctg-observation-nct01121939-2016-02-05-71f0eb4a1f21))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01121939 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-02-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01121939-2016-02-05-71f0eb4a1f21`](#source-ctg-observation-nct01121939-2016-02-05-71f0eb4a1f21))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01121939-2016-02-05-71f0eb4a1f21`](#source-ctg-observation-nct01121939-2016-02-05-71f0eb4a1f21))

### Sources

<a id="source-ctg-observation-nct01121939-2016-02-05-71f0eb4a1f21"></a>
- **ClinicalTrials.gov record NCT01121939 · retained source version 2016-02-05:71f0eb4a1f2152691571387f28c59d0dcafb5eac84665f2dc852c2c918c94073** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01121939) (`ctg-observation-nct01121939-2016-02-05-71f0eb4a1f21`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01121939." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01121939-octreotide-v1 SHA-256: 02a7a4a5464dd351aa0076b48a021751b0a946e2b76dead6fa186a8eb90a7cd3.

---

<a id="clinicaltrials-gov-nct01204476-octreotide-v1"></a>

## ClinicalTrials.gov record NCT01204476

> PeptideScanner retained ClinicalTrials.gov record NCT01204476 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-07-15, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct01204476-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-07-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01204476-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01204476-octreotide-v1
- Content SHA-256: `c545a19fdc5314b7f9d9a0f6ae9df668f33896aab48a208900c10d80414c1a47`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01204476 ([`ctg-observation-nct01204476-2016-07-15-50fbda57e0f4`](#source-ctg-observation-nct01204476-2016-07-15-50fbda57e0f4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01204476 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-07-15, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01204476-2016-07-15-50fbda57e0f4`](#source-ctg-observation-nct01204476-2016-07-15-50fbda57e0f4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01204476 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-07-15, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01204476-2016-07-15-50fbda57e0f4`](#source-ctg-observation-nct01204476-2016-07-15-50fbda57e0f4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01204476-2016-07-15-50fbda57e0f4`](#source-ctg-observation-nct01204476-2016-07-15-50fbda57e0f4))

### Sources

<a id="source-ctg-observation-nct01204476-2016-07-15-50fbda57e0f4"></a>
- **ClinicalTrials.gov record NCT01204476 · retained source version 2016-07-15:50fbda57e0f441c912351d0485634794b67449d4796acb72b2391912df3b2b1c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01204476) (`ctg-observation-nct01204476-2016-07-15-50fbda57e0f4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01204476." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01204476-octreotide-v1 SHA-256: c545a19fdc5314b7f9d9a0f6ae9df668f33896aab48a208900c10d80414c1a47.

---

<a id="clinicaltrials-gov-nct01229943-octreotide-v1"></a>

## ClinicalTrials.gov record NCT01229943

> PeptideScanner retained ClinicalTrials.gov record NCT01229943 at 2026-07-30T19:36:31.409Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct01229943-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-08-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01229943-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01229943-octreotide-v1
- Content SHA-256: `dab279a1b1923f2a40ef5da656ad6e79e7d92525ec3fbc12cd330ecd749a77d3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01229943 ([`ctg-observation-nct01229943-2022-08-04-1f007666b922`](#source-ctg-observation-nct01229943-2022-08-04-1f007666b922))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01229943 at 2026-07-30T19:36:31.409Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01229943-2022-08-04-1f007666b922`](#source-ctg-observation-nct01229943-2022-08-04-1f007666b922))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01229943 at 2026-07-30T19:36:31.409Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01229943-2022-08-04-1f007666b922`](#source-ctg-observation-nct01229943-2022-08-04-1f007666b922))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01229943-2022-08-04-1f007666b922`](#source-ctg-observation-nct01229943-2022-08-04-1f007666b922))

### Sources

<a id="source-ctg-observation-nct01229943-2022-08-04-1f007666b922"></a>
- **ClinicalTrials.gov record NCT01229943 · retained source version 2022-08-04:1f007666b92202d8c7f6d947a64dca6403fba5bd2200fd1fa1753254d76b1286** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01229943) (`ctg-observation-nct01229943-2022-08-04-1f007666b922`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01229943." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01229943-octreotide-v1 SHA-256: dab279a1b1923f2a40ef5da656ad6e79e7d92525ec3fbc12cd330ecd749a77d3.

---

<a id="clinicaltrials-gov-nct01561066-octreotide-v1"></a>

## ClinicalTrials.gov record NCT01561066

> PeptideScanner retained ClinicalTrials.gov record NCT01561066 at 2026-07-30T21:55:56.621Z. Its registry update date was 2013-02-26, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct01561066-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-02-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01561066-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01561066-octreotide-v1
- Content SHA-256: `723c2f1a576355be2171b60ab8b86590711d8000a72d2185dce7775ae3d2e207`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01561066 ([`ctg-observation-nct01561066-2013-02-26-7dd1af92cf44`](#source-ctg-observation-nct01561066-2013-02-26-7dd1af92cf44))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01561066 at 2026-07-30T21:55:56.621Z. Its registry update date was 2013-02-26, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01561066-2013-02-26-7dd1af92cf44`](#source-ctg-observation-nct01561066-2013-02-26-7dd1af92cf44))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01561066 at 2026-07-30T21:55:56.621Z. Its registry update date was 2013-02-26, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01561066-2013-02-26-7dd1af92cf44`](#source-ctg-observation-nct01561066-2013-02-26-7dd1af92cf44))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01561066-2013-02-26-7dd1af92cf44`](#source-ctg-observation-nct01561066-2013-02-26-7dd1af92cf44))

### Sources

<a id="source-ctg-observation-nct01561066-2013-02-26-7dd1af92cf44"></a>
- **ClinicalTrials.gov record NCT01561066 · retained source version 2013-02-26:7dd1af92cf44a565e5c10855b1cd66b3349774cd49e5a302463d6e059a01cc31** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01561066) (`ctg-observation-nct01561066-2013-02-26-7dd1af92cf44`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01561066." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01561066-octreotide-v1 SHA-256: 723c2f1a576355be2171b60ab8b86590711d8000a72d2185dce7775ae3d2e207.

---

<a id="clinicaltrials-gov-nct01865760-octreotide-v1"></a>

## ClinicalTrials.gov record NCT01865760

> PeptideScanner retained ClinicalTrials.gov record NCT01865760 at 2026-07-30T20:44:36.695Z. Its registry update date was 2019-10-28, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct01865760-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-10-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01865760-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01865760-octreotide-v1
- Content SHA-256: `d774b1e13ddf55a2a0cd9b4b5f8b20b7169d260a01aea3b3b57403a450c44349`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01865760 ([`ctg-observation-nct01865760-2019-10-28-bf31613b3fb0`](#source-ctg-observation-nct01865760-2019-10-28-bf31613b3fb0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01865760 at 2026-07-30T20:44:36.695Z. Its registry update date was 2019-10-28, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01865760-2019-10-28-bf31613b3fb0`](#source-ctg-observation-nct01865760-2019-10-28-bf31613b3fb0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01865760 at 2026-07-30T20:44:36.695Z. Its registry update date was 2019-10-28, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01865760-2019-10-28-bf31613b3fb0`](#source-ctg-observation-nct01865760-2019-10-28-bf31613b3fb0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01865760-2019-10-28-bf31613b3fb0`](#source-ctg-observation-nct01865760-2019-10-28-bf31613b3fb0))

### Sources

<a id="source-ctg-observation-nct01865760-2019-10-28-bf31613b3fb0"></a>
- **ClinicalTrials.gov record NCT01865760 · retained source version 2019-10-28:bf31613b3fb0e685747ac127315e57b2d27a32c98b966a312b701ac8f64de263** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01865760) (`ctg-observation-nct01865760-2019-10-28-bf31613b3fb0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01865760." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01865760-octreotide-v1 SHA-256: d774b1e13ddf55a2a0cd9b4b5f8b20b7169d260a01aea3b3b57403a450c44349.

---

<a id="clinicaltrials-gov-nct01917773-octreotide-v1"></a>

## ClinicalTrials.gov record NCT01917773

> PeptideScanner retained ClinicalTrials.gov record NCT01917773 at 2026-07-30T21:39:57.679Z. Its registry update date was 2015-12-21, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct01917773-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-12-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01917773-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01917773-octreotide-v1
- Content SHA-256: `9d6e91951a3c6b569f9855ea1216a3e61c558db0feb03c31d98d59ffa0da049d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01917773 ([`ctg-observation-nct01917773-2015-12-21-5234f6aeb512`](#source-ctg-observation-nct01917773-2015-12-21-5234f6aeb512))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01917773 at 2026-07-30T21:39:57.679Z. Its registry update date was 2015-12-21, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01917773-2015-12-21-5234f6aeb512`](#source-ctg-observation-nct01917773-2015-12-21-5234f6aeb512))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01917773 at 2026-07-30T21:39:57.679Z. Its registry update date was 2015-12-21, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct01917773-2015-12-21-5234f6aeb512`](#source-ctg-observation-nct01917773-2015-12-21-5234f6aeb512))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01917773-2015-12-21-5234f6aeb512`](#source-ctg-observation-nct01917773-2015-12-21-5234f6aeb512))

### Sources

<a id="source-ctg-observation-nct01917773-2015-12-21-5234f6aeb512"></a>
- **ClinicalTrials.gov record NCT01917773 · retained source version 2015-12-21:5234f6aeb512b335626e526d2fe886578c8cb70e4491b1a646dd867b763f9962** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01917773) (`ctg-observation-nct01917773-2015-12-21-5234f6aeb512`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01917773." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct01917773-octreotide-v1 SHA-256: 9d6e91951a3c6b569f9855ea1216a3e61c558db0feb03c31d98d59ffa0da049d.

---

<a id="clinicaltrials-gov-nct02010385-octreotide-v1"></a>

## ClinicalTrials.gov record NCT02010385

> PeptideScanner retained ClinicalTrials.gov record NCT02010385 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-23, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct02010385-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-05-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02010385-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02010385-octreotide-v1
- Content SHA-256: `25072ca5d6ebccb888ba6918dede8611fa40bdf87003bb4dfe443ca44cabc4c7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02010385 ([`ctg-observation-nct02010385-2022-05-23-9b8e52709e72`](#source-ctg-observation-nct02010385-2022-05-23-9b8e52709e72))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02010385 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-23, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02010385-2022-05-23-9b8e52709e72`](#source-ctg-observation-nct02010385-2022-05-23-9b8e52709e72))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02010385 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-23, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02010385-2022-05-23-9b8e52709e72`](#source-ctg-observation-nct02010385-2022-05-23-9b8e52709e72))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02010385-2022-05-23-9b8e52709e72`](#source-ctg-observation-nct02010385-2022-05-23-9b8e52709e72))

### Sources

<a id="source-ctg-observation-nct02010385-2022-05-23-9b8e52709e72"></a>
- **ClinicalTrials.gov record NCT02010385 · retained source version 2022-05-23:9b8e52709e7261b6ce601a9aea234207b06df5e2a706753615520ec8c631c932** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02010385) (`ctg-observation-nct02010385-2022-05-23-9b8e52709e72`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02010385." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02010385-octreotide-v1 SHA-256: 25072ca5d6ebccb888ba6918dede8611fa40bdf87003bb4dfe443ca44cabc4c7.

---

<a id="clinicaltrials-gov-nct02217800-octreotide-v1"></a>

## ClinicalTrials.gov record NCT02217800

> PeptideScanner retained ClinicalTrials.gov record NCT02217800 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-02-15, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct02217800-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-02-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02217800-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02217800-octreotide-v1
- Content SHA-256: `5782c099ceb80c8f057ca521d02389b3c5e2d0981df009d4a13e7b79c32251ff`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02217800 ([`ctg-observation-nct02217800-2018-02-15-a15b35ad79fa`](#source-ctg-observation-nct02217800-2018-02-15-a15b35ad79fa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02217800 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-02-15, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02217800-2018-02-15-a15b35ad79fa`](#source-ctg-observation-nct02217800-2018-02-15-a15b35ad79fa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02217800 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-02-15, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02217800-2018-02-15-a15b35ad79fa`](#source-ctg-observation-nct02217800-2018-02-15-a15b35ad79fa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02217800-2018-02-15-a15b35ad79fa`](#source-ctg-observation-nct02217800-2018-02-15-a15b35ad79fa))

### Sources

<a id="source-ctg-observation-nct02217800-2018-02-15-a15b35ad79fa"></a>
- **ClinicalTrials.gov record NCT02217800 · retained source version 2018-02-15:a15b35ad79fa40328960d80428ce0a614501bbb60d3fec950f9f60b45a42d474** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02217800) (`ctg-observation-nct02217800-2018-02-15-a15b35ad79fa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02217800." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02217800-octreotide-v1 SHA-256: 5782c099ceb80c8f057ca521d02389b3c5e2d0981df009d4a13e7b79c32251ff.

---

<a id="clinicaltrials-gov-nct02305069-octreotide-v1"></a>

## ClinicalTrials.gov record NCT02305069

> PeptideScanner retained ClinicalTrials.gov record NCT02305069 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-12-02, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct02305069-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-12-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02305069-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02305069-octreotide-v1
- Content SHA-256: `f0644774b7f731918bf959d2fbfecf959035c899a5fd8280ee7ffc669a73ba24`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02305069 ([`ctg-observation-nct02305069-2014-12-02-939523994926`](#source-ctg-observation-nct02305069-2014-12-02-939523994926))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02305069 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-12-02, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02305069-2014-12-02-939523994926`](#source-ctg-observation-nct02305069-2014-12-02-939523994926))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02305069 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-12-02, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02305069-2014-12-02-939523994926`](#source-ctg-observation-nct02305069-2014-12-02-939523994926))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02305069-2014-12-02-939523994926`](#source-ctg-observation-nct02305069-2014-12-02-939523994926))

### Sources

<a id="source-ctg-observation-nct02305069-2014-12-02-939523994926"></a>
- **ClinicalTrials.gov record NCT02305069 · retained source version 2014-12-02:9395239949260be96800e990cb173f3cf678d5a6341968207821ecc60a2029b5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02305069) (`ctg-observation-nct02305069-2014-12-02-939523994926`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02305069." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02305069-octreotide-v1 SHA-256: f0644774b7f731918bf959d2fbfecf959035c899a5fd8280ee7ffc669a73ba24.

---

<a id="clinicaltrials-gov-nct02333565-octreotide-v1"></a>

## ClinicalTrials.gov record NCT02333565

> PeptideScanner retained ClinicalTrials.gov record NCT02333565 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-25, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct02333565-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-05-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02333565-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02333565-octreotide-v1
- Content SHA-256: `ea552de8b4afd5c9a2f504690358e3413dd6c76b8b174d9efcc746f01fe63c66`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02333565 ([`ctg-observation-nct02333565-2023-05-25-93af084857cc`](#source-ctg-observation-nct02333565-2023-05-25-93af084857cc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02333565 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-25, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02333565-2023-05-25-93af084857cc`](#source-ctg-observation-nct02333565-2023-05-25-93af084857cc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02333565 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-25, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02333565-2023-05-25-93af084857cc`](#source-ctg-observation-nct02333565-2023-05-25-93af084857cc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02333565-2023-05-25-93af084857cc`](#source-ctg-observation-nct02333565-2023-05-25-93af084857cc))

### Sources

<a id="source-ctg-observation-nct02333565-2023-05-25-93af084857cc"></a>
- **ClinicalTrials.gov record NCT02333565 · retained source version 2023-05-25:93af084857ccc50982048c79395b21b74237d926d219db1b704678129b889e75** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02333565) (`ctg-observation-nct02333565-2023-05-25-93af084857cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02333565." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02333565-octreotide-v1 SHA-256: ea552de8b4afd5c9a2f504690358e3413dd6c76b8b174d9efcc746f01fe63c66.

---

<a id="clinicaltrials-gov-nct02381249-octreotide-v1"></a>

## ClinicalTrials.gov record NCT02381249

> PeptideScanner retained ClinicalTrials.gov record NCT02381249 at 2026-07-30T19:04:52.219Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct02381249-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-11-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02381249-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02381249-octreotide-v1
- Content SHA-256: `a90afc5fe7f845d85a723bc6859f92e82c4d0c137cec20d3d39662391b93daeb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02381249 ([`ctg-observation-nct02381249-2023-11-27-e1b90a69a2f7`](#source-ctg-observation-nct02381249-2023-11-27-e1b90a69a2f7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02381249 at 2026-07-30T19:04:52.219Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02381249-2023-11-27-e1b90a69a2f7`](#source-ctg-observation-nct02381249-2023-11-27-e1b90a69a2f7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02381249 at 2026-07-30T19:04:52.219Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02381249-2023-11-27-e1b90a69a2f7`](#source-ctg-observation-nct02381249-2023-11-27-e1b90a69a2f7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02381249-2023-11-27-e1b90a69a2f7`](#source-ctg-observation-nct02381249-2023-11-27-e1b90a69a2f7))

### Sources

<a id="source-ctg-observation-nct02381249-2023-11-27-e1b90a69a2f7"></a>
- **ClinicalTrials.gov record NCT02381249 · retained source version 2023-11-27:e1b90a69a2f703a4cfda565d1d62d6500a8efb7511134fcfd34599b6984c5f63** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02381249) (`ctg-observation-nct02381249-2023-11-27-e1b90a69a2f7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02381249." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02381249-octreotide-v1 SHA-256: a90afc5fe7f845d85a723bc6859f92e82c4d0c137cec20d3d39662391b93daeb.

---

<a id="clinicaltrials-gov-nct02384122-octreotide-v1"></a>

## ClinicalTrials.gov record NCT02384122

> PeptideScanner retained ClinicalTrials.gov record NCT02384122 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-24, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct02384122-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-05-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02384122-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02384122-octreotide-v1
- Content SHA-256: `3f1de3b2259776e66811911d9a361c2db80fa39a59b51a291b9043a8600585e3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02384122 ([`ctg-observation-nct02384122-2023-05-24-b7ed48cf8281`](#source-ctg-observation-nct02384122-2023-05-24-b7ed48cf8281))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02384122 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-24, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02384122-2023-05-24-b7ed48cf8281`](#source-ctg-observation-nct02384122-2023-05-24-b7ed48cf8281))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02384122 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-24, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02384122-2023-05-24-b7ed48cf8281`](#source-ctg-observation-nct02384122-2023-05-24-b7ed48cf8281))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02384122-2023-05-24-b7ed48cf8281`](#source-ctg-observation-nct02384122-2023-05-24-b7ed48cf8281))

### Sources

<a id="source-ctg-observation-nct02384122-2023-05-24-b7ed48cf8281"></a>
- **ClinicalTrials.gov record NCT02384122 · retained source version 2023-05-24:b7ed48cf8281840e72aba65669cab493ba385f4d02f4ad4a16520d59ed8c0edf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02384122) (`ctg-observation-nct02384122-2023-05-24-b7ed48cf8281`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02384122." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02384122-octreotide-v1 SHA-256: 3f1de3b2259776e66811911d9a361c2db80fa39a59b51a291b9043a8600585e3.

---

<a id="clinicaltrials-gov-nct02385617-octreotide-v1"></a>

## ClinicalTrials.gov record NCT02385617

> PeptideScanner retained ClinicalTrials.gov record NCT02385617 at 2026-07-30T19:04:52.214Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct02385617-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-11-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02385617-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02385617-octreotide-v1
- Content SHA-256: `987e09820063f5ad16989cd64f27641c5b7ce950fb7666150cbaf33d4e0e9d56`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02385617 ([`ctg-observation-nct02385617-2023-11-27-94b794c0a0b9`](#source-ctg-observation-nct02385617-2023-11-27-94b794c0a0b9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02385617 at 2026-07-30T19:04:52.214Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02385617-2023-11-27-94b794c0a0b9`](#source-ctg-observation-nct02385617-2023-11-27-94b794c0a0b9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02385617 at 2026-07-30T19:04:52.214Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02385617-2023-11-27-94b794c0a0b9`](#source-ctg-observation-nct02385617-2023-11-27-94b794c0a0b9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02385617-2023-11-27-94b794c0a0b9`](#source-ctg-observation-nct02385617-2023-11-27-94b794c0a0b9))

### Sources

<a id="source-ctg-observation-nct02385617-2023-11-27-94b794c0a0b9"></a>
- **ClinicalTrials.gov record NCT02385617 · retained source version 2023-11-27:94b794c0a0b9cab6eb0b9412603a01a4bbada616bd37c47c36a8ce64d7f170b9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02385617) (`ctg-observation-nct02385617-2023-11-27-94b794c0a0b9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02385617." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02385617-octreotide-v1 SHA-256: 987e09820063f5ad16989cd64f27641c5b7ce950fb7666150cbaf33d4e0e9d56.

---

<a id="clinicaltrials-gov-nct02457156-octreotide-v1"></a>

## ClinicalTrials.gov record NCT02457156

> PeptideScanner retained ClinicalTrials.gov record NCT02457156 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-13, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct02457156-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-03-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02457156-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02457156-octreotide-v1
- Content SHA-256: `6abab940e5f2e202bf9f9bec6c6a3a0960323d4d3e9bec98464f94f677df23e0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02457156 ([`ctg-observation-nct02457156-2025-03-13-8ac2688d9095`](#source-ctg-observation-nct02457156-2025-03-13-8ac2688d9095))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02457156 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-13, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02457156-2025-03-13-8ac2688d9095`](#source-ctg-observation-nct02457156-2025-03-13-8ac2688d9095))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02457156 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-13, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02457156-2025-03-13-8ac2688d9095`](#source-ctg-observation-nct02457156-2025-03-13-8ac2688d9095))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02457156-2025-03-13-8ac2688d9095`](#source-ctg-observation-nct02457156-2025-03-13-8ac2688d9095))

### Sources

<a id="source-ctg-observation-nct02457156-2025-03-13-8ac2688d9095"></a>
- **ClinicalTrials.gov record NCT02457156 · retained source version 2025-03-13:8ac2688d90951970a9e146dc02264411517a8704366dcb9ff44bac767704981b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02457156) (`ctg-observation-nct02457156-2025-03-13-8ac2688d9095`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02457156." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02457156-octreotide-v1 SHA-256: 6abab940e5f2e202bf9f9bec6c6a3a0960323d4d3e9bec98464f94f677df23e0.

---

<a id="clinicaltrials-gov-nct02474914-octreotide-v1"></a>

## ClinicalTrials.gov record NCT02474914

> PeptideScanner retained ClinicalTrials.gov record NCT02474914 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-08-22, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct02474914-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-08-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02474914-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02474914-octreotide-v1
- Content SHA-256: `b75d0fb8512e6b6d40c2d3612db5623558021e15f13ac153c4bbddaf2c7e112a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02474914 ([`ctg-observation-nct02474914-2017-08-22-8bd8733723af`](#source-ctg-observation-nct02474914-2017-08-22-8bd8733723af))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02474914 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-08-22, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02474914-2017-08-22-8bd8733723af`](#source-ctg-observation-nct02474914-2017-08-22-8bd8733723af))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02474914 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-08-22, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02474914-2017-08-22-8bd8733723af`](#source-ctg-observation-nct02474914-2017-08-22-8bd8733723af))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02474914-2017-08-22-8bd8733723af`](#source-ctg-observation-nct02474914-2017-08-22-8bd8733723af))

### Sources

<a id="source-ctg-observation-nct02474914-2017-08-22-8bd8733723af"></a>
- **ClinicalTrials.gov record NCT02474914 · retained source version 2017-08-22:8bd8733723afe20d8c1079d80c9a16ac486b28e6f9c694a23498ff1bc503c28e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02474914) (`ctg-observation-nct02474914-2017-08-22-8bd8733723af`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02474914." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02474914-octreotide-v1 SHA-256: b75d0fb8512e6b6d40c2d3612db5623558021e15f13ac153c4bbddaf2c7e112a.

---

<a id="clinicaltrials-gov-nct02916433-octreotide-v1"></a>

## ClinicalTrials.gov record NCT02916433

> PeptideScanner retained ClinicalTrials.gov record NCT02916433 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-08, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct02916433-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-10-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02916433-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02916433-octreotide-v1
- Content SHA-256: `b56cbc0e9cc40692384f909a706f64acad71224f1c1e908b4eb8f8351767dcb2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02916433 ([`ctg-observation-nct02916433-2020-10-08-b78bd3a31500`](#source-ctg-observation-nct02916433-2020-10-08-b78bd3a31500))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02916433 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-08, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02916433-2020-10-08-b78bd3a31500`](#source-ctg-observation-nct02916433-2020-10-08-b78bd3a31500))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02916433 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-08, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct02916433-2020-10-08-b78bd3a31500`](#source-ctg-observation-nct02916433-2020-10-08-b78bd3a31500))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02916433-2020-10-08-b78bd3a31500`](#source-ctg-observation-nct02916433-2020-10-08-b78bd3a31500))

### Sources

<a id="source-ctg-observation-nct02916433-2020-10-08-b78bd3a31500"></a>
- **ClinicalTrials.gov record NCT02916433 · retained source version 2020-10-08:b78bd3a3150093f02d4e78766b0c23d361918cbd96096e9ff57b9dde426f5f4c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02916433) (`ctg-observation-nct02916433-2020-10-08-b78bd3a31500`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02916433." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct02916433-octreotide-v1 SHA-256: b56cbc0e9cc40692384f909a706f64acad71224f1c1e908b4eb8f8351767dcb2.

---

<a id="clinicaltrials-gov-nct03000946-octreotide-v1"></a>

## ClinicalTrials.gov record NCT03000946

> PeptideScanner retained ClinicalTrials.gov record NCT03000946 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct03000946-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03000946-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03000946-octreotide-v1
- Content SHA-256: `8bbf817f2047a87480954bfcb51f108dbf1ba838239528a08a5ea160baf19f8f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03000946 ([`ctg-observation-nct03000946-2025-09-11-ec2160b57d0c`](#source-ctg-observation-nct03000946-2025-09-11-ec2160b57d0c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03000946 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03000946-2025-09-11-ec2160b57d0c`](#source-ctg-observation-nct03000946-2025-09-11-ec2160b57d0c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03000946 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03000946-2025-09-11-ec2160b57d0c`](#source-ctg-observation-nct03000946-2025-09-11-ec2160b57d0c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03000946-2025-09-11-ec2160b57d0c`](#source-ctg-observation-nct03000946-2025-09-11-ec2160b57d0c))

### Sources

<a id="source-ctg-observation-nct03000946-2025-09-11-ec2160b57d0c"></a>
- **ClinicalTrials.gov record NCT03000946 · retained source version 2025-09-11:ec2160b57d0c37c44d023255b9b3c07448d02fcf8e718ab07ce94e60170e79ac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03000946) (`ctg-observation-nct03000946-2025-09-11-ec2160b57d0c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03000946." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03000946-octreotide-v1 SHA-256: 8bbf817f2047a87480954bfcb51f108dbf1ba838239528a08a5ea160baf19f8f.

---

<a id="clinicaltrials-gov-nct03061604-octreotide-v1"></a>

## ClinicalTrials.gov record NCT03061604

> PeptideScanner retained ClinicalTrials.gov record NCT03061604 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-14, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct03061604-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-11-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03061604-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03061604-octreotide-v1
- Content SHA-256: `5a4ae7d2282c71533ba76f46d331517cb56518450a989c19cbb34bf56961d29c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03061604 ([`ctg-observation-nct03061604-2017-11-14-f9cc96b3c3d7`](#source-ctg-observation-nct03061604-2017-11-14-f9cc96b3c3d7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03061604 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-14, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03061604-2017-11-14-f9cc96b3c3d7`](#source-ctg-observation-nct03061604-2017-11-14-f9cc96b3c3d7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03061604 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-14, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03061604-2017-11-14-f9cc96b3c3d7`](#source-ctg-observation-nct03061604-2017-11-14-f9cc96b3c3d7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03061604-2017-11-14-f9cc96b3c3d7`](#source-ctg-observation-nct03061604-2017-11-14-f9cc96b3c3d7))

### Sources

<a id="source-ctg-observation-nct03061604-2017-11-14-f9cc96b3c3d7"></a>
- **ClinicalTrials.gov record NCT03061604 · retained source version 2017-11-14:f9cc96b3c3d7245ba4069da506ce3942a0dd4cf75bb9dd0be723e4232aefaa1c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03061604) (`ctg-observation-nct03061604-2017-11-14-f9cc96b3c3d7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03061604." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03061604-octreotide-v1 SHA-256: 5a4ae7d2282c71533ba76f46d331517cb56518450a989c19cbb34bf56961d29c.

---

<a id="clinicaltrials-gov-nct03289741-octreotide-v1"></a>

## ClinicalTrials.gov record NCT03289741

> PeptideScanner retained ClinicalTrials.gov record NCT03289741 at 2026-07-30T18:27:14.159Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct03289741-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-05-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03289741-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03289741-octreotide-v1
- Content SHA-256: `f6265c6ee95ff8e37d180a8c15844a4220e3ee3457ea99e63f7856919959f7c0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03289741 ([`ctg-observation-nct03289741-2025-05-09-92e2b759810f`](#source-ctg-observation-nct03289741-2025-05-09-92e2b759810f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03289741 at 2026-07-30T18:27:14.159Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03289741-2025-05-09-92e2b759810f`](#source-ctg-observation-nct03289741-2025-05-09-92e2b759810f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03289741 at 2026-07-30T18:27:14.159Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03289741-2025-05-09-92e2b759810f`](#source-ctg-observation-nct03289741-2025-05-09-92e2b759810f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03289741-2025-05-09-92e2b759810f`](#source-ctg-observation-nct03289741-2025-05-09-92e2b759810f))

### Sources

<a id="source-ctg-observation-nct03289741-2025-05-09-92e2b759810f"></a>
- **ClinicalTrials.gov record NCT03289741 · retained source version 2025-05-09:92e2b759810f1211f99bd7378170730c750b51a8f885a6f6ae2b5b01117ca29a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03289741) (`ctg-observation-nct03289741-2025-05-09-92e2b759810f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03289741." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03289741-octreotide-v1 SHA-256: f6265c6ee95ff8e37d180a8c15844a4220e3ee3457ea99e63f7856919959f7c0.

---

<a id="clinicaltrials-gov-nct03520569-octreotide-v1"></a>

## ClinicalTrials.gov record NCT03520569

> PeptideScanner retained ClinicalTrials.gov record NCT03520569 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-13, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct03520569-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-05-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03520569-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03520569-octreotide-v1
- Content SHA-256: `ad3f70dca15d65a888889d933448ada913a0a61fb91f6615407b98dcb4115b54`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03520569 ([`ctg-observation-nct03520569-2022-05-13-aef68a1777b1`](#source-ctg-observation-nct03520569-2022-05-13-aef68a1777b1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03520569 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-13, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03520569-2022-05-13-aef68a1777b1`](#source-ctg-observation-nct03520569-2022-05-13-aef68a1777b1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03520569 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-13, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03520569-2022-05-13-aef68a1777b1`](#source-ctg-observation-nct03520569-2022-05-13-aef68a1777b1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03520569-2022-05-13-aef68a1777b1`](#source-ctg-observation-nct03520569-2022-05-13-aef68a1777b1))

### Sources

<a id="source-ctg-observation-nct03520569-2022-05-13-aef68a1777b1"></a>
- **ClinicalTrials.gov record NCT03520569 · retained source version 2022-05-13:aef68a1777b1beef8c962318ea13e5e33c4d05d70d3091e2d94735baeeaed449** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03520569) (`ctg-observation-nct03520569-2022-05-13-aef68a1777b1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03520569." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03520569-octreotide-v1 SHA-256: ad3f70dca15d65a888889d933448ada913a0a61fb91f6615407b98dcb4115b54.

---

<a id="clinicaltrials-gov-nct03734627-octreotide-v1"></a>

## ClinicalTrials.gov record NCT03734627

> PeptideScanner retained ClinicalTrials.gov record NCT03734627 at 2026-07-30T19:59:58.328Z. Its registry update date was 2021-08-16, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct03734627-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-08-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03734627-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03734627-octreotide-v1
- Content SHA-256: `d03895740e9efcfcfde09f939170136de6c2cde67cdf0000e6229dab4aea130a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03734627 ([`ctg-observation-nct03734627-2021-08-16-98ec54abb8ae`](#source-ctg-observation-nct03734627-2021-08-16-98ec54abb8ae))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03734627 at 2026-07-30T19:59:58.328Z. Its registry update date was 2021-08-16, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03734627-2021-08-16-98ec54abb8ae`](#source-ctg-observation-nct03734627-2021-08-16-98ec54abb8ae))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03734627 at 2026-07-30T19:59:58.328Z. Its registry update date was 2021-08-16, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03734627-2021-08-16-98ec54abb8ae`](#source-ctg-observation-nct03734627-2021-08-16-98ec54abb8ae))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03734627-2021-08-16-98ec54abb8ae`](#source-ctg-observation-nct03734627-2021-08-16-98ec54abb8ae))

### Sources

<a id="source-ctg-observation-nct03734627-2021-08-16-98ec54abb8ae"></a>
- **ClinicalTrials.gov record NCT03734627 · retained source version 2021-08-16:98ec54abb8ae6bdd03ef86ee9d2caf9dd61367482d8c1de51c4ff7bbb1362013** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03734627) (`ctg-observation-nct03734627-2021-08-16-98ec54abb8ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03734627." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03734627-octreotide-v1 SHA-256: d03895740e9efcfcfde09f939170136de6c2cde67cdf0000e6229dab4aea130a.

---

<a id="clinicaltrials-gov-nct03846180-octreotide-v1"></a>

## ClinicalTrials.gov record NCT03846180

> PeptideScanner retained ClinicalTrials.gov record NCT03846180 at 2026-07-30T20:48:52.443Z. Its registry update date was 2019-07-05, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct03846180-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-07-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03846180-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03846180-octreotide-v1
- Content SHA-256: `ef2a29d65b770da97e6b558f8f5d18856748b446ff0d0ff4f2f05c8619780dd4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03846180 ([`ctg-observation-nct03846180-2019-07-05-3d9c66cb24d3`](#source-ctg-observation-nct03846180-2019-07-05-3d9c66cb24d3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03846180 at 2026-07-30T20:48:52.443Z. Its registry update date was 2019-07-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03846180-2019-07-05-3d9c66cb24d3`](#source-ctg-observation-nct03846180-2019-07-05-3d9c66cb24d3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03846180 at 2026-07-30T20:48:52.443Z. Its registry update date was 2019-07-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03846180-2019-07-05-3d9c66cb24d3`](#source-ctg-observation-nct03846180-2019-07-05-3d9c66cb24d3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03846180-2019-07-05-3d9c66cb24d3`](#source-ctg-observation-nct03846180-2019-07-05-3d9c66cb24d3))

### Sources

<a id="source-ctg-observation-nct03846180-2019-07-05-3d9c66cb24d3"></a>
- **ClinicalTrials.gov record NCT03846180 · retained source version 2019-07-05:3d9c66cb24d37e347241729c627f5547f83b478e24e9e4794c8f776ae40fe073** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03846180) (`ctg-observation-nct03846180-2019-07-05-3d9c66cb24d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03846180." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03846180-octreotide-v1 SHA-256: ef2a29d65b770da97e6b558f8f5d18856748b446ff0d0ff4f2f05c8619780dd4.

---

<a id="clinicaltrials-gov-nct03879694-octreotide-v1"></a>

## ClinicalTrials.gov record NCT03879694

> PeptideScanner retained ClinicalTrials.gov record NCT03879694 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct03879694-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03879694-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03879694-octreotide-v1
- Content SHA-256: `6f386b283b1fdee61cb8136040ccc58356083448863fd7cbcb020affb727e185`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03879694 ([`ctg-observation-nct03879694-2026-02-06-8ecbe3e85336`](#source-ctg-observation-nct03879694-2026-02-06-8ecbe3e85336))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03879694 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03879694-2026-02-06-8ecbe3e85336`](#source-ctg-observation-nct03879694-2026-02-06-8ecbe3e85336))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03879694 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct03879694-2026-02-06-8ecbe3e85336`](#source-ctg-observation-nct03879694-2026-02-06-8ecbe3e85336))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03879694-2026-02-06-8ecbe3e85336`](#source-ctg-observation-nct03879694-2026-02-06-8ecbe3e85336))

### Sources

<a id="source-ctg-observation-nct03879694-2026-02-06-8ecbe3e85336"></a>
- **ClinicalTrials.gov record NCT03879694 · retained source version 2026-02-06:8ecbe3e8533677e2c453e2f0701c7406a248e06a769aefa8788274435f752c9b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03879694) (`ctg-observation-nct03879694-2026-02-06-8ecbe3e85336`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03879694." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct03879694-octreotide-v1 SHA-256: 6f386b283b1fdee61cb8136040ccc58356083448863fd7cbcb020affb727e185.

---

<a id="clinicaltrials-gov-nct04129255-octreotide-v1"></a>

## ClinicalTrials.gov record NCT04129255

> PeptideScanner retained ClinicalTrials.gov record NCT04129255 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-10, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct04129255-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-09-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04129255-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct04129255-octreotide-v1
- Content SHA-256: `c5d86df79f3afdd21270f6eb6746fa665676d61244f0b9731e5e181a4b1318ce`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04129255 ([`ctg-observation-nct04129255-2020-09-10-78b1233d39fb`](#source-ctg-observation-nct04129255-2020-09-10-78b1233d39fb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04129255 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-10, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct04129255-2020-09-10-78b1233d39fb`](#source-ctg-observation-nct04129255-2020-09-10-78b1233d39fb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04129255 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-10, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct04129255-2020-09-10-78b1233d39fb`](#source-ctg-observation-nct04129255-2020-09-10-78b1233d39fb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04129255-2020-09-10-78b1233d39fb`](#source-ctg-observation-nct04129255-2020-09-10-78b1233d39fb))

### Sources

<a id="source-ctg-observation-nct04129255-2020-09-10-78b1233d39fb"></a>
- **ClinicalTrials.gov record NCT04129255 · retained source version 2020-09-10:78b1233d39fb5be2fcb42303141f27ea3d0bdec4c60055718c3c5be65ca61c25** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04129255) (`ctg-observation-nct04129255-2020-09-10-78b1233d39fb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04129255." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct04129255-octreotide-v1 SHA-256: c5d86df79f3afdd21270f6eb6746fa665676d61244f0b9731e5e181a4b1318ce.

---

<a id="clinicaltrials-gov-nct04281680-octreotide-v1"></a>

## ClinicalTrials.gov record NCT04281680

> PeptideScanner retained ClinicalTrials.gov record NCT04281680 at 2026-07-30T20:32:04.760Z. Its registry update date was 2020-02-24, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct04281680-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-02-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04281680-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct04281680-octreotide-v1
- Content SHA-256: `025dad9bef49e138eefcc811500c424e4943906e56a9ca488c5c6ee95653e0f4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04281680 ([`ctg-observation-nct04281680-2020-02-24-bf320c7f3aa5`](#source-ctg-observation-nct04281680-2020-02-24-bf320c7f3aa5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04281680 at 2026-07-30T20:32:04.760Z. Its registry update date was 2020-02-24, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct04281680-2020-02-24-bf320c7f3aa5`](#source-ctg-observation-nct04281680-2020-02-24-bf320c7f3aa5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04281680 at 2026-07-30T20:32:04.760Z. Its registry update date was 2020-02-24, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct04281680-2020-02-24-bf320c7f3aa5`](#source-ctg-observation-nct04281680-2020-02-24-bf320c7f3aa5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04281680-2020-02-24-bf320c7f3aa5`](#source-ctg-observation-nct04281680-2020-02-24-bf320c7f3aa5))

### Sources

<a id="source-ctg-observation-nct04281680-2020-02-24-bf320c7f3aa5"></a>
- **ClinicalTrials.gov record NCT04281680 · retained source version 2020-02-24:bf320c7f3aa508a6ef708c8d8305f28a0ecbd3ab6820b41e13aa3bc35d490893** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04281680) (`ctg-observation-nct04281680-2020-02-24-bf320c7f3aa5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04281680." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct04281680-octreotide-v1 SHA-256: 025dad9bef49e138eefcc811500c424e4943906e56a9ca488c5c6ee95653e0f4.

---

<a id="clinicaltrials-gov-nct06193616-octreotide-v1"></a>

## ClinicalTrials.gov record NCT06193616

> PeptideScanner retained ClinicalTrials.gov record NCT06193616 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-05, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct06193616-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06193616-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct06193616-octreotide-v1
- Content SHA-256: `adc98b2b938315ed662f0cbd8576c2fe6d4d3b424b47dbcacefa3c948bfa3a34`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06193616 ([`ctg-observation-nct06193616-2025-09-05-326905b1f47f`](#source-ctg-observation-nct06193616-2025-09-05-326905b1f47f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06193616 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct06193616-2025-09-05-326905b1f47f`](#source-ctg-observation-nct06193616-2025-09-05-326905b1f47f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06193616 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-05, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct06193616-2025-09-05-326905b1f47f`](#source-ctg-observation-nct06193616-2025-09-05-326905b1f47f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06193616-2025-09-05-326905b1f47f`](#source-ctg-observation-nct06193616-2025-09-05-326905b1f47f))

### Sources

<a id="source-ctg-observation-nct06193616-2025-09-05-326905b1f47f"></a>
- **ClinicalTrials.gov record NCT06193616 · retained source version 2025-09-05:326905b1f47f92268eb70be33771d95d766ed8bb64a907ae5be9234e05c859c6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06193616) (`ctg-observation-nct06193616-2025-09-05-326905b1f47f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06193616." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct06193616-octreotide-v1 SHA-256: adc98b2b938315ed662f0cbd8576c2fe6d4d3b424b47dbcacefa3c948bfa3a34.

---

<a id="clinicaltrials-gov-nct06974344-octreotide-v1"></a>

## ClinicalTrials.gov record NCT06974344

> PeptideScanner retained ClinicalTrials.gov record NCT06974344 at 2026-07-30T18:27:14.162Z. Its registry update date was 2025-05-15, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct06974344-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-05-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06974344-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct06974344-octreotide-v1
- Content SHA-256: `3044d6344f423146820193ce116854cd94588dbe556e28caa25eb505609cc097`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06974344 ([`ctg-observation-nct06974344-2025-05-15-a19339934e0e`](#source-ctg-observation-nct06974344-2025-05-15-a19339934e0e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06974344 at 2026-07-30T18:27:14.162Z. Its registry update date was 2025-05-15, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct06974344-2025-05-15-a19339934e0e`](#source-ctg-observation-nct06974344-2025-05-15-a19339934e0e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06974344 at 2026-07-30T18:27:14.162Z. Its registry update date was 2025-05-15, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct06974344-2025-05-15-a19339934e0e`](#source-ctg-observation-nct06974344-2025-05-15-a19339934e0e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06974344-2025-05-15-a19339934e0e`](#source-ctg-observation-nct06974344-2025-05-15-a19339934e0e))

### Sources

<a id="source-ctg-observation-nct06974344-2025-05-15-a19339934e0e"></a>
- **ClinicalTrials.gov record NCT06974344 · retained source version 2025-05-15:a19339934e0e91eef19b28093df2f4241e74fc98f1a7fbb3ea948c3002701e30** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06974344) (`ctg-observation-nct06974344-2025-05-15-a19339934e0e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06974344." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct06974344-octreotide-v1 SHA-256: 3044d6344f423146820193ce116854cd94588dbe556e28caa25eb505609cc097.

---

<a id="clinicaltrials-gov-nct07262957-octreotide-v1"></a>

## ClinicalTrials.gov record NCT07262957

> PeptideScanner retained ClinicalTrials.gov record NCT07262957 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct07262957-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07262957-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct07262957-octreotide-v1
- Content SHA-256: `8abb72ece087081f04c3951302133f9e1f59eb587f7f3df736cf84a38b93a41d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07262957 ([`ctg-observation-nct07262957-2025-12-22-f3fc02d04d29`](#source-ctg-observation-nct07262957-2025-12-22-f3fc02d04d29))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07262957 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct07262957-2025-12-22-f3fc02d04d29`](#source-ctg-observation-nct07262957-2025-12-22-f3fc02d04d29))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07262957 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct07262957-2025-12-22-f3fc02d04d29`](#source-ctg-observation-nct07262957-2025-12-22-f3fc02d04d29))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07262957-2025-12-22-f3fc02d04d29`](#source-ctg-observation-nct07262957-2025-12-22-f3fc02d04d29))

### Sources

<a id="source-ctg-observation-nct07262957-2025-12-22-f3fc02d04d29"></a>
- **ClinicalTrials.gov record NCT07262957 · retained source version 2025-12-22:f3fc02d04d296e70449b1cf72e14282a4758b47a1d16b2adecf330790d31dbdd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07262957) (`ctg-observation-nct07262957-2025-12-22-f3fc02d04d29`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07262957." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct07262957-octreotide-v1 SHA-256: 8abb72ece087081f04c3951302133f9e1f59eb587f7f3df736cf84a38b93a41d.

---

<a id="clinicaltrials-gov-nct07460908-octreotide-v1"></a>

## ClinicalTrials.gov record NCT07460908

> PeptideScanner retained ClinicalTrials.gov record NCT07460908 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was octreotide.

- Evidence object: `story:clinicaltrials-gov-nct07460908-octreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07460908-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct07460908-octreotide-v1
- Content SHA-256: `40b57ac5f65dae3f1af7e2c8874ce7145bda67b9717db68bd2e682ed3ae509db`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07460908 ([`ctg-observation-nct07460908-2026-03-10-54ef295416fc`](#source-ctg-observation-nct07460908-2026-03-10-54ef295416fc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07460908 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct07460908-2026-03-10-54ef295416fc`](#source-ctg-observation-nct07460908-2026-03-10-54ef295416fc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07460908 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was octreotide. ([`ctg-observation-nct07460908-2026-03-10-54ef295416fc`](#source-ctg-observation-nct07460908-2026-03-10-54ef295416fc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07460908-2026-03-10-54ef295416fc`](#source-ctg-observation-nct07460908-2026-03-10-54ef295416fc))

### Sources

<a id="source-ctg-observation-nct07460908-2026-03-10-54ef295416fc"></a>
- **ClinicalTrials.gov record NCT07460908 · retained source version 2026-03-10:54ef295416fcca9dae8259e7672e267ccfcedf6b5b2f9ac76beecfc21a28ea18** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07460908) (`ctg-observation-nct07460908-2026-03-10-54ef295416fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07460908." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#clinicaltrials-gov-nct07460908-octreotide-v1 SHA-256: 40b57ac5f65dae3f1af7e2c8874ce7145bda67b9717db68bd2e682ed3ae509db.

---

<a id="dailymed-label-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-v1"></a>

## Octreotide DailyMed SPL version 1

> DailyMed lists Structured Product Labeling version 1 for the reviewed Octreotide label family with a published date of 2023-12-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1:v1`
- Evidence domain: Regulatory
- Date in source: 2023-12-01
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#dailymed-label-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-v1
- Content SHA-256: `b41598e6358a3801dc30be26cbd92210b72d1e9631f027a8c1f04b42afe5d2ef`

### Claims and source pins

#### Headline

Octreotide DailyMed SPL version 1 ([`dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-history`](#source-dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-history))

#### Summary

DailyMed lists Structured Product Labeling version 1 for the reviewed Octreotide label family with a published date of 2023-12-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-history`](#source-dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 1 for the reviewed Octreotide label family with a published date of 2023-12-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-history`](#source-dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-history`](#source-dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-history))

### Sources

<a id="source-dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-history"></a>
- **DailyMed SPL SET ID 387d7f8d-9762-4f6b-99e1-bdc50b8a1633 · SPL version 1 · published 2023-12-01 · retained ZIP SHA-256 d2ecd5dd6d50dd1541f443c0cd9c2b47e7848f0e97ab0a8764d65915780a4798** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=387d7f8d-9762-4f6b-99e1-bdc50b8a1633&version=1) (`dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Octreotide DailyMed SPL version 1." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#dailymed-label-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v1-v1 SHA-256: b41598e6358a3801dc30be26cbd92210b72d1e9631f027a8c1f04b42afe5d2ef.

---

<a id="dailymed-label-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-v1"></a>

## Octreotide DailyMed SPL version 2

> DailyMed lists Structured Product Labeling version 2 for the reviewed Octreotide label family with a published date of 2026-02-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-02
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#dailymed-label-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-v1
- Content SHA-256: `e8ad47eaecd35e7a4c9a4d19dece11daf6a2aead16b53365ac9eee7214b0fdcb`

### Claims and source pins

#### Headline

Octreotide DailyMed SPL version 2 ([`dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-history`](#source-dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-history))

#### Summary

DailyMed lists Structured Product Labeling version 2 for the reviewed Octreotide label family with a published date of 2026-02-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-history`](#source-dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 2 for the reviewed Octreotide label family with a published date of 2026-02-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-history`](#source-dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-history`](#source-dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-history))

### Sources

<a id="source-dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-history"></a>
- **DailyMed SPL SET ID 387d7f8d-9762-4f6b-99e1-bdc50b8a1633 · SPL version 2 · published 2026-02-02 · retained ZIP SHA-256 ef983a96082e22365e0421c84727fd1f1c4edba8f562651f80efe7222ff70491** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=387d7f8d-9762-4f6b-99e1-bdc50b8a1633&version=2) (`dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Octreotide DailyMed SPL version 2." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#dailymed-label-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2-v1 SHA-256: e8ad47eaecd35e7a4c9a4d19dece11daf6a2aead16b53365ac9eee7214b0fdcb.

---

<a id="fda-drugs-anda075957-v1"></a>

## Drugs@FDA application ANDA075957

> The official Drugs@FDA dataset lists original submission 1 for ANDA 075957 with status AP dated 2005-10-03, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda075957:v1`
- Evidence domain: Regulatory
- Date in source: 2005-10-03
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda075957/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda075957-v1
- Content SHA-256: `9c33367b609b3d3baa7913ce100e202242d2b2f148201451a4441c0cc47a3cbf`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA075957 ([`fda-drugs-anda075957-2005-10-03-c284ebe1a260`](#source-fda-drugs-anda075957-2005-10-03-c284ebe1a260))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 075957 with status AP dated 2005-10-03, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda075957-2005-10-03-c284ebe1a260`](#source-fda-drugs-anda075957-2005-10-03-c284ebe1a260))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 075957 with status AP dated 2005-10-03, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda075957-2005-10-03-c284ebe1a260`](#source-fda-drugs-anda075957-2005-10-03-c284ebe1a260))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda075957-2005-10-03-c284ebe1a260`](#source-fda-drugs-anda075957-2005-10-03-c284ebe1a260))

### Sources

<a id="source-fda-drugs-anda075957-2005-10-03-c284ebe1a260"></a>
- **Drugs@FDA application ANDA075957 · original submission status AP · 2005-10-03 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA075957%22&limit=1) (`fda-drugs-anda075957-2005-10-03-c284ebe1a260`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA075957." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda075957-v1 SHA-256: 9c33367b609b3d3baa7913ce100e202242d2b2f148201451a4441c0cc47a3cbf.

---

<a id="fda-drugs-anda075959-v1"></a>

## Drugs@FDA application ANDA075959

> The official Drugs@FDA dataset lists original submission 1 for ANDA 075959 with status AP dated 2005-11-21, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda075959:v1`
- Evidence domain: Regulatory
- Date in source: 2005-11-21
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda075959/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda075959-v1
- Content SHA-256: `2b0c90747487b880124298d0af1a9ed16221d8df0d6ab607cede1e52510d2ba7`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA075959 ([`fda-drugs-anda075959-2005-11-21-1521042e10cc`](#source-fda-drugs-anda075959-2005-11-21-1521042e10cc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 075959 with status AP dated 2005-11-21, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda075959-2005-11-21-1521042e10cc`](#source-fda-drugs-anda075959-2005-11-21-1521042e10cc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 075959 with status AP dated 2005-11-21, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda075959-2005-11-21-1521042e10cc`](#source-fda-drugs-anda075959-2005-11-21-1521042e10cc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda075959-2005-11-21-1521042e10cc`](#source-fda-drugs-anda075959-2005-11-21-1521042e10cc))

### Sources

<a id="source-fda-drugs-anda075959-2005-11-21-1521042e10cc"></a>
- **Drugs@FDA application ANDA075959 · original submission status AP · 2005-11-21 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA075959%22&limit=1) (`fda-drugs-anda075959-2005-11-21-1521042e10cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA075959." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda075959-v1 SHA-256: 2b0c90747487b880124298d0af1a9ed16221d8df0d6ab607cede1e52510d2ba7.

---

<a id="fda-drugs-anda076313-v1"></a>

## Drugs@FDA application ANDA076313

> The official Drugs@FDA dataset lists original submission 1 for ANDA 076313 with status AP dated 2005-03-28, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda076313:v1`
- Evidence domain: Regulatory
- Date in source: 2005-03-28
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda076313/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda076313-v1
- Content SHA-256: `de0c2cadded0132963da595d48052ae567b2192c72fa6e07c9cd44383d72526a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA076313 ([`fda-drugs-anda076313-2005-03-28-256c127ffbf0`](#source-fda-drugs-anda076313-2005-03-28-256c127ffbf0))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 076313 with status AP dated 2005-03-28, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda076313-2005-03-28-256c127ffbf0`](#source-fda-drugs-anda076313-2005-03-28-256c127ffbf0))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 076313 with status AP dated 2005-03-28, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda076313-2005-03-28-256c127ffbf0`](#source-fda-drugs-anda076313-2005-03-28-256c127ffbf0))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda076313-2005-03-28-256c127ffbf0`](#source-fda-drugs-anda076313-2005-03-28-256c127ffbf0))

### Sources

<a id="source-fda-drugs-anda076313-2005-03-28-256c127ffbf0"></a>
- **Drugs@FDA application ANDA076313 · original submission status AP · 2005-03-28 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA076313%22&limit=1) (`fda-drugs-anda076313-2005-03-28-256c127ffbf0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA076313." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda076313-v1 SHA-256: de0c2cadded0132963da595d48052ae567b2192c72fa6e07c9cd44383d72526a.

---

<a id="fda-drugs-anda076330-v1"></a>

## Drugs@FDA application ANDA076330

> The official Drugs@FDA dataset lists original submission 1 for ANDA 076330 with status AP dated 2005-04-08, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda076330:v1`
- Evidence domain: Regulatory
- Date in source: 2005-04-08
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda076330/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda076330-v1
- Content SHA-256: `a04cd425694717dba017cd98c80e01fe4f26baa1785345a6e22d847461815e32`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA076330 ([`fda-drugs-anda076330-2005-04-08-3b3a38e01dae`](#source-fda-drugs-anda076330-2005-04-08-3b3a38e01dae))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 076330 with status AP dated 2005-04-08, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda076330-2005-04-08-3b3a38e01dae`](#source-fda-drugs-anda076330-2005-04-08-3b3a38e01dae))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 076330 with status AP dated 2005-04-08, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda076330-2005-04-08-3b3a38e01dae`](#source-fda-drugs-anda076330-2005-04-08-3b3a38e01dae))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda076330-2005-04-08-3b3a38e01dae`](#source-fda-drugs-anda076330-2005-04-08-3b3a38e01dae))

### Sources

<a id="source-fda-drugs-anda076330-2005-04-08-3b3a38e01dae"></a>
- **Drugs@FDA application ANDA076330 · original submission status AP · 2005-04-08 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA076330%22&limit=1) (`fda-drugs-anda076330-2005-04-08-3b3a38e01dae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA076330." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda076330-v1 SHA-256: a04cd425694717dba017cd98c80e01fe4f26baa1785345a6e22d847461815e32.

---

<a id="fda-drugs-anda077329-v1"></a>

## Drugs@FDA application ANDA077329

> The official Drugs@FDA dataset lists original submission 1 for ANDA 077329 with status AP dated 2008-03-04, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda077329:v1`
- Evidence domain: Regulatory
- Date in source: 2008-03-04
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda077329/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077329-v1
- Content SHA-256: `78bc8c1004c765292a57c7148458765a470f2df54e1efe460adb72121afe5a9d`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA077329 ([`fda-drugs-anda077329-2008-03-04-875e64b99ad3`](#source-fda-drugs-anda077329-2008-03-04-875e64b99ad3))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 077329 with status AP dated 2008-03-04, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077329-2008-03-04-875e64b99ad3`](#source-fda-drugs-anda077329-2008-03-04-875e64b99ad3))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 077329 with status AP dated 2008-03-04, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077329-2008-03-04-875e64b99ad3`](#source-fda-drugs-anda077329-2008-03-04-875e64b99ad3))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda077329-2008-03-04-875e64b99ad3`](#source-fda-drugs-anda077329-2008-03-04-875e64b99ad3))

### Sources

<a id="source-fda-drugs-anda077329-2008-03-04-875e64b99ad3"></a>
- **Drugs@FDA application ANDA077329 · original submission status AP · 2008-03-04 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA077329%22&limit=1) (`fda-drugs-anda077329-2008-03-04-875e64b99ad3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA077329." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077329-v1 SHA-256: 78bc8c1004c765292a57c7148458765a470f2df54e1efe460adb72121afe5a9d.

---

<a id="fda-drugs-anda077330-v1"></a>

## Drugs@FDA application ANDA077330

> The official Drugs@FDA dataset lists original submission 1 for ANDA 077330 with status AP dated 2008-03-04, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda077330:v1`
- Evidence domain: Regulatory
- Date in source: 2008-03-04
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda077330/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077330-v1
- Content SHA-256: `cbffa6a1a8e05ddecacfdfee7ed0b0cb351ff727ff3904addf7546c7b1c559cb`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA077330 ([`fda-drugs-anda077330-2008-03-04-fef52438f295`](#source-fda-drugs-anda077330-2008-03-04-fef52438f295))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 077330 with status AP dated 2008-03-04, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077330-2008-03-04-fef52438f295`](#source-fda-drugs-anda077330-2008-03-04-fef52438f295))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 077330 with status AP dated 2008-03-04, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077330-2008-03-04-fef52438f295`](#source-fda-drugs-anda077330-2008-03-04-fef52438f295))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda077330-2008-03-04-fef52438f295`](#source-fda-drugs-anda077330-2008-03-04-fef52438f295))

### Sources

<a id="source-fda-drugs-anda077330-2008-03-04-fef52438f295"></a>
- **Drugs@FDA application ANDA077330 · original submission status AP · 2008-03-04 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA077330%22&limit=1) (`fda-drugs-anda077330-2008-03-04-fef52438f295`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA077330." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077330-v1 SHA-256: cbffa6a1a8e05ddecacfdfee7ed0b0cb351ff727ff3904addf7546c7b1c559cb.

---

<a id="fda-drugs-anda077331-v1"></a>

## Drugs@FDA application ANDA077331

> The official Drugs@FDA dataset lists original submission 1 for ANDA 077331 with status AP dated 2008-03-04, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda077331:v1`
- Evidence domain: Regulatory
- Date in source: 2008-03-04
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda077331/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077331-v1
- Content SHA-256: `b5e9d964f582f8e94a53aad70d3f66bfa251833a2b8ee71255d9fc4d6db4644f`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA077331 ([`fda-drugs-anda077331-2008-03-04-a5c111dd5bdf`](#source-fda-drugs-anda077331-2008-03-04-a5c111dd5bdf))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 077331 with status AP dated 2008-03-04, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077331-2008-03-04-a5c111dd5bdf`](#source-fda-drugs-anda077331-2008-03-04-a5c111dd5bdf))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 077331 with status AP dated 2008-03-04, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077331-2008-03-04-a5c111dd5bdf`](#source-fda-drugs-anda077331-2008-03-04-a5c111dd5bdf))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda077331-2008-03-04-a5c111dd5bdf`](#source-fda-drugs-anda077331-2008-03-04-a5c111dd5bdf))

### Sources

<a id="source-fda-drugs-anda077331-2008-03-04-a5c111dd5bdf"></a>
- **Drugs@FDA application ANDA077331 · original submission status AP · 2008-03-04 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA077331%22&limit=1) (`fda-drugs-anda077331-2008-03-04-a5c111dd5bdf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA077331." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077331-v1 SHA-256: b5e9d964f582f8e94a53aad70d3f66bfa251833a2b8ee71255d9fc4d6db4644f.

---

<a id="fda-drugs-anda077372-v1"></a>

## Drugs@FDA application ANDA077372

> The official Drugs@FDA dataset lists original submission 1 for ANDA 077372 with status AP dated 2007-08-14, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda077372:v1`
- Evidence domain: Regulatory
- Date in source: 2007-08-14
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda077372/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077372-v1
- Content SHA-256: `24152cbd4bdd1eea34bb45bdd855f1765f74f6bab1b862dcb0dff049b14d45ba`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA077372 ([`fda-drugs-anda077372-2007-08-14-71022f2d9488`](#source-fda-drugs-anda077372-2007-08-14-71022f2d9488))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 077372 with status AP dated 2007-08-14, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077372-2007-08-14-71022f2d9488`](#source-fda-drugs-anda077372-2007-08-14-71022f2d9488))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 077372 with status AP dated 2007-08-14, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077372-2007-08-14-71022f2d9488`](#source-fda-drugs-anda077372-2007-08-14-71022f2d9488))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda077372-2007-08-14-71022f2d9488`](#source-fda-drugs-anda077372-2007-08-14-71022f2d9488))

### Sources

<a id="source-fda-drugs-anda077372-2007-08-14-71022f2d9488"></a>
- **Drugs@FDA application ANDA077372 · original submission status AP · 2007-08-14 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA077372%22&limit=1) (`fda-drugs-anda077372-2007-08-14-71022f2d9488`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA077372." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077372-v1 SHA-256: 24152cbd4bdd1eea34bb45bdd855f1765f74f6bab1b862dcb0dff049b14d45ba.

---

<a id="fda-drugs-anda077373-v1"></a>

## Drugs@FDA application ANDA077373

> The official Drugs@FDA dataset lists original submission 1 for ANDA 077373 with status AP dated 2007-08-14, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda077373:v1`
- Evidence domain: Regulatory
- Date in source: 2007-08-14
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda077373/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077373-v1
- Content SHA-256: `4b074a867ee29d16463033e7f4f5f8e976bbb0b22828ac7259a3c1ff8b58315f`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA077373 ([`fda-drugs-anda077373-2007-08-14-f509b0d33a0c`](#source-fda-drugs-anda077373-2007-08-14-f509b0d33a0c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 077373 with status AP dated 2007-08-14, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077373-2007-08-14-f509b0d33a0c`](#source-fda-drugs-anda077373-2007-08-14-f509b0d33a0c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 077373 with status AP dated 2007-08-14, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077373-2007-08-14-f509b0d33a0c`](#source-fda-drugs-anda077373-2007-08-14-f509b0d33a0c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda077373-2007-08-14-f509b0d33a0c`](#source-fda-drugs-anda077373-2007-08-14-f509b0d33a0c))

### Sources

<a id="source-fda-drugs-anda077373-2007-08-14-f509b0d33a0c"></a>
- **Drugs@FDA application ANDA077373 · original submission status AP · 2007-08-14 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA077373%22&limit=1) (`fda-drugs-anda077373-2007-08-14-f509b0d33a0c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA077373." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077373-v1 SHA-256: 4b074a867ee29d16463033e7f4f5f8e976bbb0b22828ac7259a3c1ff8b58315f.

---

<a id="fda-drugs-anda077450-v1"></a>

## Drugs@FDA application ANDA077450

> The official Drugs@FDA dataset lists original submission 1 for ANDA 077450 with status AP dated 2006-02-10, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda077450:v1`
- Evidence domain: Regulatory
- Date in source: 2006-02-10
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda077450/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077450-v1
- Content SHA-256: `48583cea728be5f8885324099ab23859930abbf07ff47a8dea8cfd3853fa12e6`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA077450 ([`fda-drugs-anda077450-2006-02-10-51a71e5ba5e4`](#source-fda-drugs-anda077450-2006-02-10-51a71e5ba5e4))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 077450 with status AP dated 2006-02-10, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077450-2006-02-10-51a71e5ba5e4`](#source-fda-drugs-anda077450-2006-02-10-51a71e5ba5e4))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 077450 with status AP dated 2006-02-10, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077450-2006-02-10-51a71e5ba5e4`](#source-fda-drugs-anda077450-2006-02-10-51a71e5ba5e4))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda077450-2006-02-10-51a71e5ba5e4`](#source-fda-drugs-anda077450-2006-02-10-51a71e5ba5e4))

### Sources

<a id="source-fda-drugs-anda077450-2006-02-10-51a71e5ba5e4"></a>
- **Drugs@FDA application ANDA077450 · original submission status AP · 2006-02-10 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA077450%22&limit=1) (`fda-drugs-anda077450-2006-02-10-51a71e5ba5e4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA077450." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077450-v1 SHA-256: 48583cea728be5f8885324099ab23859930abbf07ff47a8dea8cfd3853fa12e6.

---

<a id="fda-drugs-anda077457-v1"></a>

## Drugs@FDA application ANDA077457

> The official Drugs@FDA dataset lists original submission 1 for ANDA 077457 with status AP dated 2006-02-10, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda077457:v1`
- Evidence domain: Regulatory
- Date in source: 2006-02-10
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda077457/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077457-v1
- Content SHA-256: `d4b4405e06f99440239f69c73499c6444c9a38146526049fe5f0aa48422591b8`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA077457 ([`fda-drugs-anda077457-2006-02-10-734222338ef3`](#source-fda-drugs-anda077457-2006-02-10-734222338ef3))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 077457 with status AP dated 2006-02-10, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077457-2006-02-10-734222338ef3`](#source-fda-drugs-anda077457-2006-02-10-734222338ef3))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 077457 with status AP dated 2006-02-10, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda077457-2006-02-10-734222338ef3`](#source-fda-drugs-anda077457-2006-02-10-734222338ef3))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda077457-2006-02-10-734222338ef3`](#source-fda-drugs-anda077457-2006-02-10-734222338ef3))

### Sources

<a id="source-fda-drugs-anda077457-2006-02-10-734222338ef3"></a>
- **Drugs@FDA application ANDA077457 · original submission status AP · 2006-02-10 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA077457%22&limit=1) (`fda-drugs-anda077457-2006-02-10-734222338ef3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA077457." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda077457-v1 SHA-256: d4b4405e06f99440239f69c73499c6444c9a38146526049fe5f0aa48422591b8.

---

<a id="fda-drugs-anda079198-v1"></a>

## Drugs@FDA application ANDA079198

> The official Drugs@FDA dataset lists original submission 1 for ANDA 079198 with status AP dated 2011-02-10, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda079198:v1`
- Evidence domain: Regulatory
- Date in source: 2011-02-10
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda079198/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda079198-v1
- Content SHA-256: `245cf06e410b12e32c88a7ae674ea369ba541b5ce04dc0b1b8135dcb8081736a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA079198 ([`fda-drugs-anda079198-2011-02-10-4a15ee3f3541`](#source-fda-drugs-anda079198-2011-02-10-4a15ee3f3541))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 079198 with status AP dated 2011-02-10, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda079198-2011-02-10-4a15ee3f3541`](#source-fda-drugs-anda079198-2011-02-10-4a15ee3f3541))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 079198 with status AP dated 2011-02-10, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda079198-2011-02-10-4a15ee3f3541`](#source-fda-drugs-anda079198-2011-02-10-4a15ee3f3541))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda079198-2011-02-10-4a15ee3f3541`](#source-fda-drugs-anda079198-2011-02-10-4a15ee3f3541))

### Sources

<a id="source-fda-drugs-anda079198-2011-02-10-4a15ee3f3541"></a>
- **Drugs@FDA application ANDA079198 · original submission status AP · 2011-02-10 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA079198%22&limit=1) (`fda-drugs-anda079198-2011-02-10-4a15ee3f3541`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA079198." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda079198-v1 SHA-256: 245cf06e410b12e32c88a7ae674ea369ba541b5ce04dc0b1b8135dcb8081736a.

---

<a id="fda-drugs-anda090834-v1"></a>

## Drugs@FDA application ANDA090834

> The official Drugs@FDA dataset lists original submission 1 for ANDA 090834 with status AP dated 2013-11-12, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda090834:v1`
- Evidence domain: Regulatory
- Date in source: 2013-11-12
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda090834/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda090834-v1
- Content SHA-256: `705532e6e6229260454184f6f3e3b69fc17130553f5d8da1be44894e14e63bf7`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA090834 ([`fda-drugs-anda090834-2013-11-12-fc6d08ca5d7b`](#source-fda-drugs-anda090834-2013-11-12-fc6d08ca5d7b))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 090834 with status AP dated 2013-11-12, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda090834-2013-11-12-fc6d08ca5d7b`](#source-fda-drugs-anda090834-2013-11-12-fc6d08ca5d7b))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 090834 with status AP dated 2013-11-12, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda090834-2013-11-12-fc6d08ca5d7b`](#source-fda-drugs-anda090834-2013-11-12-fc6d08ca5d7b))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda090834-2013-11-12-fc6d08ca5d7b`](#source-fda-drugs-anda090834-2013-11-12-fc6d08ca5d7b))

### Sources

<a id="source-fda-drugs-anda090834-2013-11-12-fc6d08ca5d7b"></a>
- **Drugs@FDA application ANDA090834 · original submission status AP · 2013-11-12 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA090834%22&limit=1) (`fda-drugs-anda090834-2013-11-12-fc6d08ca5d7b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA090834." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda090834-v1 SHA-256: 705532e6e6229260454184f6f3e3b69fc17130553f5d8da1be44894e14e63bf7.

---

<a id="fda-drugs-anda090985-v1"></a>

## Drugs@FDA application ANDA090985

> The official Drugs@FDA dataset lists original submission 1 for ANDA 090985 with status AP dated 2011-05-11, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda090985:v1`
- Evidence domain: Regulatory
- Date in source: 2011-05-11
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda090985/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda090985-v1
- Content SHA-256: `6679885435c50cbb21ad18640dc193ca83921fd3a7f7e3e59fc854e7db1710ff`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA090985 ([`fda-drugs-anda090985-2011-05-11-6e7d5b345dd6`](#source-fda-drugs-anda090985-2011-05-11-6e7d5b345dd6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 090985 with status AP dated 2011-05-11, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda090985-2011-05-11-6e7d5b345dd6`](#source-fda-drugs-anda090985-2011-05-11-6e7d5b345dd6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 090985 with status AP dated 2011-05-11, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda090985-2011-05-11-6e7d5b345dd6`](#source-fda-drugs-anda090985-2011-05-11-6e7d5b345dd6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda090985-2011-05-11-6e7d5b345dd6`](#source-fda-drugs-anda090985-2011-05-11-6e7d5b345dd6))

### Sources

<a id="source-fda-drugs-anda090985-2011-05-11-6e7d5b345dd6"></a>
- **Drugs@FDA application ANDA090985 · original submission status AP · 2011-05-11 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA090985%22&limit=1) (`fda-drugs-anda090985-2011-05-11-6e7d5b345dd6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA090985." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda090985-v1 SHA-256: 6679885435c50cbb21ad18640dc193ca83921fd3a7f7e3e59fc854e7db1710ff.

---

<a id="fda-drugs-anda090986-v1"></a>

## Drugs@FDA application ANDA090986

> The official Drugs@FDA dataset lists original submission 1 for ANDA 090986 with status AP dated 2011-05-11, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda090986:v1`
- Evidence domain: Regulatory
- Date in source: 2011-05-11
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda090986/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda090986-v1
- Content SHA-256: `c9209ad2fbafaffcf716ed61aebad0ae417f71d937e24100b293ce4d56c974a9`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA090986 ([`fda-drugs-anda090986-2011-05-11-c288ad3f2c0f`](#source-fda-drugs-anda090986-2011-05-11-c288ad3f2c0f))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 090986 with status AP dated 2011-05-11, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda090986-2011-05-11-c288ad3f2c0f`](#source-fda-drugs-anda090986-2011-05-11-c288ad3f2c0f))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 090986 with status AP dated 2011-05-11, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda090986-2011-05-11-c288ad3f2c0f`](#source-fda-drugs-anda090986-2011-05-11-c288ad3f2c0f))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda090986-2011-05-11-c288ad3f2c0f`](#source-fda-drugs-anda090986-2011-05-11-c288ad3f2c0f))

### Sources

<a id="source-fda-drugs-anda090986-2011-05-11-c288ad3f2c0f"></a>
- **Drugs@FDA application ANDA090986 · original submission status AP · 2011-05-11 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA090986%22&limit=1) (`fda-drugs-anda090986-2011-05-11-c288ad3f2c0f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA090986." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda090986-v1 SHA-256: c9209ad2fbafaffcf716ed61aebad0ae417f71d937e24100b293ce4d56c974a9.

---

<a id="fda-drugs-anda091041-v1"></a>

## Drugs@FDA application ANDA091041

> The official Drugs@FDA dataset lists original submission 1 for ANDA 091041 with status AP dated 2013-11-12, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda091041:v1`
- Evidence domain: Regulatory
- Date in source: 2013-11-12
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda091041/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda091041-v1
- Content SHA-256: `aa73ca7ffb5dc5c80bd899e316551583c0e76a14622ec879a0b138cefd9c7068`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA091041 ([`fda-drugs-anda091041-2013-11-12-84d574538562`](#source-fda-drugs-anda091041-2013-11-12-84d574538562))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 091041 with status AP dated 2013-11-12, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda091041-2013-11-12-84d574538562`](#source-fda-drugs-anda091041-2013-11-12-84d574538562))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 091041 with status AP dated 2013-11-12, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda091041-2013-11-12-84d574538562`](#source-fda-drugs-anda091041-2013-11-12-84d574538562))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda091041-2013-11-12-84d574538562`](#source-fda-drugs-anda091041-2013-11-12-84d574538562))

### Sources

<a id="source-fda-drugs-anda091041-2013-11-12-84d574538562"></a>
- **Drugs@FDA application ANDA091041 · original submission status AP · 2013-11-12 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA091041%22&limit=1) (`fda-drugs-anda091041-2013-11-12-84d574538562`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA091041." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda091041-v1 SHA-256: aa73ca7ffb5dc5c80bd899e316551583c0e76a14622ec879a0b138cefd9c7068.

---

<a id="fda-drugs-anda203765-v1"></a>

## Drugs@FDA application ANDA203765

> The official Drugs@FDA dataset lists original submission 1 for ANDA 203765 with status AP dated 2018-09-07, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda203765:v1`
- Evidence domain: Regulatory
- Date in source: 2018-09-07
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda203765/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda203765-v1
- Content SHA-256: `8092bbeb9d52f616a1ce7f8a3345b79e2a94c257694b97f8432eb8b41a0a1640`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA203765 ([`fda-drugs-anda203765-2018-09-07-4485e34f2fd5`](#source-fda-drugs-anda203765-2018-09-07-4485e34f2fd5))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 203765 with status AP dated 2018-09-07, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda203765-2018-09-07-4485e34f2fd5`](#source-fda-drugs-anda203765-2018-09-07-4485e34f2fd5))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 203765 with status AP dated 2018-09-07, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda203765-2018-09-07-4485e34f2fd5`](#source-fda-drugs-anda203765-2018-09-07-4485e34f2fd5))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda203765-2018-09-07-4485e34f2fd5`](#source-fda-drugs-anda203765-2018-09-07-4485e34f2fd5))

### Sources

<a id="source-fda-drugs-anda203765-2018-09-07-4485e34f2fd5"></a>
- **Drugs@FDA application ANDA203765 · original submission status AP · 2018-09-07 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA203765%22&limit=1) (`fda-drugs-anda203765-2018-09-07-4485e34f2fd5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA203765." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda203765-v1 SHA-256: 8092bbeb9d52f616a1ce7f8a3345b79e2a94c257694b97f8432eb8b41a0a1640.

---

<a id="fda-drugs-anda204669-v1"></a>

## Drugs@FDA application ANDA204669

> The official Drugs@FDA dataset lists original submission 1 for ANDA 204669 with status AP dated 2018-12-27, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda204669:v1`
- Evidence domain: Regulatory
- Date in source: 2018-12-27
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda204669/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda204669-v1
- Content SHA-256: `4380b427ec15d49b1ab47ce9e858aeea4c92da454327e3adcd10e66f12f59518`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA204669 ([`fda-drugs-anda204669-2018-12-27-1b0000bfe4d3`](#source-fda-drugs-anda204669-2018-12-27-1b0000bfe4d3))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 204669 with status AP dated 2018-12-27, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda204669-2018-12-27-1b0000bfe4d3`](#source-fda-drugs-anda204669-2018-12-27-1b0000bfe4d3))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 204669 with status AP dated 2018-12-27, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda204669-2018-12-27-1b0000bfe4d3`](#source-fda-drugs-anda204669-2018-12-27-1b0000bfe4d3))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda204669-2018-12-27-1b0000bfe4d3`](#source-fda-drugs-anda204669-2018-12-27-1b0000bfe4d3))

### Sources

<a id="source-fda-drugs-anda204669-2018-12-27-1b0000bfe4d3"></a>
- **Drugs@FDA application ANDA204669 · original submission status AP · 2018-12-27 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA204669%22&limit=1) (`fda-drugs-anda204669-2018-12-27-1b0000bfe4d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA204669." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda204669-v1 SHA-256: 4380b427ec15d49b1ab47ce9e858aeea4c92da454327e3adcd10e66f12f59518.

---

<a id="fda-drugs-anda210317-v1"></a>

## Drugs@FDA application ANDA210317

> The official Drugs@FDA dataset lists original submission 1 for ANDA 210317 with status AP dated 2023-12-05, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda210317:v1`
- Evidence domain: Regulatory
- Date in source: 2023-12-05
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda210317/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda210317-v1
- Content SHA-256: `1f182923c17be2c165380555b0416c47b830634ed06746754d903785183d2f96`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA210317 ([`fda-drugs-anda210317-2023-12-05-5133a63f261c`](#source-fda-drugs-anda210317-2023-12-05-5133a63f261c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 210317 with status AP dated 2023-12-05, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda210317-2023-12-05-5133a63f261c`](#source-fda-drugs-anda210317-2023-12-05-5133a63f261c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 210317 with status AP dated 2023-12-05, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda210317-2023-12-05-5133a63f261c`](#source-fda-drugs-anda210317-2023-12-05-5133a63f261c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda210317-2023-12-05-5133a63f261c`](#source-fda-drugs-anda210317-2023-12-05-5133a63f261c))

### Sources

<a id="source-fda-drugs-anda210317-2023-12-05-5133a63f261c"></a>
- **Drugs@FDA application ANDA210317 · original submission status AP · 2023-12-05 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA210317%22&limit=1) (`fda-drugs-anda210317-2023-12-05-5133a63f261c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA210317." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda210317-v1 SHA-256: 1f182923c17be2c165380555b0416c47b830634ed06746754d903785183d2f96.

---

<a id="fda-drugs-anda216589-v1"></a>

## Drugs@FDA application ANDA216589

> The official Drugs@FDA dataset lists original submission 1 for ANDA 216589 with status AP dated 2025-12-12, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda216589:v1`
- Evidence domain: Regulatory
- Date in source: 2025-12-12
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda216589/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda216589-v1
- Content SHA-256: `94b5ed447a1b5380720e0ed10b2f9c8e77fdf30e3c01531dff75f82a785aba51`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA216589 ([`fda-drugs-anda216589-2025-12-12-b2debf11c7cc`](#source-fda-drugs-anda216589-2025-12-12-b2debf11c7cc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 216589 with status AP dated 2025-12-12, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda216589-2025-12-12-b2debf11c7cc`](#source-fda-drugs-anda216589-2025-12-12-b2debf11c7cc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 216589 with status AP dated 2025-12-12, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda216589-2025-12-12-b2debf11c7cc`](#source-fda-drugs-anda216589-2025-12-12-b2debf11c7cc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda216589-2025-12-12-b2debf11c7cc`](#source-fda-drugs-anda216589-2025-12-12-b2debf11c7cc))

### Sources

<a id="source-fda-drugs-anda216589-2025-12-12-b2debf11c7cc"></a>
- **Drugs@FDA application ANDA216589 · original submission status AP · 2025-12-12 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA216589%22&limit=1) (`fda-drugs-anda216589-2025-12-12-b2debf11c7cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA216589." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda216589-v1 SHA-256: 94b5ed447a1b5380720e0ed10b2f9c8e77fdf30e3c01531dff75f82a785aba51.

---

<a id="fda-drugs-anda216807-v1"></a>

## Drugs@FDA application ANDA216807

> The official Drugs@FDA dataset lists original submission 1 for ANDA 216807 with status AP dated 2023-06-13, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda216807:v1`
- Evidence domain: Regulatory
- Date in source: 2023-06-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda216807/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda216807-v1
- Content SHA-256: `e892294494346957a5e0cc0b7457fb2406004dd2a42c881c14fb51fee4133f5a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA216807 ([`fda-drugs-anda216807-2023-06-13-1443e958ca18`](#source-fda-drugs-anda216807-2023-06-13-1443e958ca18))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 216807 with status AP dated 2023-06-13, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda216807-2023-06-13-1443e958ca18`](#source-fda-drugs-anda216807-2023-06-13-1443e958ca18))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 216807 with status AP dated 2023-06-13, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda216807-2023-06-13-1443e958ca18`](#source-fda-drugs-anda216807-2023-06-13-1443e958ca18))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda216807-2023-06-13-1443e958ca18`](#source-fda-drugs-anda216807-2023-06-13-1443e958ca18))

### Sources

<a id="source-fda-drugs-anda216807-2023-06-13-1443e958ca18"></a>
- **Drugs@FDA application ANDA216807 · original submission status AP · 2023-06-13 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA216807%22&limit=1) (`fda-drugs-anda216807-2023-06-13-1443e958ca18`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA216807." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda216807-v1 SHA-256: e892294494346957a5e0cc0b7457fb2406004dd2a42c881c14fb51fee4133f5a.

---

<a id="fda-drugs-anda216839-v1"></a>

## Drugs@FDA application ANDA216839

> The official Drugs@FDA dataset lists original submission 1 for ANDA 216839 with status AP dated 2023-06-22, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda216839:v1`
- Evidence domain: Regulatory
- Date in source: 2023-06-22
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda216839/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda216839-v1
- Content SHA-256: `2b9fcee3d3065d7e36c7f45e3409eacad65838816d3300070e67b5075e382789`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA216839 ([`fda-drugs-anda216839-2023-06-22-9880ba7cd1fc`](#source-fda-drugs-anda216839-2023-06-22-9880ba7cd1fc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 216839 with status AP dated 2023-06-22, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda216839-2023-06-22-9880ba7cd1fc`](#source-fda-drugs-anda216839-2023-06-22-9880ba7cd1fc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 216839 with status AP dated 2023-06-22, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda216839-2023-06-22-9880ba7cd1fc`](#source-fda-drugs-anda216839-2023-06-22-9880ba7cd1fc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda216839-2023-06-22-9880ba7cd1fc`](#source-fda-drugs-anda216839-2023-06-22-9880ba7cd1fc))

### Sources

<a id="source-fda-drugs-anda216839-2023-06-22-9880ba7cd1fc"></a>
- **Drugs@FDA application ANDA216839 · original submission status AP · 2023-06-22 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA216839%22&limit=1) (`fda-drugs-anda216839-2023-06-22-9880ba7cd1fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA216839." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda216839-v1 SHA-256: 2b9fcee3d3065d7e36c7f45e3409eacad65838816d3300070e67b5075e382789.

---

<a id="fda-drugs-anda217860-v1"></a>

## Drugs@FDA application ANDA217860

> The official Drugs@FDA dataset lists original submission 1 for ANDA 217860 with status AP dated 2024-05-02, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda217860:v1`
- Evidence domain: Regulatory
- Date in source: 2024-05-02
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda217860/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda217860-v1
- Content SHA-256: `9995964632f7fcd9582c83d5f23013cfea394af83dc969999a9fbbbd74ce0ecc`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA217860 ([`fda-drugs-anda217860-2024-05-02-2cb41e15257a`](#source-fda-drugs-anda217860-2024-05-02-2cb41e15257a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 217860 with status AP dated 2024-05-02, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda217860-2024-05-02-2cb41e15257a`](#source-fda-drugs-anda217860-2024-05-02-2cb41e15257a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 217860 with status AP dated 2024-05-02, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-anda217860-2024-05-02-2cb41e15257a`](#source-fda-drugs-anda217860-2024-05-02-2cb41e15257a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda217860-2024-05-02-2cb41e15257a`](#source-fda-drugs-anda217860-2024-05-02-2cb41e15257a))

### Sources

<a id="source-fda-drugs-anda217860-2024-05-02-2cb41e15257a"></a>
- **Drugs@FDA application ANDA217860 · original submission status AP · 2024-05-02 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217860%22&limit=1) (`fda-drugs-anda217860-2024-05-02-2cb41e15257a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA217860." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-anda217860-v1 SHA-256: 9995964632f7fcd9582c83d5f23013cfea394af83dc969999a9fbbbd74ce0ecc.

---

<a id="fda-drugs-nda019667-v1"></a>

## Drugs@FDA application NDA019667

> The official Drugs@FDA dataset lists original submission 1 for NDA 019667 with status AP dated 1988-10-21, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda019667:v1`
- Evidence domain: Regulatory
- Date in source: 1988-10-21
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda019667/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-nda019667-v1
- Content SHA-256: `d40414b1ce5581adbdb93596ab7c178283d101ed8a3ed7b37dbbaacbb4d6a478`

### Claims and source pins

#### Headline

Drugs@FDA application NDA019667 ([`fda-drugs-nda019667-1988-10-21-b49b130f234b`](#source-fda-drugs-nda019667-1988-10-21-b49b130f234b))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 019667 with status AP dated 1988-10-21, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-nda019667-1988-10-21-b49b130f234b`](#source-fda-drugs-nda019667-1988-10-21-b49b130f234b))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 019667 with status AP dated 1988-10-21, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-nda019667-1988-10-21-b49b130f234b`](#source-fda-drugs-nda019667-1988-10-21-b49b130f234b))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda019667-1988-10-21-b49b130f234b`](#source-fda-drugs-nda019667-1988-10-21-b49b130f234b))

### Sources

<a id="source-fda-drugs-nda019667-1988-10-21-b49b130f234b"></a>
- **Drugs@FDA application NDA019667 · original submission status AP · 1988-10-21 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019667%22&limit=1) (`fda-drugs-nda019667-1988-10-21-b49b130f234b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA019667." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-nda019667-v1 SHA-256: d40414b1ce5581adbdb93596ab7c178283d101ed8a3ed7b37dbbaacbb4d6a478.

---

<a id="fda-drugs-nda021008-v1"></a>

## Drugs@FDA application NDA021008

> The official Drugs@FDA dataset lists original submission 1 for NDA 021008 with status AP dated 1998-11-25, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021008:v1`
- Evidence domain: Regulatory
- Date in source: 1998-11-25
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021008/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-nda021008-v1
- Content SHA-256: `7934f222055a7a8d08247d97698e0e2fc84c60d68973581475e71983bbd17ccb`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021008 ([`fda-drugs-nda021008-1998-11-25-5b27b64436f4`](#source-fda-drugs-nda021008-1998-11-25-5b27b64436f4))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021008 with status AP dated 1998-11-25, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-nda021008-1998-11-25-5b27b64436f4`](#source-fda-drugs-nda021008-1998-11-25-5b27b64436f4))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021008 with status AP dated 1998-11-25, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-nda021008-1998-11-25-5b27b64436f4`](#source-fda-drugs-nda021008-1998-11-25-5b27b64436f4))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021008-1998-11-25-5b27b64436f4`](#source-fda-drugs-nda021008-1998-11-25-5b27b64436f4))

### Sources

<a id="source-fda-drugs-nda021008-1998-11-25-5b27b64436f4"></a>
- **Drugs@FDA application NDA021008 · original submission status AP · 1998-11-25 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021008%22&limit=1) (`fda-drugs-nda021008-1998-11-25-5b27b64436f4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021008." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-nda021008-v1 SHA-256: 7934f222055a7a8d08247d97698e0e2fc84c60d68973581475e71983bbd17ccb.

---

<a id="fda-drugs-nda208232-v1"></a>

## Drugs@FDA application NDA208232

> The official Drugs@FDA dataset lists original submission 1 for NDA 208232 with status AP dated 2020-06-26, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda208232:v1`
- Evidence domain: Regulatory
- Date in source: 2020-06-26
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda208232/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-nda208232-v1
- Content SHA-256: `769a0766a9bffdda4e51b147209b695acd3689cce154ae90ce6a8c50ee899541`

### Claims and source pins

#### Headline

Drugs@FDA application NDA208232 ([`fda-drugs-nda208232-2020-06-26-da026b3e2a4a`](#source-fda-drugs-nda208232-2020-06-26-da026b3e2a4a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 208232 with status AP dated 2020-06-26, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-nda208232-2020-06-26-da026b3e2a4a`](#source-fda-drugs-nda208232-2020-06-26-da026b3e2a4a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 208232 with status AP dated 2020-06-26, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-nda208232-2020-06-26-da026b3e2a4a`](#source-fda-drugs-nda208232-2020-06-26-da026b3e2a4a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda208232-2020-06-26-da026b3e2a4a`](#source-fda-drugs-nda208232-2020-06-26-da026b3e2a4a))

### Sources

<a id="source-fda-drugs-nda208232-2020-06-26-da026b3e2a4a"></a>
- **Drugs@FDA application NDA208232 · original submission status AP · 2020-06-26 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA208232%22&limit=1) (`fda-drugs-nda208232-2020-06-26-da026b3e2a4a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA208232." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-nda208232-v1 SHA-256: 769a0766a9bffdda4e51b147209b695acd3689cce154ae90ce6a8c50ee899541.

---

<a id="fda-drugs-nda213224-v1"></a>

## Drugs@FDA application NDA213224

> The official Drugs@FDA dataset lists original submission 1 for NDA 213224 with status AP dated 2024-09-27, and names octreotide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda213224:v1`
- Evidence domain: Regulatory
- Date in source: 2024-09-27
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda213224/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-nda213224-v1
- Content SHA-256: `9afd831ae801d65d9cc6fbde43f9ecca0a7a95b5e63b35e7ff13ccdaaec8649e`

### Claims and source pins

#### Headline

Drugs@FDA application NDA213224 ([`fda-drugs-nda213224-2024-09-27-08bf6f091098`](#source-fda-drugs-nda213224-2024-09-27-08bf6f091098))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 213224 with status AP dated 2024-09-27, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-nda213224-2024-09-27-08bf6f091098`](#source-fda-drugs-nda213224-2024-09-27-08bf6f091098))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 213224 with status AP dated 2024-09-27, and names octreotide acetate among the application record's active ingredients. ([`fda-drugs-nda213224-2024-09-27-08bf6f091098`](#source-fda-drugs-nda213224-2024-09-27-08bf6f091098))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda213224-2024-09-27-08bf6f091098`](#source-fda-drugs-nda213224-2024-09-27-08bf6f091098))

### Sources

<a id="source-fda-drugs-nda213224-2024-09-27-08bf6f091098"></a>
- **Drugs@FDA application NDA213224 · original submission status AP · 2024-09-27 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA213224%22&limit=1) (`fda-drugs-nda213224-2024-09-27-08bf6f091098`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA213224." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-drugs-nda213224-v1 SHA-256: 9afd831ae801d65d9cc6fbde43f9ecca0a7a95b5e63b35e7ff13ccdaaec8649e.

---

<a id="fda-enforcement-d-0058-2023-v1"></a>

## FDA enforcement report D-0058-2023

> FDA's dated enforcement report D-0058-2023 lists Class I and source status Terminated for Viatris Inc. PeptideScanner connects the report to reviewed application ANDA079198 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0058-2023:v1`
- Evidence domain: Safety
- Date in source: 2022-11-16
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0058-2023/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-enforcement-d-0058-2023-v1
- Content SHA-256: `3b143df39c0ce63620fa1d4dc63477751fbda34c314738f661e84cbb95545af9`

### Claims and source pins

#### Headline

FDA enforcement report D-0058-2023 ([`fda-enforcement-d-0058-2023-a937086fc205`](#source-fda-enforcement-d-0058-2023-a937086fc205))

#### Summary

FDA's dated enforcement report D-0058-2023 lists Class I and source status Terminated for Viatris Inc. PeptideScanner connects the report to reviewed application ANDA079198 through exact openFDA application-number annotations. ([`fda-enforcement-d-0058-2023-a937086fc205`](#source-fda-enforcement-d-0058-2023-a937086fc205))

#### Paragraph 1

FDA's dated enforcement report D-0058-2023 lists Class I and source status Terminated for Viatris Inc. PeptideScanner connects the report to reviewed application ANDA079198 through exact openFDA application-number annotations. ([`fda-enforcement-d-0058-2023-a937086fc205`](#source-fda-enforcement-d-0058-2023-a937086fc205))

#### Paragraph 2

FDA's source-reported reason is: Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe. ([`fda-enforcement-d-0058-2023-a937086fc205`](#source-fda-enforcement-d-0058-2023-a937086fc205))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0058-2023-a937086fc205`](#source-fda-enforcement-d-0058-2023-a937086fc205))

### Sources

<a id="source-fda-enforcement-d-0058-2023-a937086fc205"></a>
- **FDA enforcement report D-0058-2023 · Class I · report date 2022-11-16 · source status Terminated** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0058-2023%22&limit=1) (`fda-enforcement-d-0058-2023-a937086fc205`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0058-2023." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-enforcement-d-0058-2023-v1 SHA-256: 3b143df39c0ce63620fa1d4dc63477751fbda34c314738f661e84cbb95545af9.

---

<a id="fda-enforcement-d-0404-2026-v1"></a>

## FDA enforcement report D-0404-2026

> FDA's dated enforcement report D-0404-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0404-2026:v1`
- Evidence domain: Safety
- Date in source: 2026-04-01
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0404-2026/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-enforcement-d-0404-2026-v1
- Content SHA-256: `c5b3843216de035ed71d8177949a1330c97f636d4bbe2cd5354213c387cc518b`

### Claims and source pins

#### Headline

FDA enforcement report D-0404-2026 ([`fda-enforcement-d-0404-2026-3cd4daf8b65e`](#source-fda-enforcement-d-0404-2026-3cd4daf8b65e))

#### Summary

FDA's dated enforcement report D-0404-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations. ([`fda-enforcement-d-0404-2026-3cd4daf8b65e`](#source-fda-enforcement-d-0404-2026-3cd4daf8b65e))

#### Paragraph 1

FDA's dated enforcement report D-0404-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations. ([`fda-enforcement-d-0404-2026-3cd4daf8b65e`](#source-fda-enforcement-d-0404-2026-3cd4daf8b65e))

#### Paragraph 2

FDA's source-reported reason is: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer. ([`fda-enforcement-d-0404-2026-3cd4daf8b65e`](#source-fda-enforcement-d-0404-2026-3cd4daf8b65e))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0404-2026-3cd4daf8b65e`](#source-fda-enforcement-d-0404-2026-3cd4daf8b65e))

### Sources

<a id="source-fda-enforcement-d-0404-2026-3cd4daf8b65e"></a>
- **FDA enforcement report D-0404-2026 · Class II · report date 2026-04-01 · source status Ongoing** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0404-2026%22&limit=1) (`fda-enforcement-d-0404-2026-3cd4daf8b65e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0404-2026." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-enforcement-d-0404-2026-v1 SHA-256: c5b3843216de035ed71d8177949a1330c97f636d4bbe2cd5354213c387cc518b.

---

<a id="fda-enforcement-d-0405-2026-v1"></a>

## FDA enforcement report D-0405-2026

> FDA's dated enforcement report D-0405-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0405-2026:v1`
- Evidence domain: Safety
- Date in source: 2026-04-01
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0405-2026/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-enforcement-d-0405-2026-v1
- Content SHA-256: `64cc22bf65f20bc115055edd2df7bfefbd85ea6232b18dc1946aefc3a6e321af`

### Claims and source pins

#### Headline

FDA enforcement report D-0405-2026 ([`fda-enforcement-d-0405-2026-0a835bef258e`](#source-fda-enforcement-d-0405-2026-0a835bef258e))

#### Summary

FDA's dated enforcement report D-0405-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations. ([`fda-enforcement-d-0405-2026-0a835bef258e`](#source-fda-enforcement-d-0405-2026-0a835bef258e))

#### Paragraph 1

FDA's dated enforcement report D-0405-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations. ([`fda-enforcement-d-0405-2026-0a835bef258e`](#source-fda-enforcement-d-0405-2026-0a835bef258e))

#### Paragraph 2

FDA's source-reported reason is: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer. ([`fda-enforcement-d-0405-2026-0a835bef258e`](#source-fda-enforcement-d-0405-2026-0a835bef258e))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0405-2026-0a835bef258e`](#source-fda-enforcement-d-0405-2026-0a835bef258e))

### Sources

<a id="source-fda-enforcement-d-0405-2026-0a835bef258e"></a>
- **FDA enforcement report D-0405-2026 · Class II · report date 2026-04-01 · source status Ongoing** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0405-2026%22&limit=1) (`fda-enforcement-d-0405-2026-0a835bef258e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0405-2026." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-enforcement-d-0405-2026-v1 SHA-256: 64cc22bf65f20bc115055edd2df7bfefbd85ea6232b18dc1946aefc3a6e321af.

---

<a id="fda-enforcement-d-0406-2026-v1"></a>

## FDA enforcement report D-0406-2026

> FDA's dated enforcement report D-0406-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0406-2026:v1`
- Evidence domain: Safety
- Date in source: 2026-04-01
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0406-2026/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-enforcement-d-0406-2026-v1
- Content SHA-256: `47eddefedc6575d0a9e3fc6838368fbc8e4c0376b9698549fce89ef3f9a1d345`

### Claims and source pins

#### Headline

FDA enforcement report D-0406-2026 ([`fda-enforcement-d-0406-2026-5d9e3af16859`](#source-fda-enforcement-d-0406-2026-5d9e3af16859))

#### Summary

FDA's dated enforcement report D-0406-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations. ([`fda-enforcement-d-0406-2026-5d9e3af16859`](#source-fda-enforcement-d-0406-2026-5d9e3af16859))

#### Paragraph 1

FDA's dated enforcement report D-0406-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations. ([`fda-enforcement-d-0406-2026-5d9e3af16859`](#source-fda-enforcement-d-0406-2026-5d9e3af16859))

#### Paragraph 2

FDA's source-reported reason is: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer. ([`fda-enforcement-d-0406-2026-5d9e3af16859`](#source-fda-enforcement-d-0406-2026-5d9e3af16859))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0406-2026-5d9e3af16859`](#source-fda-enforcement-d-0406-2026-5d9e3af16859))

### Sources

<a id="source-fda-enforcement-d-0406-2026-5d9e3af16859"></a>
- **FDA enforcement report D-0406-2026 · Class II · report date 2026-04-01 · source status Ongoing** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0406-2026%22&limit=1) (`fda-enforcement-d-0406-2026-5d9e3af16859`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0406-2026." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-enforcement-d-0406-2026-v1 SHA-256: 47eddefedc6575d0a9e3fc6838368fbc8e4c0376b9698549fce89ef3f9a1d345.

---

<a id="fda-enforcement-d-0519-2026-v1"></a>

## FDA enforcement report D-0519-2026

> FDA's dated enforcement report D-0519-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0519-2026:v1`
- Evidence domain: Safety
- Date in source: 2026-05-13
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0519-2026/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-enforcement-d-0519-2026-v1
- Content SHA-256: `8d5c9797ec9bd9f46704484626726de41d53df59fc19350c3e8072e36940eb08`

### Claims and source pins

#### Headline

FDA enforcement report D-0519-2026 ([`fda-enforcement-d-0519-2026-703cb5d30dc9`](#source-fda-enforcement-d-0519-2026-703cb5d30dc9))

#### Summary

FDA's dated enforcement report D-0519-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations. ([`fda-enforcement-d-0519-2026-703cb5d30dc9`](#source-fda-enforcement-d-0519-2026-703cb5d30dc9))

#### Paragraph 1

FDA's dated enforcement report D-0519-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations. ([`fda-enforcement-d-0519-2026-703cb5d30dc9`](#source-fda-enforcement-d-0519-2026-703cb5d30dc9))

#### Paragraph 2

FDA's source-reported reason is: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer. ([`fda-enforcement-d-0519-2026-703cb5d30dc9`](#source-fda-enforcement-d-0519-2026-703cb5d30dc9))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0519-2026-703cb5d30dc9`](#source-fda-enforcement-d-0519-2026-703cb5d30dc9))

### Sources

<a id="source-fda-enforcement-d-0519-2026-703cb5d30dc9"></a>
- **FDA enforcement report D-0519-2026 · Class II · report date 2026-05-13 · source status Ongoing** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0519-2026%22&limit=1) (`fda-enforcement-d-0519-2026-703cb5d30dc9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0519-2026." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#fda-enforcement-d-0519-2026-v1 SHA-256: 8d5c9797ec9bd9f46704484626726de41d53df59fc19350c3e8072e36940eb08.

---

<a id="federal-register-2017-25920-v1"></a>

## Federal Register notice 2017-25920

> The Federal Register published notice 2017-25920, attributed to FDA and its parent HHS department, on 2017-12-01. Its official title is “Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.

- Evidence object: `story:federal-register-2017-25920:v1`
- Evidence domain: Regulatory
- Date in source: 2017-12-01
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2017-25920/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-2017-25920-v1
- Content SHA-256: `5508141e9588486791ca771ed378b8ee98af442c4ea954084532ad826a4c020f`

### Claims and source pins

#### Headline

Federal Register notice 2017-25920 ([`federal-register-2017-25920-572e86104ece`](#source-federal-register-2017-25920-572e86104ece))

#### Summary

The Federal Register published notice 2017-25920, attributed to FDA and its parent HHS department, on 2017-12-01. Its official title is “Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide. ([`federal-register-2017-25920-572e86104ece`](#source-federal-register-2017-25920-572e86104ece))

#### Paragraph 1

The Federal Register published notice 2017-25920, attributed to FDA and its parent HHS department, on 2017-12-01. Its official title is “Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide. ([`federal-register-2017-25920-572e86104ece`](#source-federal-register-2017-25920-572e86104ece))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2017-25920-572e86104ece`](#source-federal-register-2017-25920-572e86104ece))

### Sources

<a id="source-federal-register-2017-25920-572e86104ece"></a>
- **Federal Register notice 2017-25920 · published 2017-12-01 · Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2017-12-01/pdf/2017-25920.pdf) (`federal-register-2017-25920-572e86104ece`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2017-25920." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-2017-25920-v1 SHA-256: 5508141e9588486791ca771ed378b8ee98af442c4ea954084532ad826a4c020f.

---

<a id="federal-register-2021-11575-v1"></a>

## Federal Register notice 2021-11575

> The Federal Register published notice 2021-11575, attributed to FDA and its parent HHS department, on 2021-06-02. Its official title is “Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.

- Evidence object: `story:federal-register-2021-11575:v1`
- Evidence domain: Regulatory
- Date in source: 2021-06-02
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2021-11575/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-2021-11575-v1
- Content SHA-256: `3cdbe1602117c04dce3d8bbe93c8cb1bac09a060369825e3b205c3e767ffe25a`

### Claims and source pins

#### Headline

Federal Register notice 2021-11575 ([`federal-register-2021-11575-3702765ad412`](#source-federal-register-2021-11575-3702765ad412))

#### Summary

The Federal Register published notice 2021-11575, attributed to FDA and its parent HHS department, on 2021-06-02. Its official title is “Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide. ([`federal-register-2021-11575-3702765ad412`](#source-federal-register-2021-11575-3702765ad412))

#### Paragraph 1

The Federal Register published notice 2021-11575, attributed to FDA and its parent HHS department, on 2021-06-02. Its official title is “Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide. ([`federal-register-2021-11575-3702765ad412`](#source-federal-register-2021-11575-3702765ad412))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2021-11575-3702765ad412`](#source-federal-register-2021-11575-3702765ad412))

### Sources

<a id="source-federal-register-2021-11575-3702765ad412"></a>
- **Federal Register notice 2021-11575 · published 2021-06-02 · Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2021-06-02/pdf/2021-11575.pdf) (`federal-register-2021-11575-3702765ad412`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2021-11575." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-2021-11575-v1 SHA-256: 3cdbe1602117c04dce3d8bbe93c8cb1bac09a060369825e3b205c3e767ffe25a.

---

<a id="federal-register-2026-03963-v1"></a>

## Federal Register notice 2026-03963

> The Federal Register published notice 2026-03963, attributed to FDA and its parent HHS department, on 2026-02-27. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide and Semaglutide.

- Evidence object: `story:federal-register-2026-03963:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-27
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2026-03963/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-2026-03963-v1
- Content SHA-256: `4488ae88cee410d9c9871e94d523591ed7629cb1e918361a617ec3162bdb816f`

### Claims and source pins

#### Headline

Federal Register notice 2026-03963 ([`federal-register-2026-03963-afc959dbc936`](#source-federal-register-2026-03963-afc959dbc936))

#### Summary

The Federal Register published notice 2026-03963, attributed to FDA and its parent HHS department, on 2026-02-27. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide and Semaglutide. ([`federal-register-2026-03963-afc959dbc936`](#source-federal-register-2026-03963-afc959dbc936))

#### Paragraph 1

The Federal Register published notice 2026-03963, attributed to FDA and its parent HHS department, on 2026-02-27. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide and Semaglutide. ([`federal-register-2026-03963-afc959dbc936`](#source-federal-register-2026-03963-afc959dbc936))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2026-03963-afc959dbc936`](#source-federal-register-2026-03963-afc959dbc936))

### Sources

<a id="source-federal-register-2026-03963-afc959dbc936"></a>
- **Federal Register notice 2026-03963 · published 2026-02-27 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2026-02-27/pdf/2026-03963.pdf) (`federal-register-2026-03963-afc959dbc936`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2026-03963." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-2026-03963-v1 SHA-256: 4488ae88cee410d9c9871e94d523591ed7629cb1e918361a617ec3162bdb816f.

---

<a id="federal-register-e6-17284-v1"></a>

## Federal Register notice E6-17284

> The Federal Register published notice E6-17284, attributed to FDA and its parent HHS department, on 2006-10-18. Its official title is “Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.

- Evidence object: `story:federal-register-e6-17284:v1`
- Evidence domain: Regulatory
- Date in source: 2006-10-18
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-e6-17284/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-e6-17284-v1
- Content SHA-256: `924f2daf17e976183f36bfda4ce1a0c1eff7c54ced5682a413f2135b60e140db`

### Claims and source pins

#### Headline

Federal Register notice E6-17284 ([`federal-register-e6-17284-20271bed9ddc`](#source-federal-register-e6-17284-20271bed9ddc))

#### Summary

The Federal Register published notice E6-17284, attributed to FDA and its parent HHS department, on 2006-10-18. Its official title is “Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide. ([`federal-register-e6-17284-20271bed9ddc`](#source-federal-register-e6-17284-20271bed9ddc))

#### Paragraph 1

The Federal Register published notice E6-17284, attributed to FDA and its parent HHS department, on 2006-10-18. Its official title is “Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide. ([`federal-register-e6-17284-20271bed9ddc`](#source-federal-register-e6-17284-20271bed9ddc))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e6-17284-20271bed9ddc`](#source-federal-register-e6-17284-20271bed9ddc))

### Sources

<a id="source-federal-register-e6-17284-20271bed9ddc"></a>
- **Federal Register notice E6-17284 · published 2006-10-18 · Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2006-10-18/pdf/E6-17284.pdf) (`federal-register-e6-17284-20271bed9ddc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E6-17284." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-e6-17284-v1 SHA-256: 924f2daf17e976183f36bfda4ce1a0c1eff7c54ced5682a413f2135b60e140db.

---

<a id="federal-register-e7-4877-v1"></a>

## Federal Register notice E7-4877

> The Federal Register published notice E7-4877, attributed to FDA and its parent HHS department, on 2007-03-19. Its official title is “Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.

- Evidence object: `story:federal-register-e7-4877:v1`
- Evidence domain: Regulatory
- Date in source: 2007-03-19
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-e7-4877/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-e7-4877-v1
- Content SHA-256: `258cde9fcb7f936af5c780ac74fde8c07f9bf4ae9e336acd679f43ef53dd5e62`

### Claims and source pins

#### Headline

Federal Register notice E7-4877 ([`federal-register-e7-4877-f1ce5f3c1c44`](#source-federal-register-e7-4877-f1ce5f3c1c44))

#### Summary

The Federal Register published notice E7-4877, attributed to FDA and its parent HHS department, on 2007-03-19. Its official title is “Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide. ([`federal-register-e7-4877-f1ce5f3c1c44`](#source-federal-register-e7-4877-f1ce5f3c1c44))

#### Paragraph 1

The Federal Register published notice E7-4877, attributed to FDA and its parent HHS department, on 2007-03-19. Its official title is “Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide. ([`federal-register-e7-4877-f1ce5f3c1c44`](#source-federal-register-e7-4877-f1ce5f3c1c44))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e7-4877-f1ce5f3c1c44`](#source-federal-register-e7-4877-f1ce5f3c1c44))

### Sources

<a id="source-federal-register-e7-4877-f1ce5f3c1c44"></a>
- **Federal Register notice E7-4877 · published 2007-03-19 · Pediatric Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2007-03-19/pdf/E7-4877.pdf) (`federal-register-e7-4877-f1ce5f3c1c44`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E7-4877." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-e7-4877-v1 SHA-256: 258cde9fcb7f936af5c780ac74fde8c07f9bf4ae9e336acd679f43ef53dd5e62.

---

<a id="federal-register-e8-24356-v1"></a>

## Federal Register notice E8-24356

> The Federal Register published notice E8-24356, attributed to FDA and its parent HHS department, on 2008-10-15. Its official title is “Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.

- Evidence object: `story:federal-register-e8-24356:v1`
- Evidence domain: Regulatory
- Date in source: 2008-10-15
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-e8-24356/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-e8-24356-v1
- Content SHA-256: `08548e87e7a5a8bbf4fa533e6d14adf43cc08e89106a46d7bd7c6fbc64878e32`

### Claims and source pins

#### Headline

Federal Register notice E8-24356 ([`federal-register-e8-24356-379bda7d34ca`](#source-federal-register-e8-24356-379bda7d34ca))

#### Summary

The Federal Register published notice E8-24356, attributed to FDA and its parent HHS department, on 2008-10-15. Its official title is “Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide. ([`federal-register-e8-24356-379bda7d34ca`](#source-federal-register-e8-24356-379bda7d34ca))

#### Paragraph 1

The Federal Register published notice E8-24356, attributed to FDA and its parent HHS department, on 2008-10-15. Its official title is “Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide. ([`federal-register-e8-24356-379bda7d34ca`](#source-federal-register-e8-24356-379bda7d34ca))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e8-24356-379bda7d34ca`](#source-federal-register-e8-24356-379bda7d34ca))

### Sources

<a id="source-federal-register-e8-24356-379bda7d34ca"></a>
- **Federal Register notice E8-24356 · published 2008-10-15 · Pediatric Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2008-10-15/pdf/E8-24356.pdf) (`federal-register-e8-24356-379bda7d34ca`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E8-24356." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#federal-register-e8-24356-v1 SHA-256: 08548e87e7a5a8bbf4fa533e6d14adf43cc08e89106a46d7bd7c6fbc64878e32.

---

<a id="pubmed-pmid-1397864-octreotide-v1"></a>

## \[Treatment of pseudocyst in chronic pancreatitis by puncture-drainage and octreotide combination\].

> PubMed lists PMID 1397864 in Gastroenterologie clinique et biologique as Case Reports, Letter, with publication-date metadata of 1992 (year precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1397864-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1397864-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1397864-octreotide-v1
- Content SHA-256: `4f30ecede597d7cbbd4d0e9244c7663af2eeb09100e638641cb6c3cbb7b7b666`

### Claims and source pins

#### Headline

\[Treatment of pseudocyst in chronic pancreatitis by puncture-drainage and octreotide combination\]. ([`pubmed-observation-pmid-1397864-2013-11-21-3f54f4857299`](#source-pubmed-observation-pmid-1397864-2013-11-21-3f54f4857299))

#### Summary

PubMed lists PMID 1397864 in Gastroenterologie clinique et biologique as Case Reports, Letter, with publication-date metadata of 1992 (year precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1397864-2013-11-21-3f54f4857299`](#source-pubmed-observation-pmid-1397864-2013-11-21-3f54f4857299))

#### Paragraph 1

PubMed lists PMID 1397864 in Gastroenterologie clinique et biologique as Case Reports, Letter, with publication-date metadata of 1992 (year precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1397864-2013-11-21-3f54f4857299`](#source-pubmed-observation-pmid-1397864-2013-11-21-3f54f4857299))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1397864-2013-11-21-3f54f4857299`](#source-pubmed-observation-pmid-1397864-2013-11-21-3f54f4857299))

### Sources

<a id="source-pubmed-observation-pmid-1397864-2013-11-21-3f54f4857299"></a>
- **\[Treatment of pseudocyst in chronic pancreatitis by puncture-drainage and octreotide combination\]. · retained source version 1:2013-11-21:current:3f54f4857299d762768443cc224de0d25da6f8cd319513a739617bf0d5e94469** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1397864/) (`pubmed-observation-pmid-1397864-2013-11-21-3f54f4857299`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Treatment of pseudocyst in chronic pancreatitis by puncture-drainage and octreotide combination\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1397864-octreotide-v1 SHA-256: 4f30ecede597d7cbbd4d0e9244c7663af2eeb09100e638641cb6c3cbb7b7b666.

---

<a id="pubmed-pmid-1519586-octreotide-v1"></a>

## Octreotide in the management of postoperative enterocutaneous fistulas and stress ulcer bleeding.

> PubMed lists PMID 1519586 in The American journal of gastroenterology as Case Reports, Journal Article, with publication-date metadata of 1992-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1519586-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1519586-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1519586-octreotide-v1
- Content SHA-256: `336e83bfc28f7a598dbd0d2736c1c88f83e39546c914db8a2ce090b8859f035a`

### Claims and source pins

#### Headline

Octreotide in the management of postoperative enterocutaneous fistulas and stress ulcer bleeding. ([`pubmed-observation-pmid-1519586-2013-11-21-7884a3a635a8`](#source-pubmed-observation-pmid-1519586-2013-11-21-7884a3a635a8))

#### Summary

PubMed lists PMID 1519586 in The American journal of gastroenterology as Case Reports, Journal Article, with publication-date metadata of 1992-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1519586-2013-11-21-7884a3a635a8`](#source-pubmed-observation-pmid-1519586-2013-11-21-7884a3a635a8))

#### Paragraph 1

PubMed lists PMID 1519586 in The American journal of gastroenterology as Case Reports, Journal Article, with publication-date metadata of 1992-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1519586-2013-11-21-7884a3a635a8`](#source-pubmed-observation-pmid-1519586-2013-11-21-7884a3a635a8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1519586-2013-11-21-7884a3a635a8`](#source-pubmed-observation-pmid-1519586-2013-11-21-7884a3a635a8))

### Sources

<a id="source-pubmed-observation-pmid-1519586-2013-11-21-7884a3a635a8"></a>
- **Octreotide in the management of postoperative enterocutaneous fistulas and stress ulcer bleeding. · retained source version 1:2013-11-21:current:7884a3a635a8f6b15e581de2c3b146933b75e89218f32178aec2757304947dd8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1519586/) (`pubmed-observation-pmid-1519586-2013-11-21-7884a3a635a8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Octreotide in the management of postoperative enterocutaneous fistulas and stress ulcer bleeding." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1519586-octreotide-v1 SHA-256: 336e83bfc28f7a598dbd0d2736c1c88f83e39546c914db8a2ce090b8859f035a.

---

<a id="pubmed-pmid-1523600-octreotide-v1"></a>

## \[Octreotide and vascular headache\].

> PubMed lists PMID 1523600 in Therapie as Letter, with publication-date metadata of 1992 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1523600-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1523600-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1523600-octreotide-v1
- Content SHA-256: `e6c05a0ac36f4df4f96715762888cf05f6b5c53a81320a2f7cb826c60cd2316a`

### Claims and source pins

#### Headline

\[Octreotide and vascular headache\]. ([`pubmed-observation-pmid-1523600-2013-11-21-e3d9ccfbfef8`](#source-pubmed-observation-pmid-1523600-2013-11-21-e3d9ccfbfef8))

#### Summary

PubMed lists PMID 1523600 in Therapie as Letter, with publication-date metadata of 1992 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1523600-2013-11-21-e3d9ccfbfef8`](#source-pubmed-observation-pmid-1523600-2013-11-21-e3d9ccfbfef8))

#### Paragraph 1

PubMed lists PMID 1523600 in Therapie as Letter, with publication-date metadata of 1992 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1523600-2013-11-21-e3d9ccfbfef8`](#source-pubmed-observation-pmid-1523600-2013-11-21-e3d9ccfbfef8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1523600-2013-11-21-e3d9ccfbfef8`](#source-pubmed-observation-pmid-1523600-2013-11-21-e3d9ccfbfef8))

### Sources

<a id="source-pubmed-observation-pmid-1523600-2013-11-21-e3d9ccfbfef8"></a>
- **\[Octreotide and vascular headache\]. · retained source version 1:2013-11-21:current:e3d9ccfbfef8117ef866e5d530c050efbff5601aaedad9614ae495b82d2d6ed2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1523600/) (`pubmed-observation-pmid-1523600-2013-11-21-e3d9ccfbfef8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Octreotide and vascular headache\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1523600-octreotide-v1 SHA-256: e6c05a0ac36f4df4f96715762888cf05f6b5c53a81320a2f7cb826c60cd2316a.

---

<a id="pubmed-pmid-15299335-octreotide-v1"></a>

## PubMed record PMID 15299335

> PeptideScanner retained PubMed bibliographic metadata for PMID 15299335 at 2026-07-30T22:40:22.107Z. PubMed recorded a metadata revision date of 2007-07-24 and an Entrez history date of 1995-01-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-15299335-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-07-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15299335-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-15299335-octreotide-v1
- Content SHA-256: `6c78d72bb01e5f634844628db1d997deace4f4efd79dec2219e4b76c17ec01e9`

### Claims and source pins

#### Headline

PubMed record PMID 15299335 ([`pubmed-observation-pmid-15299335-2007-07-24-288d1c3a2962`](#source-pubmed-observation-pmid-15299335-2007-07-24-288d1c3a2962))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 15299335 at 2026-07-30T22:40:22.107Z. PubMed recorded a metadata revision date of 2007-07-24 and an Entrez history date of 1995-01-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-15299335-2007-07-24-288d1c3a2962`](#source-pubmed-observation-pmid-15299335-2007-07-24-288d1c3a2962))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 15299335 at 2026-07-30T22:40:22.107Z. PubMed recorded a metadata revision date of 2007-07-24 and an Entrez history date of 1995-01-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-15299335-2007-07-24-288d1c3a2962`](#source-pubmed-observation-pmid-15299335-2007-07-24-288d1c3a2962))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15299335-2007-07-24-288d1c3a2962`](#source-pubmed-observation-pmid-15299335-2007-07-24-288d1c3a2962))

### Sources

<a id="source-pubmed-observation-pmid-15299335-2007-07-24-288d1c3a2962"></a>
- **PubMed record PMID 15299335 · retained source version 1:2007-07-24:current:288d1c3a29626df179480b85097736bc8e5b346079b88366bd28c81d3260c96a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15299335/) (`pubmed-observation-pmid-15299335-2007-07-24-288d1c3a2962`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 15299335." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-15299335-octreotide-v1 SHA-256: 6c78d72bb01e5f634844628db1d997deace4f4efd79dec2219e4b76c17ec01e9.

---

<a id="pubmed-pmid-15299336-octreotide-v1"></a>

## PubMed record PMID 15299336

> PeptideScanner retained PubMed bibliographic metadata for PMID 15299336 at 2026-07-30T22:40:22.107Z. PubMed recorded a metadata revision date of 2007-07-24 and an Entrez history date of 1995-01-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-15299336-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-07-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15299336-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-15299336-octreotide-v1
- Content SHA-256: `c671c470fec9fe2c0bb0442d538a8f248268a07bc88e075d8dbbee25d87e26f3`

### Claims and source pins

#### Headline

PubMed record PMID 15299336 ([`pubmed-observation-pmid-15299336-2007-07-24-fc8edabdf66e`](#source-pubmed-observation-pmid-15299336-2007-07-24-fc8edabdf66e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 15299336 at 2026-07-30T22:40:22.107Z. PubMed recorded a metadata revision date of 2007-07-24 and an Entrez history date of 1995-01-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-15299336-2007-07-24-fc8edabdf66e`](#source-pubmed-observation-pmid-15299336-2007-07-24-fc8edabdf66e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 15299336 at 2026-07-30T22:40:22.107Z. PubMed recorded a metadata revision date of 2007-07-24 and an Entrez history date of 1995-01-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-15299336-2007-07-24-fc8edabdf66e`](#source-pubmed-observation-pmid-15299336-2007-07-24-fc8edabdf66e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15299336-2007-07-24-fc8edabdf66e`](#source-pubmed-observation-pmid-15299336-2007-07-24-fc8edabdf66e))

### Sources

<a id="source-pubmed-observation-pmid-15299336-2007-07-24-fc8edabdf66e"></a>
- **PubMed record PMID 15299336 · retained source version 1:2007-07-24:current:fc8edabdf66eb86cb5ba9468aabaded05251011c0e0bc0b3b97bb8058a874dd4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15299336/) (`pubmed-observation-pmid-15299336-2007-07-24-fc8edabdf66e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 15299336." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-15299336-octreotide-v1 SHA-256: c671c470fec9fe2c0bb0442d538a8f248268a07bc88e075d8dbbee25d87e26f3.

---

<a id="pubmed-pmid-1603422-octreotide-v1"></a>

## \[Possible use of octreotide in gastrointestinal pathology and in diabetes mellitus\].

> PubMed lists PMID 1603422 in Minerva chirurgica as Journal Article, Review, with publication-date metadata of 1992-04-30 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1603422-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1603422-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1603422-octreotide-v1
- Content SHA-256: `8e7e1883c25f93b8d43c3fde9f375f8f99d2919beaa528f0915f5dcf2dab3399`

### Claims and source pins

#### Headline

\[Possible use of octreotide in gastrointestinal pathology and in diabetes mellitus\]. ([`pubmed-observation-pmid-1603422-2013-11-21-5986c5c7de62`](#source-pubmed-observation-pmid-1603422-2013-11-21-5986c5c7de62))

#### Summary

PubMed lists PMID 1603422 in Minerva chirurgica as Journal Article, Review, with publication-date metadata of 1992-04-30 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1603422-2013-11-21-5986c5c7de62`](#source-pubmed-observation-pmid-1603422-2013-11-21-5986c5c7de62))

#### Paragraph 1

PubMed lists PMID 1603422 in Minerva chirurgica as Journal Article, Review, with publication-date metadata of 1992-04-30 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1603422-2013-11-21-5986c5c7de62`](#source-pubmed-observation-pmid-1603422-2013-11-21-5986c5c7de62))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1603422-2013-11-21-5986c5c7de62`](#source-pubmed-observation-pmid-1603422-2013-11-21-5986c5c7de62))

### Sources

<a id="source-pubmed-observation-pmid-1603422-2013-11-21-5986c5c7de62"></a>
- **\[Possible use of octreotide in gastrointestinal pathology and in diabetes mellitus\]. · retained source version 1:2013-11-21:current:5986c5c7de626319b85bb917b2bcdd4dbcaf7b20f56d10cc8bdcc1d61d2eef30** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1603422/) (`pubmed-observation-pmid-1603422-2013-11-21-5986c5c7de62`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Possible use of octreotide in gastrointestinal pathology and in diabetes mellitus\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1603422-octreotide-v1 SHA-256: 8e7e1883c25f93b8d43c3fde9f375f8f99d2919beaa528f0915f5dcf2dab3399.

---

<a id="pubmed-pmid-1614574-octreotide-v1"></a>

## \[Insulinoma and octreotide\].

> PubMed lists PMID 1614574 in Nederlands tijdschrift voor geneeskunde as Comment, Letter, with publication-date metadata of 1992-06-20 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1614574-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1614574-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1614574-octreotide-v1
- Content SHA-256: `41a5b6df2a29e428b56bffe28a1936edd24bf021060ca4efd5c22afa02186b93`

### Claims and source pins

#### Headline

\[Insulinoma and octreotide\]. ([`pubmed-observation-pmid-1614574-2013-11-21-61b74fb41b83`](#source-pubmed-observation-pmid-1614574-2013-11-21-61b74fb41b83))

#### Summary

PubMed lists PMID 1614574 in Nederlands tijdschrift voor geneeskunde as Comment, Letter, with publication-date metadata of 1992-06-20 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1614574-2013-11-21-61b74fb41b83`](#source-pubmed-observation-pmid-1614574-2013-11-21-61b74fb41b83))

#### Paragraph 1

PubMed lists PMID 1614574 in Nederlands tijdschrift voor geneeskunde as Comment, Letter, with publication-date metadata of 1992-06-20 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1614574-2013-11-21-61b74fb41b83`](#source-pubmed-observation-pmid-1614574-2013-11-21-61b74fb41b83))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1614574-2013-11-21-61b74fb41b83`](#source-pubmed-observation-pmid-1614574-2013-11-21-61b74fb41b83))

### Sources

<a id="source-pubmed-observation-pmid-1614574-2013-11-21-61b74fb41b83"></a>
- **\[Insulinoma and octreotide\]. · retained source version 1:2013-11-21:current:61b74fb41b83b8ae11ee57c9d8e2e40ff6d7cbd9ad5a954bc473d42cfb4f2164** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1614574/) (`pubmed-observation-pmid-1614574-2013-11-21-61b74fb41b83`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Insulinoma and octreotide\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1614574-octreotide-v1 SHA-256: 41a5b6df2a29e428b56bffe28a1936edd24bf021060ca4efd5c22afa02186b93.

---

<a id="pubmed-pmid-1619006-octreotide-v1"></a>

## A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly.

> PubMed lists PMID 1619006 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1992-07 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1619006-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1619006-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1619006-octreotide-v1
- Content SHA-256: `0a141a78817341f25eaedad4297a1d30181b5e2c9b4a6a34071eddbd2c0ca347`

### Claims and source pins

#### Headline

A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ([`pubmed-observation-pmid-1619006-2013-11-21-65e1d6d873f6`](#source-pubmed-observation-pmid-1619006-2013-11-21-65e1d6d873f6))

#### Summary

PubMed lists PMID 1619006 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1992-07 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1619006-2013-11-21-65e1d6d873f6`](#source-pubmed-observation-pmid-1619006-2013-11-21-65e1d6d873f6))

#### Paragraph 1

PubMed lists PMID 1619006 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1992-07 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1619006-2013-11-21-65e1d6d873f6`](#source-pubmed-observation-pmid-1619006-2013-11-21-65e1d6d873f6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1619006-2013-11-21-65e1d6d873f6`](#source-pubmed-observation-pmid-1619006-2013-11-21-65e1d6d873f6))

### Sources

<a id="source-pubmed-observation-pmid-1619006-2013-11-21-65e1d6d873f6"></a>
- **A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. · retained source version 1:2013-11-21:current:65e1d6d873f624ae4a3a414eccafcc06450254fb79e5974a2e8b832d3f4ac9b4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1619006/) (`pubmed-observation-pmid-1619006-2013-11-21-65e1d6d873f6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1619006-octreotide-v1 SHA-256: 0a141a78817341f25eaedad4297a1d30181b5e2c9b4a6a34071eddbd2c0ca347.

---

<a id="pubmed-pmid-1620938-octreotide-v1"></a>

## \[Octreotide: clinical experience\].

> PubMed lists PMID 1620938 in Revista clinica espanola as Journal Article, Review, with publication-date metadata of 1992-05 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1620938-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1620938-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1620938-octreotide-v1
- Content SHA-256: `21b8a032129da1c555327f33c6f462c771165ea0595a9ad5e0daad60c4b2ec9a`

### Claims and source pins

#### Headline

\[Octreotide: clinical experience\]. ([`pubmed-observation-pmid-1620938-2013-11-21-81fa9f17d5db`](#source-pubmed-observation-pmid-1620938-2013-11-21-81fa9f17d5db))

#### Summary

PubMed lists PMID 1620938 in Revista clinica espanola as Journal Article, Review, with publication-date metadata of 1992-05 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1620938-2013-11-21-81fa9f17d5db`](#source-pubmed-observation-pmid-1620938-2013-11-21-81fa9f17d5db))

#### Paragraph 1

PubMed lists PMID 1620938 in Revista clinica espanola as Journal Article, Review, with publication-date metadata of 1992-05 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1620938-2013-11-21-81fa9f17d5db`](#source-pubmed-observation-pmid-1620938-2013-11-21-81fa9f17d5db))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1620938-2013-11-21-81fa9f17d5db`](#source-pubmed-observation-pmid-1620938-2013-11-21-81fa9f17d5db))

### Sources

<a id="source-pubmed-observation-pmid-1620938-2013-11-21-81fa9f17d5db"></a>
- **\[Octreotide: clinical experience\]. · retained source version 1:2013-11-21:current:81fa9f17d5dba5465821e881ea37a54510d203c69d003af082bc37bdacf925c5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1620938/) (`pubmed-observation-pmid-1620938-2013-11-21-81fa9f17d5db`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Octreotide: clinical experience\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1620938-octreotide-v1 SHA-256: 21b8a032129da1c555327f33c6f462c771165ea0595a9ad5e0daad60c4b2ec9a.

---

<a id="pubmed-pmid-1631261-octreotide-v1"></a>

## Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly.

> PubMed lists PMID 1631261 in The Quarterly journal of medicine as Journal Article, with publication-date metadata of 1992-04 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1631261-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1631261-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1631261-octreotide-v1
- Content SHA-256: `cfe6302cc65b88c4d7702433331d2d0fac1c5900578a98886c09083679587932`

### Claims and source pins

#### Headline

Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly. ([`pubmed-observation-pmid-1631261-2013-11-21-06409f495e5c`](#source-pubmed-observation-pmid-1631261-2013-11-21-06409f495e5c))

#### Summary

PubMed lists PMID 1631261 in The Quarterly journal of medicine as Journal Article, with publication-date metadata of 1992-04 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1631261-2013-11-21-06409f495e5c`](#source-pubmed-observation-pmid-1631261-2013-11-21-06409f495e5c))

#### Paragraph 1

PubMed lists PMID 1631261 in The Quarterly journal of medicine as Journal Article, with publication-date metadata of 1992-04 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1631261-2013-11-21-06409f495e5c`](#source-pubmed-observation-pmid-1631261-2013-11-21-06409f495e5c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1631261-2013-11-21-06409f495e5c`](#source-pubmed-observation-pmid-1631261-2013-11-21-06409f495e5c))

### Sources

<a id="source-pubmed-observation-pmid-1631261-2013-11-21-06409f495e5c"></a>
- **Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly. · retained source version 1:2013-11-21:current:06409f495e5c20a4275f69f644399557499514913401325102c92e93e8e100bd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1631261/) (`pubmed-observation-pmid-1631261-2013-11-21-06409f495e5c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1631261-octreotide-v1 SHA-256: cfe6302cc65b88c4d7702433331d2d0fac1c5900578a98886c09083679587932.

---

<a id="pubmed-pmid-1632118-octreotide-v1"></a>

## \[Octreotide in intestinal pseudo-obstruction?\].

> PubMed lists PMID 1632118 in Zeitschrift fur Gastroenterologie as Journal Article, with publication-date metadata of 1992-05 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1632118-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1632118-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1632118-octreotide-v1
- Content SHA-256: `0bad2dbc18918ba5fae1ec22a4eb8ba5b90af06ff6e117efc9040234aad89940`

### Claims and source pins

#### Headline

\[Octreotide in intestinal pseudo-obstruction?\]. ([`pubmed-observation-pmid-1632118-2013-11-21-f3576deab3d7`](#source-pubmed-observation-pmid-1632118-2013-11-21-f3576deab3d7))

#### Summary

PubMed lists PMID 1632118 in Zeitschrift fur Gastroenterologie as Journal Article, with publication-date metadata of 1992-05 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1632118-2013-11-21-f3576deab3d7`](#source-pubmed-observation-pmid-1632118-2013-11-21-f3576deab3d7))

#### Paragraph 1

PubMed lists PMID 1632118 in Zeitschrift fur Gastroenterologie as Journal Article, with publication-date metadata of 1992-05 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1632118-2013-11-21-f3576deab3d7`](#source-pubmed-observation-pmid-1632118-2013-11-21-f3576deab3d7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1632118-2013-11-21-f3576deab3d7`](#source-pubmed-observation-pmid-1632118-2013-11-21-f3576deab3d7))

### Sources

<a id="source-pubmed-observation-pmid-1632118-2013-11-21-f3576deab3d7"></a>
- **\[Octreotide in intestinal pseudo-obstruction?\]. · retained source version 1:2013-11-21:current:f3576deab3d74aea19d59c43e18f761963318f8bb17215e1a85ee06c3003a9b9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1632118/) (`pubmed-observation-pmid-1632118-2013-11-21-f3576deab3d7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Octreotide in intestinal pseudo-obstruction?\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1632118-octreotide-v1 SHA-256: 0bad2dbc18918ba5fae1ec22a4eb8ba5b90af06ff6e117efc9040234aad89940.

---

<a id="pubmed-pmid-1687076-octreotide-v1"></a>

## Evaluation of somatostatin and the somatostatin analogue octreotide as therapeutic agents in gastrointestinal disorders.

> PubMed lists PMID 1687076 in The Netherlands journal of medicine as Journal Article, Review, with publication-date metadata of 1991-12 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1687076-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1687076-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1687076-octreotide-v1
- Content SHA-256: `a972abb66bc504abbfb491ade05ef6636075b63a379229365298adf038356491`

### Claims and source pins

#### Headline

Evaluation of somatostatin and the somatostatin analogue octreotide as therapeutic agents in gastrointestinal disorders. ([`pubmed-observation-pmid-1687076-2013-11-21-4c9af057dc62`](#source-pubmed-observation-pmid-1687076-2013-11-21-4c9af057dc62))

#### Summary

PubMed lists PMID 1687076 in The Netherlands journal of medicine as Journal Article, Review, with publication-date metadata of 1991-12 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1687076-2013-11-21-4c9af057dc62`](#source-pubmed-observation-pmid-1687076-2013-11-21-4c9af057dc62))

#### Paragraph 1

PubMed lists PMID 1687076 in The Netherlands journal of medicine as Journal Article, Review, with publication-date metadata of 1991-12 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1687076-2013-11-21-4c9af057dc62`](#source-pubmed-observation-pmid-1687076-2013-11-21-4c9af057dc62))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1687076-2013-11-21-4c9af057dc62`](#source-pubmed-observation-pmid-1687076-2013-11-21-4c9af057dc62))

### Sources

<a id="source-pubmed-observation-pmid-1687076-2013-11-21-4c9af057dc62"></a>
- **Evaluation of somatostatin and the somatostatin analogue octreotide as therapeutic agents in gastrointestinal disorders. · retained source version 1:2013-11-21:current:4c9af057dc620930f4f4fe6bce7d8e318d0a9b83d96038363c40165822316198** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1687076/) (`pubmed-observation-pmid-1687076-2013-11-21-4c9af057dc62`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Evaluation of somatostatin and the somatostatin analogue octreotide as therapeutic agents in gastrointestinal disorders." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1687076-octreotide-v1 SHA-256: a972abb66bc504abbfb491ade05ef6636075b63a379229365298adf038356491.

---

<a id="pubmed-pmid-16957757-octreotide-v1"></a>

## PubMed record PMID 16957757

> PeptideScanner retained PubMed bibliographic metadata for PMID 16957757 at 2026-07-30T22:50:21.672Z. PubMed recorded a metadata revision date of 2006-09-07 and an Entrez history date of 2006-09-08. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-16957757-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2006-09-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16957757-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-16957757-octreotide-v1
- Content SHA-256: `e70e991e2284444ab0c307fa98ebf70f47658c86d062ca4c6f46401d2769fe9d`

### Claims and source pins

#### Headline

PubMed record PMID 16957757 ([`pubmed-observation-pmid-16957757-2006-09-07-d21abcfd4ae6`](#source-pubmed-observation-pmid-16957757-2006-09-07-d21abcfd4ae6))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 16957757 at 2026-07-30T22:50:21.672Z. PubMed recorded a metadata revision date of 2006-09-07 and an Entrez history date of 2006-09-08. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-16957757-2006-09-07-d21abcfd4ae6`](#source-pubmed-observation-pmid-16957757-2006-09-07-d21abcfd4ae6))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 16957757 at 2026-07-30T22:50:21.672Z. PubMed recorded a metadata revision date of 2006-09-07 and an Entrez history date of 2006-09-08. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-16957757-2006-09-07-d21abcfd4ae6`](#source-pubmed-observation-pmid-16957757-2006-09-07-d21abcfd4ae6))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16957757-2006-09-07-d21abcfd4ae6`](#source-pubmed-observation-pmid-16957757-2006-09-07-d21abcfd4ae6))

### Sources

<a id="source-pubmed-observation-pmid-16957757-2006-09-07-d21abcfd4ae6"></a>
- **PubMed record PMID 16957757 · retained source version 1:2006-09-07:current:d21abcfd4ae6862f8929c10fa4e9975d7264032cc4bb3432d0d6ee4de6a058cf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16957757/) (`pubmed-observation-pmid-16957757-2006-09-07-d21abcfd4ae6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 16957757." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-16957757-octreotide-v1 SHA-256: e70e991e2284444ab0c307fa98ebf70f47658c86d062ca4c6f46401d2769fe9d.

---

<a id="pubmed-pmid-1713038-octreotide-v1"></a>

## Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide.

> PubMed lists PMID 1713038 in Acta oncologica (Stockholm, Sweden) as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 1991 (year precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1713038-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1713038-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1713038-octreotide-v1
- Content SHA-256: `5bc0ee456157262505aac8621a03fd7be2864386c64bb5216665cadb05f04c49`

### Claims and source pins

#### Headline

Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. ([`pubmed-observation-pmid-1713038-2013-11-21-6dc35141afcd`](#source-pubmed-observation-pmid-1713038-2013-11-21-6dc35141afcd))

#### Summary

PubMed lists PMID 1713038 in Acta oncologica (Stockholm, Sweden) as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 1991 (year precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1713038-2013-11-21-6dc35141afcd`](#source-pubmed-observation-pmid-1713038-2013-11-21-6dc35141afcd))

#### Paragraph 1

PubMed lists PMID 1713038 in Acta oncologica (Stockholm, Sweden) as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 1991 (year precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1713038-2013-11-21-6dc35141afcd`](#source-pubmed-observation-pmid-1713038-2013-11-21-6dc35141afcd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1713038-2013-11-21-6dc35141afcd`](#source-pubmed-observation-pmid-1713038-2013-11-21-6dc35141afcd))

### Sources

<a id="source-pubmed-observation-pmid-1713038-2013-11-21-6dc35141afcd"></a>
- **Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. · retained source version 1:2013-11-21:current:6dc35141afcdc0b22a07f8e845f2512f6d8bc24fe2246b7dcaddad601b6aa56a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1713038/) (`pubmed-observation-pmid-1713038-2013-11-21-6dc35141afcd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1713038-octreotide-v1 SHA-256: 5bc0ee456157262505aac8621a03fd7be2864386c64bb5216665cadb05f04c49.

---

<a id="pubmed-pmid-1714136-octreotide-v1"></a>

## \[Somatostatin and octreotide in therapy of gastrointestinal diseases\].

> PubMed lists PMID 1714136 in Zeitschrift fur Gastroenterologie. Verhandlungsband as Journal Article, Review, with publication-date metadata of 1991-03 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1714136-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1714136-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1714136-octreotide-v1
- Content SHA-256: `b3564dfd3faee7c21c999995a8c1bd88675dc16c353ade55378e303139f185ce`

### Claims and source pins

#### Headline

\[Somatostatin and octreotide in therapy of gastrointestinal diseases\]. ([`pubmed-observation-pmid-1714136-2013-11-21-8a19c828227a`](#source-pubmed-observation-pmid-1714136-2013-11-21-8a19c828227a))

#### Summary

PubMed lists PMID 1714136 in Zeitschrift fur Gastroenterologie. Verhandlungsband as Journal Article, Review, with publication-date metadata of 1991-03 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1714136-2013-11-21-8a19c828227a`](#source-pubmed-observation-pmid-1714136-2013-11-21-8a19c828227a))

#### Paragraph 1

PubMed lists PMID 1714136 in Zeitschrift fur Gastroenterologie. Verhandlungsband as Journal Article, Review, with publication-date metadata of 1991-03 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1714136-2013-11-21-8a19c828227a`](#source-pubmed-observation-pmid-1714136-2013-11-21-8a19c828227a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1714136-2013-11-21-8a19c828227a`](#source-pubmed-observation-pmid-1714136-2013-11-21-8a19c828227a))

### Sources

<a id="source-pubmed-observation-pmid-1714136-2013-11-21-8a19c828227a"></a>
- **\[Somatostatin and octreotide in therapy of gastrointestinal diseases\]. · retained source version 1:2013-11-21:current:8a19c828227ab3175aa38f2a98b1a15791ca26dd7d109792065f6dfaf19813b8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1714136/) (`pubmed-observation-pmid-1714136-2013-11-21-8a19c828227a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Somatostatin and octreotide in therapy of gastrointestinal diseases\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1714136-octreotide-v1 SHA-256: b3564dfd3faee7c21c999995a8c1bd88675dc16c353ade55378e303139f185ce.

---

<a id="pubmed-pmid-17335137-octreotide-v1"></a>

## PubMed record PMID 17335137

> PeptideScanner retained PubMed bibliographic metadata for PMID 17335137 at 2026-07-30T22:40:22.973Z. PubMed recorded a metadata revision date of 2007-03-05 and an Entrez history date of 2007-03-06. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-17335137-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-03-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17335137-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-17335137-octreotide-v1
- Content SHA-256: `17f7a73b8c2ca990baef24c59d1b6eda849d26b15f1dee37f703584b16818d81`

### Claims and source pins

#### Headline

PubMed record PMID 17335137 ([`pubmed-observation-pmid-17335137-2007-03-05-3c57f77b1016`](#source-pubmed-observation-pmid-17335137-2007-03-05-3c57f77b1016))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 17335137 at 2026-07-30T22:40:22.973Z. PubMed recorded a metadata revision date of 2007-03-05 and an Entrez history date of 2007-03-06. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17335137-2007-03-05-3c57f77b1016`](#source-pubmed-observation-pmid-17335137-2007-03-05-3c57f77b1016))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 17335137 at 2026-07-30T22:40:22.973Z. PubMed recorded a metadata revision date of 2007-03-05 and an Entrez history date of 2007-03-06. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17335137-2007-03-05-3c57f77b1016`](#source-pubmed-observation-pmid-17335137-2007-03-05-3c57f77b1016))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17335137-2007-03-05-3c57f77b1016`](#source-pubmed-observation-pmid-17335137-2007-03-05-3c57f77b1016))

### Sources

<a id="source-pubmed-observation-pmid-17335137-2007-03-05-3c57f77b1016"></a>
- **PubMed record PMID 17335137 · retained source version 1:2007-03-05:current:3c57f77b1016e144b6b8ebe898df61a975fcbbf4ad845820da93ae89f2e2699b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17335137/) (`pubmed-observation-pmid-17335137-2007-03-05-3c57f77b1016`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 17335137." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-17335137-octreotide-v1 SHA-256: 17f7a73b8c2ca990baef24c59d1b6eda849d26b15f1dee37f703584b16818d81.

---

<a id="pubmed-pmid-17357189-octreotide-v1"></a>

## PubMed record PMID 17357189

> PeptideScanner retained PubMed bibliographic metadata for PMID 17357189 at 2026-07-30T22:40:22.974Z. PubMed recorded a metadata revision date of 2007-03-14 and an Entrez history date of 2007-03-16. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-17357189-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-03-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17357189-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-17357189-octreotide-v1
- Content SHA-256: `a26eb68d30f6717974a787bfed403d070c9c02c6eacdeb61e0dfd888d176e816`

### Claims and source pins

#### Headline

PubMed record PMID 17357189 ([`pubmed-observation-pmid-17357189-2007-03-14-b55e65ff12fb`](#source-pubmed-observation-pmid-17357189-2007-03-14-b55e65ff12fb))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 17357189 at 2026-07-30T22:40:22.974Z. PubMed recorded a metadata revision date of 2007-03-14 and an Entrez history date of 2007-03-16. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17357189-2007-03-14-b55e65ff12fb`](#source-pubmed-observation-pmid-17357189-2007-03-14-b55e65ff12fb))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 17357189 at 2026-07-30T22:40:22.974Z. PubMed recorded a metadata revision date of 2007-03-14 and an Entrez history date of 2007-03-16. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17357189-2007-03-14-b55e65ff12fb`](#source-pubmed-observation-pmid-17357189-2007-03-14-b55e65ff12fb))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17357189-2007-03-14-b55e65ff12fb`](#source-pubmed-observation-pmid-17357189-2007-03-14-b55e65ff12fb))

### Sources

<a id="source-pubmed-observation-pmid-17357189-2007-03-14-b55e65ff12fb"></a>
- **PubMed record PMID 17357189 · retained source version 1:2007-03-14:current:b55e65ff12fba6aa0b8ac54dfec33ac132a8de2f3ec438cdb63bcb091c9dbc2c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17357189/) (`pubmed-observation-pmid-17357189-2007-03-14-b55e65ff12fb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 17357189." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-17357189-octreotide-v1 SHA-256: a26eb68d30f6717974a787bfed403d070c9c02c6eacdeb61e0dfd888d176e816.

---

<a id="pubmed-pmid-17922063-octreotide-v1"></a>

## \[Imaging of pediatric brain tumors using somatostatin analogue 111Ih-DTPA-D-Phe1-octreotide\].

> PubMed lists PMID 17922063 in Magyar onkologia as Journal Article, with publication-date metadata of 2007-10-07 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17922063-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17922063-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-17922063-octreotide-v1
- Content SHA-256: `2a45f2ee1453cbe00ec13d14360fbdfffd958231cd738b39d4b7a04ab4f7e60e`

### Claims and source pins

#### Headline

\[Imaging of pediatric brain tumors using somatostatin analogue 111Ih-DTPA-D-Phe1-octreotide\]. ([`pubmed-observation-pmid-17922063-2026-07-01-eac1b13e5160`](#source-pubmed-observation-pmid-17922063-2026-07-01-eac1b13e5160))

#### Summary

PubMed lists PMID 17922063 in Magyar onkologia as Journal Article, with publication-date metadata of 2007-10-07 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17922063-2026-07-01-eac1b13e5160`](#source-pubmed-observation-pmid-17922063-2026-07-01-eac1b13e5160))

#### Paragraph 1

PubMed lists PMID 17922063 in Magyar onkologia as Journal Article, with publication-date metadata of 2007-10-07 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17922063-2026-07-01-eac1b13e5160`](#source-pubmed-observation-pmid-17922063-2026-07-01-eac1b13e5160))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17922063-2026-07-01-eac1b13e5160`](#source-pubmed-observation-pmid-17922063-2026-07-01-eac1b13e5160))

### Sources

<a id="source-pubmed-observation-pmid-17922063-2026-07-01-eac1b13e5160"></a>
- **\[Imaging of pediatric brain tumors using somatostatin analogue 111Ih-DTPA-D-Phe1-octreotide\]. · retained source version 1:2026-07-01:current:eac1b13e51605cf1b65fe618b1e94da173ee4375c6ede68cfa20eb907a9f7384** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17922063/) (`pubmed-observation-pmid-17922063-2026-07-01-eac1b13e5160`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Imaging of pediatric brain tumors using somatostatin analogue 111Ih-DTPA-D-Phe1-octreotide\]." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-17922063-octreotide-v1 SHA-256: 2a45f2ee1453cbe00ec13d14360fbdfffd958231cd738b39d4b7a04ab4f7e60e.

---

<a id="pubmed-pmid-17955038-octreotide-v1"></a>

## PubMed record PMID 17955038

> PeptideScanner retained PubMed bibliographic metadata for PMID 17955038 at 2026-07-30T22:40:22.998Z. PubMed recorded a metadata revision date of 2007-12-17 and an Entrez history date of 2007-10-24. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-17955038-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-12-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17955038-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-17955038-octreotide-v1
- Content SHA-256: `f45ac75b81f6fad20e1d373756df57e8650e00a1415c6d49566cfb664bb03413`

### Claims and source pins

#### Headline

PubMed record PMID 17955038 ([`pubmed-observation-pmid-17955038-2007-12-17-3ed6b342d4a7`](#source-pubmed-observation-pmid-17955038-2007-12-17-3ed6b342d4a7))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 17955038 at 2026-07-30T22:40:22.998Z. PubMed recorded a metadata revision date of 2007-12-17 and an Entrez history date of 2007-10-24. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17955038-2007-12-17-3ed6b342d4a7`](#source-pubmed-observation-pmid-17955038-2007-12-17-3ed6b342d4a7))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 17955038 at 2026-07-30T22:40:22.998Z. PubMed recorded a metadata revision date of 2007-12-17 and an Entrez history date of 2007-10-24. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17955038-2007-12-17-3ed6b342d4a7`](#source-pubmed-observation-pmid-17955038-2007-12-17-3ed6b342d4a7))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17955038-2007-12-17-3ed6b342d4a7`](#source-pubmed-observation-pmid-17955038-2007-12-17-3ed6b342d4a7))

### Sources

<a id="source-pubmed-observation-pmid-17955038-2007-12-17-3ed6b342d4a7"></a>
- **PubMed record PMID 17955038 · retained source version 1:2007-12-17:current:3ed6b342d4a7372cfd69927f147952fe7e139c3a3437179d01572b662e8ca5ba** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17955038/) (`pubmed-observation-pmid-17955038-2007-12-17-3ed6b342d4a7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 17955038." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-17955038-octreotide-v1 SHA-256: f45ac75b81f6fad20e1d373756df57e8650e00a1415c6d49566cfb664bb03413.

---

<a id="pubmed-pmid-1980772-octreotide-v1"></a>

## \[Modification of the motility of stomach, intestine and gallbladder by octreotide\].

> PubMed lists PMID 1980772 in Zeitschrift fur Gastroenterologie as Journal Article, with publication-date metadata of 1990-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1980772-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1980772-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1980772-octreotide-v1
- Content SHA-256: `a49de07416f905598aaec5e620562abab1fd9e424140da6cbb1010ed96ca0a35`

### Claims and source pins

#### Headline

\[Modification of the motility of stomach, intestine and gallbladder by octreotide\]. ([`pubmed-observation-pmid-1980772-2013-11-21-7753958a8345`](#source-pubmed-observation-pmid-1980772-2013-11-21-7753958a8345))

#### Summary

PubMed lists PMID 1980772 in Zeitschrift fur Gastroenterologie as Journal Article, with publication-date metadata of 1990-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1980772-2013-11-21-7753958a8345`](#source-pubmed-observation-pmid-1980772-2013-11-21-7753958a8345))

#### Paragraph 1

PubMed lists PMID 1980772 in Zeitschrift fur Gastroenterologie as Journal Article, with publication-date metadata of 1990-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1980772-2013-11-21-7753958a8345`](#source-pubmed-observation-pmid-1980772-2013-11-21-7753958a8345))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1980772-2013-11-21-7753958a8345`](#source-pubmed-observation-pmid-1980772-2013-11-21-7753958a8345))

### Sources

<a id="source-pubmed-observation-pmid-1980772-2013-11-21-7753958a8345"></a>
- **\[Modification of the motility of stomach, intestine and gallbladder by octreotide\]. · retained source version 1:2013-11-21:current:7753958a8345556842940750a519a47ea745d61abd05ee7d0423cfda654be551** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1980772/) (`pubmed-observation-pmid-1980772-2013-11-21-7753958a8345`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Modification of the motility of stomach, intestine and gallbladder by octreotide\]." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1980772-octreotide-v1 SHA-256: a49de07416f905598aaec5e620562abab1fd9e424140da6cbb1010ed96ca0a35.

---

<a id="pubmed-pmid-1980774-octreotide-v1"></a>

## \[Clinical applications of octreotide in gastro-entero-pancreatic (GEP) tumors\].

> PubMed lists PMID 1980774 in Zeitschrift fur Gastroenterologie as Journal Article, Review, with publication-date metadata of 1990-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1980774-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1980774-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1980774-octreotide-v1
- Content SHA-256: `a26a5814988b648052df2dd06494696d98411894b0d3f23df6133316a3c9ad53`

### Claims and source pins

#### Headline

\[Clinical applications of octreotide in gastro-entero-pancreatic (GEP) tumors\]. ([`pubmed-observation-pmid-1980774-2013-11-21-8c5db0adeaef`](#source-pubmed-observation-pmid-1980774-2013-11-21-8c5db0adeaef))

#### Summary

PubMed lists PMID 1980774 in Zeitschrift fur Gastroenterologie as Journal Article, Review, with publication-date metadata of 1990-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1980774-2013-11-21-8c5db0adeaef`](#source-pubmed-observation-pmid-1980774-2013-11-21-8c5db0adeaef))

#### Paragraph 1

PubMed lists PMID 1980774 in Zeitschrift fur Gastroenterologie as Journal Article, Review, with publication-date metadata of 1990-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1980774-2013-11-21-8c5db0adeaef`](#source-pubmed-observation-pmid-1980774-2013-11-21-8c5db0adeaef))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1980774-2013-11-21-8c5db0adeaef`](#source-pubmed-observation-pmid-1980774-2013-11-21-8c5db0adeaef))

### Sources

<a id="source-pubmed-observation-pmid-1980774-2013-11-21-8c5db0adeaef"></a>
- **\[Clinical applications of octreotide in gastro-entero-pancreatic (GEP) tumors\]. · retained source version 1:2013-11-21:current:8c5db0adeaef4c177e5cd52383aa8aecb12e0d12669c3dc6b751f17a1667c057** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1980774/) (`pubmed-observation-pmid-1980774-2013-11-21-8c5db0adeaef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Clinical applications of octreotide in gastro-entero-pancreatic (GEP) tumors\]." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1980774-octreotide-v1 SHA-256: a26a5814988b648052df2dd06494696d98411894b0d3f23df6133316a3c9ad53.

---

<a id="pubmed-pmid-1980776-octreotide-v1"></a>

## \[Drug treatment of acute esophageal varices hemorrhage using vasoactive substances (somatostatin and octreotide)\].

> PubMed lists PMID 1980776 in Zeitschrift fur Gastroenterologie as Journal Article, Review, with publication-date metadata of 1990-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1980776-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1980776-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1980776-octreotide-v1
- Content SHA-256: `09482793568d7e83f6a5a1cb2207a40b7d857b495d918bc199d3e66ce9aab545`

### Claims and source pins

#### Headline

\[Drug treatment of acute esophageal varices hemorrhage using vasoactive substances (somatostatin and octreotide)\]. ([`pubmed-observation-pmid-1980776-2013-11-21-28fcecbe6abc`](#source-pubmed-observation-pmid-1980776-2013-11-21-28fcecbe6abc))

#### Summary

PubMed lists PMID 1980776 in Zeitschrift fur Gastroenterologie as Journal Article, Review, with publication-date metadata of 1990-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1980776-2013-11-21-28fcecbe6abc`](#source-pubmed-observation-pmid-1980776-2013-11-21-28fcecbe6abc))

#### Paragraph 1

PubMed lists PMID 1980776 in Zeitschrift fur Gastroenterologie as Journal Article, Review, with publication-date metadata of 1990-09 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1980776-2013-11-21-28fcecbe6abc`](#source-pubmed-observation-pmid-1980776-2013-11-21-28fcecbe6abc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1980776-2013-11-21-28fcecbe6abc`](#source-pubmed-observation-pmid-1980776-2013-11-21-28fcecbe6abc))

### Sources

<a id="source-pubmed-observation-pmid-1980776-2013-11-21-28fcecbe6abc"></a>
- **\[Drug treatment of acute esophageal varices hemorrhage using vasoactive substances (somatostatin and octreotide)\]. · retained source version 1:2013-11-21:current:28fcecbe6abc28e0284969ad8db413a0085c98bb10439369471fd107a4c6467d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1980776/) (`pubmed-observation-pmid-1980776-2013-11-21-28fcecbe6abc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Drug treatment of acute esophageal varices hemorrhage using vasoactive substances (somatostatin and octreotide)\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-1980776-octreotide-v1 SHA-256: 09482793568d7e83f6a5a1cb2207a40b7d857b495d918bc199d3e66ce9aab545.

---

<a id="pubmed-pmid-19864727-octreotide-v1"></a>

## PubMed record PMID 19864727

> PeptideScanner retained PubMed bibliographic metadata for PMID 19864727 at 2026-07-30T22:27:39.979Z. PubMed recorded a metadata revision date of 2009-10-29 and an Entrez history date of 2009-10-30. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-19864727-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2009-10-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19864727-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-19864727-octreotide-v1
- Content SHA-256: `04884de60235eda25d90945aaa0ab9fc60d32a03a0303cf0eedb0e46c7e1a92c`

### Claims and source pins

#### Headline

PubMed record PMID 19864727 ([`pubmed-observation-pmid-19864727-2009-10-29-998c2af8dcb0`](#source-pubmed-observation-pmid-19864727-2009-10-29-998c2af8dcb0))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 19864727 at 2026-07-30T22:27:39.979Z. PubMed recorded a metadata revision date of 2009-10-29 and an Entrez history date of 2009-10-30. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-19864727-2009-10-29-998c2af8dcb0`](#source-pubmed-observation-pmid-19864727-2009-10-29-998c2af8dcb0))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 19864727 at 2026-07-30T22:27:39.979Z. PubMed recorded a metadata revision date of 2009-10-29 and an Entrez history date of 2009-10-30. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-19864727-2009-10-29-998c2af8dcb0`](#source-pubmed-observation-pmid-19864727-2009-10-29-998c2af8dcb0))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19864727-2009-10-29-998c2af8dcb0`](#source-pubmed-observation-pmid-19864727-2009-10-29-998c2af8dcb0))

### Sources

<a id="source-pubmed-observation-pmid-19864727-2009-10-29-998c2af8dcb0"></a>
- **PubMed record PMID 19864727 · retained source version 1:2009-10-29:current:998c2af8dcb0728101d181d23927f50a37616496ca9a4020f586e6c9a95d4e14** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19864727/) (`pubmed-observation-pmid-19864727-2009-10-29-998c2af8dcb0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 19864727." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-19864727-octreotide-v1 SHA-256: 04884de60235eda25d90945aaa0ab9fc60d32a03a0303cf0eedb0e46c7e1a92c.

---

<a id="pubmed-pmid-19864763-octreotide-v1"></a>

## PubMed record PMID 19864763

> PeptideScanner retained PubMed bibliographic metadata for PMID 19864763 at 2026-07-30T22:27:39.979Z. PubMed recorded a metadata revision date of 2009-10-29 and an Entrez history date of 2009-10-30. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-19864763-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2009-10-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19864763-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-19864763-octreotide-v1
- Content SHA-256: `5b29ce425713984a11deb1967b599ad2477680ec22d7d85d0a0a6c481ce17398`

### Claims and source pins

#### Headline

PubMed record PMID 19864763 ([`pubmed-observation-pmid-19864763-2009-10-29-e359d065e0c2`](#source-pubmed-observation-pmid-19864763-2009-10-29-e359d065e0c2))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 19864763 at 2026-07-30T22:27:39.979Z. PubMed recorded a metadata revision date of 2009-10-29 and an Entrez history date of 2009-10-30. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-19864763-2009-10-29-e359d065e0c2`](#source-pubmed-observation-pmid-19864763-2009-10-29-e359d065e0c2))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 19864763 at 2026-07-30T22:27:39.979Z. PubMed recorded a metadata revision date of 2009-10-29 and an Entrez history date of 2009-10-30. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-19864763-2009-10-29-e359d065e0c2`](#source-pubmed-observation-pmid-19864763-2009-10-29-e359d065e0c2))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19864763-2009-10-29-e359d065e0c2`](#source-pubmed-observation-pmid-19864763-2009-10-29-e359d065e0c2))

### Sources

<a id="source-pubmed-observation-pmid-19864763-2009-10-29-e359d065e0c2"></a>
- **PubMed record PMID 19864763 · retained source version 1:2009-10-29:current:e359d065e0c28855296414ef2a34f8a8eec9b5e6a4689845568d98919b40ab62** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19864763/) (`pubmed-observation-pmid-19864763-2009-10-29-e359d065e0c2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 19864763." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-19864763-octreotide-v1 SHA-256: 5b29ce425713984a11deb1967b599ad2477680ec22d7d85d0a0a6c481ce17398.

---

<a id="pubmed-pmid-2045464-octreotide-v1"></a>

## The orthostatic tachycardia syndrome: evaluation of autonomic function and treatment with octreotide and ergot alkaloids.

> PubMed lists PMID 2045464 in The Journal of clinical endocrinology and metabolism as Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1991-07 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2045464-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2045464-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-2045464-octreotide-v1
- Content SHA-256: `262ab63f4eb99cf70355f592eca6fade1c27fa03a5a531cc6efbab0f65a748f7`

### Claims and source pins

#### Headline

The orthostatic tachycardia syndrome: evaluation of autonomic function and treatment with octreotide and ergot alkaloids. ([`pubmed-observation-pmid-2045464-2013-11-21-c79e875f6921`](#source-pubmed-observation-pmid-2045464-2013-11-21-c79e875f6921))

#### Summary

PubMed lists PMID 2045464 in The Journal of clinical endocrinology and metabolism as Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1991-07 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2045464-2013-11-21-c79e875f6921`](#source-pubmed-observation-pmid-2045464-2013-11-21-c79e875f6921))

#### Paragraph 1

PubMed lists PMID 2045464 in The Journal of clinical endocrinology and metabolism as Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1991-07 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2045464-2013-11-21-c79e875f6921`](#source-pubmed-observation-pmid-2045464-2013-11-21-c79e875f6921))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2045464-2013-11-21-c79e875f6921`](#source-pubmed-observation-pmid-2045464-2013-11-21-c79e875f6921))

### Sources

<a id="source-pubmed-observation-pmid-2045464-2013-11-21-c79e875f6921"></a>
- **The orthostatic tachycardia syndrome: evaluation of autonomic function and treatment with octreotide and ergot alkaloids. · retained source version 1:2013-11-21:current:c79e875f69217382cdaebf27c1565b9a04d9a2ea925a9c6b3c1034fa2dc99777** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2045464/) (`pubmed-observation-pmid-2045464-2013-11-21-c79e875f6921`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The orthostatic tachycardia syndrome: evaluation of autonomic function and treatment with octreotide and ergot alkaloids." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-2045464-octreotide-v1 SHA-256: 262ab63f4eb99cf70355f592eca6fade1c27fa03a5a531cc6efbab0f65a748f7.

---

<a id="pubmed-pmid-2059523-octreotide-v1"></a>

## \[Pharmacological treatment of gastroenteropancreatic apudomas with an analog of somatostatin, SMS 201-995 (octreotide)\].

> PubMed lists PMID 2059523 in Revista espanola de enfermedades digestivas as English Abstract, Journal Article, with publication-date metadata of 1991-02 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2059523-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2059523-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-2059523-octreotide-v1
- Content SHA-256: `bd5844fabbdeab37a7a5190406968deaa45ac48f536c960db062484449749c9f`

### Claims and source pins

#### Headline

\[Pharmacological treatment of gastroenteropancreatic apudomas with an analog of somatostatin, SMS 201-995 (octreotide)\]. ([`pubmed-observation-pmid-2059523-2013-11-21-9a8729f4ee37`](#source-pubmed-observation-pmid-2059523-2013-11-21-9a8729f4ee37))

#### Summary

PubMed lists PMID 2059523 in Revista espanola de enfermedades digestivas as English Abstract, Journal Article, with publication-date metadata of 1991-02 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2059523-2013-11-21-9a8729f4ee37`](#source-pubmed-observation-pmid-2059523-2013-11-21-9a8729f4ee37))

#### Paragraph 1

PubMed lists PMID 2059523 in Revista espanola de enfermedades digestivas as English Abstract, Journal Article, with publication-date metadata of 1991-02 (month precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2059523-2013-11-21-9a8729f4ee37`](#source-pubmed-observation-pmid-2059523-2013-11-21-9a8729f4ee37))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2059523-2013-11-21-9a8729f4ee37`](#source-pubmed-observation-pmid-2059523-2013-11-21-9a8729f4ee37))

### Sources

<a id="source-pubmed-observation-pmid-2059523-2013-11-21-9a8729f4ee37"></a>
- **\[Pharmacological treatment of gastroenteropancreatic apudomas with an analog of somatostatin, SMS 201-995 (octreotide)\]. · retained source version 1:2013-11-21:current:9a8729f4ee3795bba86fb5c8f156b79ed924f6fc4e811457175c63f3d04a2cef** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2059523/) (`pubmed-observation-pmid-2059523-2013-11-21-9a8729f4ee37`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Pharmacological treatment of gastroenteropancreatic apudomas with an analog of somatostatin, SMS 201-995 (octreotide)\]." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-2059523-octreotide-v1 SHA-256: bd5844fabbdeab37a7a5190406968deaa45ac48f536c960db062484449749c9f.

---

<a id="pubmed-pmid-20641226-octreotide-v1"></a>

## PubMed record PMID 20641226

> PeptideScanner retained PubMed bibliographic metadata for PMID 20641226 at 2026-07-30T22:27:39.988Z. PubMed recorded a metadata revision date of 2009-06-05 and an Entrez history date of 2009-06-05. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-20641226-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2009-06-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20641226-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-20641226-octreotide-v1
- Content SHA-256: `a0ac1a92b2b1416f6587555f4f29fb3de5f719073d9ea75cbd2e7cd9234f933a`

### Claims and source pins

#### Headline

PubMed record PMID 20641226 ([`pubmed-observation-pmid-20641226-2009-06-05-e4fb97211e4b`](#source-pubmed-observation-pmid-20641226-2009-06-05-e4fb97211e4b))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 20641226 at 2026-07-30T22:27:39.988Z. PubMed recorded a metadata revision date of 2009-06-05 and an Entrez history date of 2009-06-05. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-20641226-2009-06-05-e4fb97211e4b`](#source-pubmed-observation-pmid-20641226-2009-06-05-e4fb97211e4b))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 20641226 at 2026-07-30T22:27:39.988Z. PubMed recorded a metadata revision date of 2009-06-05 and an Entrez history date of 2009-06-05. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-20641226-2009-06-05-e4fb97211e4b`](#source-pubmed-observation-pmid-20641226-2009-06-05-e4fb97211e4b))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20641226-2009-06-05-e4fb97211e4b`](#source-pubmed-observation-pmid-20641226-2009-06-05-e4fb97211e4b))

### Sources

<a id="source-pubmed-observation-pmid-20641226-2009-06-05-e4fb97211e4b"></a>
- **PubMed record PMID 20641226 · retained source version 1:2009-06-05:current:e4fb97211e4bb8fff7fb2f31cf76c3647f5b31a2a513bf8fb3f3a0029cb47aea** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20641226/) (`pubmed-observation-pmid-20641226-2009-06-05-e4fb97211e4b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 20641226." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-20641226-octreotide-v1 SHA-256: a0ac1a92b2b1416f6587555f4f29fb3de5f719073d9ea75cbd2e7cd9234f933a.

---

<a id="pubmed-pmid-20641749-octreotide-v1"></a>

## PubMed record PMID 20641749

> PeptideScanner retained PubMed bibliographic metadata for PMID 20641749 at 2026-07-30T22:40:23.016Z. PubMed recorded a metadata revision date of 2007-11-07 and an Entrez history date of 2007-11-07. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-20641749-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-11-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20641749-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-20641749-octreotide-v1
- Content SHA-256: `ee2c43340ef4766097b646223ba594a5fcea8d5ec1895314b122b68a91583661`

### Claims and source pins

#### Headline

PubMed record PMID 20641749 ([`pubmed-observation-pmid-20641749-2007-11-07-81835ed70ec1`](#source-pubmed-observation-pmid-20641749-2007-11-07-81835ed70ec1))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 20641749 at 2026-07-30T22:40:23.016Z. PubMed recorded a metadata revision date of 2007-11-07 and an Entrez history date of 2007-11-07. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-20641749-2007-11-07-81835ed70ec1`](#source-pubmed-observation-pmid-20641749-2007-11-07-81835ed70ec1))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 20641749 at 2026-07-30T22:40:23.016Z. PubMed recorded a metadata revision date of 2007-11-07 and an Entrez history date of 2007-11-07. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-20641749-2007-11-07-81835ed70ec1`](#source-pubmed-observation-pmid-20641749-2007-11-07-81835ed70ec1))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20641749-2007-11-07-81835ed70ec1`](#source-pubmed-observation-pmid-20641749-2007-11-07-81835ed70ec1))

### Sources

<a id="source-pubmed-observation-pmid-20641749-2007-11-07-81835ed70ec1"></a>
- **PubMed record PMID 20641749 · retained source version 1:2007-11-07:current:81835ed70ec1d9d4df787cf579f405adf9a8ca852699f273f8a8a6f75ca91258** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20641749/) (`pubmed-observation-pmid-20641749-2007-11-07-81835ed70ec1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 20641749." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-20641749-octreotide-v1 SHA-256: ee2c43340ef4766097b646223ba594a5fcea8d5ec1895314b122b68a91583661.

---

<a id="pubmed-pmid-22874886-octreotide-v1"></a>

## PubMed record PMID 22874886

> PeptideScanner retained PubMed bibliographic metadata for PMID 22874886 at 2026-07-30T21:57:01.388Z. PubMed recorded a metadata revision date of 2013-05-13 and an Entrez history date of 2012-08-10. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-22874886-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-05-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22874886-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-22874886-octreotide-v1
- Content SHA-256: `8b5efb4723cdf144f71546cbcdfafe2aef35e36ac58a0084f2004511f40e70f4`

### Claims and source pins

#### Headline

PubMed record PMID 22874886 ([`pubmed-observation-pmid-22874886-2013-05-13-338022f1735e`](#source-pubmed-observation-pmid-22874886-2013-05-13-338022f1735e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 22874886 at 2026-07-30T21:57:01.388Z. PubMed recorded a metadata revision date of 2013-05-13 and an Entrez history date of 2012-08-10. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22874886-2013-05-13-338022f1735e`](#source-pubmed-observation-pmid-22874886-2013-05-13-338022f1735e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 22874886 at 2026-07-30T21:57:01.388Z. PubMed recorded a metadata revision date of 2013-05-13 and an Entrez history date of 2012-08-10. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22874886-2013-05-13-338022f1735e`](#source-pubmed-observation-pmid-22874886-2013-05-13-338022f1735e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22874886-2013-05-13-338022f1735e`](#source-pubmed-observation-pmid-22874886-2013-05-13-338022f1735e))

### Sources

<a id="source-pubmed-observation-pmid-22874886-2013-05-13-338022f1735e"></a>
- **PubMed record PMID 22874886 · retained source version 1:2013-05-13:current:338022f1735e0658a63e2208b1d7021f3aa568f5b3da3797c5517e67d4eeaede** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22874886/) (`pubmed-observation-pmid-22874886-2013-05-13-338022f1735e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 22874886." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-22874886-octreotide-v1 SHA-256: 8b5efb4723cdf144f71546cbcdfafe2aef35e36ac58a0084f2004511f40e70f4.

---

<a id="pubmed-pmid-23140265-octreotide-v1"></a>

## PubMed record PMID 23140265

> PeptideScanner retained PubMed bibliographic metadata for PMID 23140265 at 2026-07-30T21:57:01.395Z. PubMed recorded a metadata revision date of 2013-01-01 and an Entrez history date of 2012-11-13. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-23140265-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-01-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23140265-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23140265-octreotide-v1
- Content SHA-256: `66c0154388dc5b8b405fc595c02c5b1636e916908e708a3bbfb495882b8a2ac8`

### Claims and source pins

#### Headline

PubMed record PMID 23140265 ([`pubmed-observation-pmid-23140265-2013-01-01-a8fc75cef1af`](#source-pubmed-observation-pmid-23140265-2013-01-01-a8fc75cef1af))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 23140265 at 2026-07-30T21:57:01.395Z. PubMed recorded a metadata revision date of 2013-01-01 and an Entrez history date of 2012-11-13. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23140265-2013-01-01-a8fc75cef1af`](#source-pubmed-observation-pmid-23140265-2013-01-01-a8fc75cef1af))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 23140265 at 2026-07-30T21:57:01.395Z. PubMed recorded a metadata revision date of 2013-01-01 and an Entrez history date of 2012-11-13. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23140265-2013-01-01-a8fc75cef1af`](#source-pubmed-observation-pmid-23140265-2013-01-01-a8fc75cef1af))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23140265-2013-01-01-a8fc75cef1af`](#source-pubmed-observation-pmid-23140265-2013-01-01-a8fc75cef1af))

### Sources

<a id="source-pubmed-observation-pmid-23140265-2013-01-01-a8fc75cef1af"></a>
- **PubMed record PMID 23140265 · retained source version 1:2013-01-01:current:a8fc75cef1afbd94a4859175e96dbcdf73a8ec5786e8b32ec2dab6739d9abb68** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23140265/) (`pubmed-observation-pmid-23140265-2013-01-01-a8fc75cef1af`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 23140265." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23140265-octreotide-v1 SHA-256: 66c0154388dc5b8b405fc595c02c5b1636e916908e708a3bbfb495882b8a2ac8.

---

<a id="pubmed-pmid-23228417-octreotide-v1"></a>

## PubMed record PMID 23228417

> PeptideScanner retained PubMed bibliographic metadata for PMID 23228417 at 2026-07-30T21:57:01.397Z. PubMed recorded a metadata revision date of 2013-03-29 and an Entrez history date of 2012-12-12. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-23228417-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-03-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23228417-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23228417-octreotide-v1
- Content SHA-256: `3992aad49ed78467d3ec1b6795f3c00fa4d0137818b141b7fc7c5ff261d16221`

### Claims and source pins

#### Headline

PubMed record PMID 23228417 ([`pubmed-observation-pmid-23228417-2013-03-29-dd4f96d2a741`](#source-pubmed-observation-pmid-23228417-2013-03-29-dd4f96d2a741))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 23228417 at 2026-07-30T21:57:01.397Z. PubMed recorded a metadata revision date of 2013-03-29 and an Entrez history date of 2012-12-12. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23228417-2013-03-29-dd4f96d2a741`](#source-pubmed-observation-pmid-23228417-2013-03-29-dd4f96d2a741))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 23228417 at 2026-07-30T21:57:01.397Z. PubMed recorded a metadata revision date of 2013-03-29 and an Entrez history date of 2012-12-12. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23228417-2013-03-29-dd4f96d2a741`](#source-pubmed-observation-pmid-23228417-2013-03-29-dd4f96d2a741))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23228417-2013-03-29-dd4f96d2a741`](#source-pubmed-observation-pmid-23228417-2013-03-29-dd4f96d2a741))

### Sources

<a id="source-pubmed-observation-pmid-23228417-2013-03-29-dd4f96d2a741"></a>
- **PubMed record PMID 23228417 · retained source version 1:2013-03-29:current:dd4f96d2a741825ed105db0505f69135e1bafeaafd322752909444937fd3831a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23228417/) (`pubmed-observation-pmid-23228417-2013-03-29-dd4f96d2a741`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 23228417." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23228417-octreotide-v1 SHA-256: 3992aad49ed78467d3ec1b6795f3c00fa4d0137818b141b7fc7c5ff261d16221.

---

<a id="pubmed-pmid-23275042-octreotide-v1"></a>

## PubMed record PMID 23275042

> PeptideScanner retained PubMed bibliographic metadata for PMID 23275042 at 2026-07-30T21:57:01.399Z. PubMed recorded a metadata revision date of 2013-05-06 and an Entrez history date of 2013-01-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-23275042-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-05-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23275042-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23275042-octreotide-v1
- Content SHA-256: `80afafe0010c0ea2e57981364e8ccb84d09e26079d6149be6e866fcbc754144d`

### Claims and source pins

#### Headline

PubMed record PMID 23275042 ([`pubmed-observation-pmid-23275042-2013-05-06-031480758ac8`](#source-pubmed-observation-pmid-23275042-2013-05-06-031480758ac8))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 23275042 at 2026-07-30T21:57:01.399Z. PubMed recorded a metadata revision date of 2013-05-06 and an Entrez history date of 2013-01-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23275042-2013-05-06-031480758ac8`](#source-pubmed-observation-pmid-23275042-2013-05-06-031480758ac8))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 23275042 at 2026-07-30T21:57:01.399Z. PubMed recorded a metadata revision date of 2013-05-06 and an Entrez history date of 2013-01-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23275042-2013-05-06-031480758ac8`](#source-pubmed-observation-pmid-23275042-2013-05-06-031480758ac8))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23275042-2013-05-06-031480758ac8`](#source-pubmed-observation-pmid-23275042-2013-05-06-031480758ac8))

### Sources

<a id="source-pubmed-observation-pmid-23275042-2013-05-06-031480758ac8"></a>
- **PubMed record PMID 23275042 · retained source version 1:2013-05-06:current:031480758ac80cd82fbb1149a3a9a2d23b911b1e31fe4048bdc9ba4042b0b6ae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23275042/) (`pubmed-observation-pmid-23275042-2013-05-06-031480758ac8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 23275042." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23275042-octreotide-v1 SHA-256: 80afafe0010c0ea2e57981364e8ccb84d09e26079d6149be6e866fcbc754144d.

---

<a id="pubmed-pmid-23591434-octreotide-v1"></a>

## PubMed record PMID 23591434

> PeptideScanner retained PubMed bibliographic metadata for PMID 23591434 at 2026-07-30T21:57:01.412Z. PubMed recorded a metadata revision date of 2013-04-17 and an Entrez history date of 2013-04-18. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-23591434-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-04-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23591434-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23591434-octreotide-v1
- Content SHA-256: `a1b7f3472d3691c5490c7871e0ec342777a414493d8f62bd1b4b92e37faf237a`

### Claims and source pins

#### Headline

PubMed record PMID 23591434 ([`pubmed-observation-pmid-23591434-2013-04-17-2bfae6030f01`](#source-pubmed-observation-pmid-23591434-2013-04-17-2bfae6030f01))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 23591434 at 2026-07-30T21:57:01.412Z. PubMed recorded a metadata revision date of 2013-04-17 and an Entrez history date of 2013-04-18. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23591434-2013-04-17-2bfae6030f01`](#source-pubmed-observation-pmid-23591434-2013-04-17-2bfae6030f01))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 23591434 at 2026-07-30T21:57:01.412Z. PubMed recorded a metadata revision date of 2013-04-17 and an Entrez history date of 2013-04-18. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23591434-2013-04-17-2bfae6030f01`](#source-pubmed-observation-pmid-23591434-2013-04-17-2bfae6030f01))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23591434-2013-04-17-2bfae6030f01`](#source-pubmed-observation-pmid-23591434-2013-04-17-2bfae6030f01))

### Sources

<a id="source-pubmed-observation-pmid-23591434-2013-04-17-2bfae6030f01"></a>
- **PubMed record PMID 23591434 · retained source version 1:2013-04-17:current:2bfae6030f01429fd152f9b8cca6c332f2d16222898a7110f1a87c72e5c837eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23591434/) (`pubmed-observation-pmid-23591434-2013-04-17-2bfae6030f01`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 23591434." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23591434-octreotide-v1 SHA-256: a1b7f3472d3691c5490c7871e0ec342777a414493d8f62bd1b4b92e37faf237a.

---

<a id="pubmed-pmid-23780564-octreotide-v1"></a>

## PubMed record PMID 23780564

> PeptideScanner retained PubMed bibliographic metadata for PMID 23780564 at 2026-07-30T21:57:02.013Z. PubMed recorded a metadata revision date of 2013-06-21 and an Entrez history date of 2013-06-20. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-23780564-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-06-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23780564-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23780564-octreotide-v1
- Content SHA-256: `652fb59c18dd85cc3ab738d9995746dd27c7d9a537bf03d0b9db04a5fc7131fe`

### Claims and source pins

#### Headline

PubMed record PMID 23780564 ([`pubmed-observation-pmid-23780564-2013-06-21-f8d4ff210368`](#source-pubmed-observation-pmid-23780564-2013-06-21-f8d4ff210368))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 23780564 at 2026-07-30T21:57:02.013Z. PubMed recorded a metadata revision date of 2013-06-21 and an Entrez history date of 2013-06-20. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23780564-2013-06-21-f8d4ff210368`](#source-pubmed-observation-pmid-23780564-2013-06-21-f8d4ff210368))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 23780564 at 2026-07-30T21:57:02.013Z. PubMed recorded a metadata revision date of 2013-06-21 and an Entrez history date of 2013-06-20. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23780564-2013-06-21-f8d4ff210368`](#source-pubmed-observation-pmid-23780564-2013-06-21-f8d4ff210368))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23780564-2013-06-21-f8d4ff210368`](#source-pubmed-observation-pmid-23780564-2013-06-21-f8d4ff210368))

### Sources

<a id="source-pubmed-observation-pmid-23780564-2013-06-21-f8d4ff210368"></a>
- **PubMed record PMID 23780564 · retained source version 1:2013-06-21:current:f8d4ff210368b44a263e22500b402c9935f2891eb5daced15c8f8caf43907036** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23780564/) (`pubmed-observation-pmid-23780564-2013-06-21-f8d4ff210368`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 23780564." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23780564-octreotide-v1 SHA-256: 652fb59c18dd85cc3ab738d9995746dd27c7d9a537bf03d0b9db04a5fc7131fe.

---

<a id="pubmed-pmid-23789763-octreotide-v1"></a>

## PubMed record PMID 23789763

> PeptideScanner retained PubMed bibliographic metadata for PMID 23789763 at 2026-07-30T21:57:02.014Z. PubMed recorded a metadata revision date of 2013-06-24 and an Entrez history date of 2013-06-25. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-23789763-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-06-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23789763-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23789763-octreotide-v1
- Content SHA-256: `ee30a037c5fb1e732dc9b71d590e46c7d478e0c82564736ef204c13910edbe4e`

### Claims and source pins

#### Headline

PubMed record PMID 23789763 ([`pubmed-observation-pmid-23789763-2013-06-24-de4aed838180`](#source-pubmed-observation-pmid-23789763-2013-06-24-de4aed838180))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 23789763 at 2026-07-30T21:57:02.014Z. PubMed recorded a metadata revision date of 2013-06-24 and an Entrez history date of 2013-06-25. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23789763-2013-06-24-de4aed838180`](#source-pubmed-observation-pmid-23789763-2013-06-24-de4aed838180))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 23789763 at 2026-07-30T21:57:02.014Z. PubMed recorded a metadata revision date of 2013-06-24 and an Entrez history date of 2013-06-25. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23789763-2013-06-24-de4aed838180`](#source-pubmed-observation-pmid-23789763-2013-06-24-de4aed838180))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23789763-2013-06-24-de4aed838180`](#source-pubmed-observation-pmid-23789763-2013-06-24-de4aed838180))

### Sources

<a id="source-pubmed-observation-pmid-23789763-2013-06-24-de4aed838180"></a>
- **PubMed record PMID 23789763 · retained source version 1:2013-06-24:current:de4aed838180634167efefcf722b63cfc48031deb986e62de5e319aba59489b3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23789763/) (`pubmed-observation-pmid-23789763-2013-06-24-de4aed838180`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 23789763." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23789763-octreotide-v1 SHA-256: ee30a037c5fb1e732dc9b71d590e46c7d478e0c82564736ef204c13910edbe4e.

---

<a id="pubmed-pmid-23925288-octreotide-v1"></a>

## PubMed record PMID 23925288

> PeptideScanner retained PubMed bibliographic metadata for PMID 23925288 at 2026-07-30T21:57:02.018Z. PubMed recorded a metadata revision date of 2013-08-08 and an Entrez history date of 2013-08-09. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-23925288-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-08-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23925288-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23925288-octreotide-v1
- Content SHA-256: `0c427e06defb7b7a59d113beff1b549f394fec7a9eaaa3f195b61ee0d4cc22e1`

### Claims and source pins

#### Headline

PubMed record PMID 23925288 ([`pubmed-observation-pmid-23925288-2013-08-08-1b29e8d74538`](#source-pubmed-observation-pmid-23925288-2013-08-08-1b29e8d74538))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 23925288 at 2026-07-30T21:57:02.018Z. PubMed recorded a metadata revision date of 2013-08-08 and an Entrez history date of 2013-08-09. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23925288-2013-08-08-1b29e8d74538`](#source-pubmed-observation-pmid-23925288-2013-08-08-1b29e8d74538))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 23925288 at 2026-07-30T21:57:02.018Z. PubMed recorded a metadata revision date of 2013-08-08 and an Entrez history date of 2013-08-09. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23925288-2013-08-08-1b29e8d74538`](#source-pubmed-observation-pmid-23925288-2013-08-08-1b29e8d74538))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23925288-2013-08-08-1b29e8d74538`](#source-pubmed-observation-pmid-23925288-2013-08-08-1b29e8d74538))

### Sources

<a id="source-pubmed-observation-pmid-23925288-2013-08-08-1b29e8d74538"></a>
- **PubMed record PMID 23925288 · retained source version 1:2013-08-08:current:1b29e8d745388855c58449b8452613529af0246dd9587dc7e3e0c1deba324f3c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23925288/) (`pubmed-observation-pmid-23925288-2013-08-08-1b29e8d74538`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 23925288." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-23925288-octreotide-v1 SHA-256: 0c427e06defb7b7a59d113beff1b549f394fec7a9eaaa3f195b61ee0d4cc22e1.

---

<a id="pubmed-pmid-37211679-octreotide-v1"></a>

## Octreotide and Octreotide-derived delivery systems.

> PubMed lists PMID 37211679 in Journal of drug targeting as Journal Article, Review, with publication-date metadata of 2023-05-23 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37211679-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37211679-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-37211679-octreotide-v1
- Content SHA-256: `590cda04e81938806a5ec18c6b93d9991173977032ed94f39b1611219c79bb78`

### Claims and source pins

#### Headline

Octreotide and Octreotide-derived delivery systems. ([`pubmed-observation-pmid-37211679-2026-06-28-f3c11f50c77d`](#source-pubmed-observation-pmid-37211679-2026-06-28-f3c11f50c77d))

#### Summary

PubMed lists PMID 37211679 in Journal of drug targeting as Journal Article, Review, with publication-date metadata of 2023-05-23 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37211679-2026-06-28-f3c11f50c77d`](#source-pubmed-observation-pmid-37211679-2026-06-28-f3c11f50c77d))

#### Paragraph 1

PubMed lists PMID 37211679 in Journal of drug targeting as Journal Article, Review, with publication-date metadata of 2023-05-23 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37211679-2026-06-28-f3c11f50c77d`](#source-pubmed-observation-pmid-37211679-2026-06-28-f3c11f50c77d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37211679-2026-06-28-f3c11f50c77d`](#source-pubmed-observation-pmid-37211679-2026-06-28-f3c11f50c77d))

### Sources

<a id="source-pubmed-observation-pmid-37211679-2026-06-28-f3c11f50c77d"></a>
- **Octreotide and Octreotide-derived delivery systems. · retained source version 1:2026-06-28:current:f3c11f50c77d576559aee49765534e6d1d0c87b85ba035db17d09abc85b5778b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37211679/) (`pubmed-observation-pmid-37211679-2026-06-28-f3c11f50c77d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Octreotide and Octreotide-derived delivery systems." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-37211679-octreotide-v1 SHA-256: 590cda04e81938806a5ec18c6b93d9991173977032ed94f39b1611219c79bb78.

---

<a id="pubmed-pmid-37951584-octreotide-v1"></a>

## PubMed record PMID 37951584

> PeptideScanner retained PubMed bibliographic metadata for PMID 37951584 at 2026-08-10T10:49:06.851Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2023-11-11. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-37951584-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-04
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37951584-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-37951584-octreotide-v1
- Content SHA-256: `fee26d413b1317710f2bd2a213ab76e00bf3b9863f6a514e8888d1837e7dd659`

### Claims and source pins

#### Headline

PubMed record PMID 37951584 ([`pubmed-observation-pmid-37951584-2026-08-04-7d9d975436e6`](#source-pubmed-observation-pmid-37951584-2026-08-04-7d9d975436e6))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 37951584 at 2026-08-10T10:49:06.851Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2023-11-11. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-37951584-2026-08-04-7d9d975436e6`](#source-pubmed-observation-pmid-37951584-2026-08-04-7d9d975436e6))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 37951584 at 2026-08-10T10:49:06.851Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2023-11-11. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-37951584-2026-08-04-7d9d975436e6`](#source-pubmed-observation-pmid-37951584-2026-08-04-7d9d975436e6))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37951584-2026-08-04-7d9d975436e6`](#source-pubmed-observation-pmid-37951584-2026-08-04-7d9d975436e6))

### Sources

<a id="source-pubmed-observation-pmid-37951584-2026-08-04-7d9d975436e6"></a>
- **PubMed record PMID 37951584 · retained source version 1:2026-08-04:current:7d9d975436e630dfeae447f78228a2d2aba533f06acb1d71c93cbe8e31607965** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37951584/) (`pubmed-observation-pmid-37951584-2026-08-04-7d9d975436e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 37951584." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-37951584-octreotide-v1 SHA-256: fee26d413b1317710f2bd2a213ab76e00bf3b9863f6a514e8888d1837e7dd659.

---

<a id="pubmed-pmid-38407358-octreotide-v1"></a>

## PubMed record PMID 38407358

> PeptideScanner retained PubMed bibliographic metadata for PMID 38407358 at 2026-08-10T10:49:06.879Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2024-02-26. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38407358-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-04
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38407358-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-38407358-octreotide-v1
- Content SHA-256: `581f66cac636a5da0255b4f8af0f30cfc7349dd815fe02ae14b4df7100930c40`

### Claims and source pins

#### Headline

PubMed record PMID 38407358 ([`pubmed-observation-pmid-38407358-2026-08-04-cd9d49e8d1c4`](#source-pubmed-observation-pmid-38407358-2026-08-04-cd9d49e8d1c4))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38407358 at 2026-08-10T10:49:06.879Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2024-02-26. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38407358-2026-08-04-cd9d49e8d1c4`](#source-pubmed-observation-pmid-38407358-2026-08-04-cd9d49e8d1c4))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38407358 at 2026-08-10T10:49:06.879Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2024-02-26. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38407358-2026-08-04-cd9d49e8d1c4`](#source-pubmed-observation-pmid-38407358-2026-08-04-cd9d49e8d1c4))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38407358-2026-08-04-cd9d49e8d1c4`](#source-pubmed-observation-pmid-38407358-2026-08-04-cd9d49e8d1c4))

### Sources

<a id="source-pubmed-observation-pmid-38407358-2026-08-04-cd9d49e8d1c4"></a>
- **PubMed record PMID 38407358 · retained source version 1:2026-08-04:current:cd9d49e8d1c42b48c88901eec69b8a84f7378f222cbaff65b497e01831b736d2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38407358/) (`pubmed-observation-pmid-38407358-2026-08-04-cd9d49e8d1c4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38407358." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-38407358-octreotide-v1 SHA-256: 581f66cac636a5da0255b4f8af0f30cfc7349dd815fe02ae14b4df7100930c40.

---

<a id="pubmed-pmid-38568449-octreotide-v1"></a>

## Latent phosphaturic mesenchymal tumor in left planta detected by \[18F\]F-AlF-NOTA-octreotide PET/CT.

> PubMed lists PMID 38568449 in European journal of nuclear medicine and molecular imaging as Case Reports, Journal Article, with publication-date metadata of 2024-04-03 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38568449-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-11
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38568449-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-38568449-octreotide-v1
- Content SHA-256: `5abadeb6f158a1418ac2c7826906116e879e4863fc4edb677c44a8a0382e7526`

### Claims and source pins

#### Headline

Latent phosphaturic mesenchymal tumor in left planta detected by \[18F\]F-AlF-NOTA-octreotide PET/CT. ([`pubmed-observation-pmid-38568449-2026-07-11-5428cc059779`](#source-pubmed-observation-pmid-38568449-2026-07-11-5428cc059779))

#### Summary

PubMed lists PMID 38568449 in European journal of nuclear medicine and molecular imaging as Case Reports, Journal Article, with publication-date metadata of 2024-04-03 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38568449-2026-07-11-5428cc059779`](#source-pubmed-observation-pmid-38568449-2026-07-11-5428cc059779))

#### Paragraph 1

PubMed lists PMID 38568449 in European journal of nuclear medicine and molecular imaging as Case Reports, Journal Article, with publication-date metadata of 2024-04-03 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38568449-2026-07-11-5428cc059779`](#source-pubmed-observation-pmid-38568449-2026-07-11-5428cc059779))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38568449-2026-07-11-5428cc059779`](#source-pubmed-observation-pmid-38568449-2026-07-11-5428cc059779))

### Sources

<a id="source-pubmed-observation-pmid-38568449-2026-07-11-5428cc059779"></a>
- **Latent phosphaturic mesenchymal tumor in left planta detected by \[18F\]F-AlF-NOTA-octreotide PET/CT. · retained source version 1:2026-07-11:current:5428cc059779304a786faaffce2924b184a8007137c6e89ea786626a883e04eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38568449/) (`pubmed-observation-pmid-38568449-2026-07-11-5428cc059779`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Latent phosphaturic mesenchymal tumor in left planta detected by \[18F\]F-AlF-NOTA-octreotide PET/CT." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-38568449-octreotide-v1 SHA-256: 5abadeb6f158a1418ac2c7826906116e879e4863fc4edb677c44a8a0382e7526.

---

<a id="pubmed-pmid-39631560-octreotide-v1"></a>

## PubMed record PMID 39631560

> PeptideScanner retained PubMed bibliographic metadata for PMID 39631560 at 2026-08-10T10:49:06.913Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2024-12-04. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39631560-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39631560-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-39631560-octreotide-v1
- Content SHA-256: `073b8ef3ae4905aae8822d24613005a97113d56ce1cfe1dc33ae0478a35d8d8d`

### Claims and source pins

#### Headline

PubMed record PMID 39631560 ([`pubmed-observation-pmid-39631560-2026-08-09-a52286c9372e`](#source-pubmed-observation-pmid-39631560-2026-08-09-a52286c9372e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39631560 at 2026-08-10T10:49:06.913Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2024-12-04. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39631560-2026-08-09-a52286c9372e`](#source-pubmed-observation-pmid-39631560-2026-08-09-a52286c9372e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39631560 at 2026-08-10T10:49:06.913Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2024-12-04. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39631560-2026-08-09-a52286c9372e`](#source-pubmed-observation-pmid-39631560-2026-08-09-a52286c9372e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39631560-2026-08-09-a52286c9372e`](#source-pubmed-observation-pmid-39631560-2026-08-09-a52286c9372e))

### Sources

<a id="source-pubmed-observation-pmid-39631560-2026-08-09-a52286c9372e"></a>
- **PubMed record PMID 39631560 · retained source version 1:2026-08-09:current:a52286c9372e4ef2271c7d4c76d5af4ac5e25834112c38c159f19f7fa60f53ea** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39631560/) (`pubmed-observation-pmid-39631560-2026-08-09-a52286c9372e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39631560." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-39631560-octreotide-v1 SHA-256: 073b8ef3ae4905aae8822d24613005a97113d56ce1cfe1dc33ae0478a35d8d8d.

---

<a id="pubmed-pmid-40086695-octreotide-v1"></a>

## Octreotide therapy in patients with a left ventricular assist device and bleeding gastrointestinal angiodysplasias.

> PubMed lists PMID 40086695 in The American journal of the medical sciences as Journal Article, with publication-date metadata of 2025-03-12 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40086695-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40086695-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-40086695-octreotide-v1
- Content SHA-256: `c1850e10eac41800c2b305e54663ae71fd561d6e7ffb0f1ee2b0aa6dcd0aac26`

### Claims and source pins

#### Headline

Octreotide therapy in patients with a left ventricular assist device and bleeding gastrointestinal angiodysplasias. ([`pubmed-observation-pmid-40086695-2026-07-26-a81c06e69624`](#source-pubmed-observation-pmid-40086695-2026-07-26-a81c06e69624))

#### Summary

PubMed lists PMID 40086695 in The American journal of the medical sciences as Journal Article, with publication-date metadata of 2025-03-12 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40086695-2026-07-26-a81c06e69624`](#source-pubmed-observation-pmid-40086695-2026-07-26-a81c06e69624))

#### Paragraph 1

PubMed lists PMID 40086695 in The American journal of the medical sciences as Journal Article, with publication-date metadata of 2025-03-12 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40086695-2026-07-26-a81c06e69624`](#source-pubmed-observation-pmid-40086695-2026-07-26-a81c06e69624))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40086695-2026-07-26-a81c06e69624`](#source-pubmed-observation-pmid-40086695-2026-07-26-a81c06e69624))

### Sources

<a id="source-pubmed-observation-pmid-40086695-2026-07-26-a81c06e69624"></a>
- **Octreotide therapy in patients with a left ventricular assist device and bleeding gastrointestinal angiodysplasias. · retained source version 1:2026-07-26:current:a81c06e69624f0499e8082fbfdee5af8c7f1da9ae0bf3534fca171d59d3fe24e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40086695/) (`pubmed-observation-pmid-40086695-2026-07-26-a81c06e69624`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Octreotide therapy in patients with a left ventricular assist device and bleeding gastrointestinal angiodysplasias." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-40086695-octreotide-v1 SHA-256: c1850e10eac41800c2b305e54663ae71fd561d6e7ffb0f1ee2b0aa6dcd0aac26.

---

<a id="pubmed-pmid-40529047-octreotide-v1"></a>

## SSTR-Mediated Precision Delivery: Overcoming Triptolide's Limitations through Octreotide Conjugation in Pancreatic Cancer Treatment.

> PubMed lists PMID 40529047 in ACS medicinal chemistry letters as Journal Article, with publication-date metadata of 2025-05-13 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40529047-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40529047-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-40529047-octreotide-v1
- Content SHA-256: `7e84526f5bbe2ba7ea5b975b2496dbeee7ece8f8d8c20fccfcc0fc8aaab34359`

### Claims and source pins

#### Headline

SSTR-Mediated Precision Delivery: Overcoming Triptolide's Limitations through Octreotide Conjugation in Pancreatic Cancer Treatment. ([`pubmed-observation-pmid-40529047-2026-07-26-0740748f7a71`](#source-pubmed-observation-pmid-40529047-2026-07-26-0740748f7a71))

#### Summary

PubMed lists PMID 40529047 in ACS medicinal chemistry letters as Journal Article, with publication-date metadata of 2025-05-13 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40529047-2026-07-26-0740748f7a71`](#source-pubmed-observation-pmid-40529047-2026-07-26-0740748f7a71))

#### Paragraph 1

PubMed lists PMID 40529047 in ACS medicinal chemistry letters as Journal Article, with publication-date metadata of 2025-05-13 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40529047-2026-07-26-0740748f7a71`](#source-pubmed-observation-pmid-40529047-2026-07-26-0740748f7a71))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40529047-2026-07-26-0740748f7a71`](#source-pubmed-observation-pmid-40529047-2026-07-26-0740748f7a71))

### Sources

<a id="source-pubmed-observation-pmid-40529047-2026-07-26-0740748f7a71"></a>
- **SSTR-Mediated Precision Delivery: Overcoming Triptolide's Limitations through Octreotide Conjugation in Pancreatic Cancer Treatment. · retained source version 1:2026-07-26:current:0740748f7a717201eedfa109dd44c79da1b133801e2a478853090f5b4dfc5087** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40529047/) (`pubmed-observation-pmid-40529047-2026-07-26-0740748f7a71`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "SSTR-Mediated Precision Delivery: Overcoming Triptolide's Limitations through Octreotide Conjugation in Pancreatic Cancer Treatment." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-40529047-octreotide-v1 SHA-256: 7e84526f5bbe2ba7ea5b975b2496dbeee7ece8f8d8c20fccfcc0fc8aaab34359.

---

<a id="pubmed-pmid-41472624-octreotide-v1"></a>

## Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury.

> PubMed lists PMID 41472624 in Clinical and translational gastroenterology as Journal Article, Comparative Study, with publication-date metadata of 2026-02-01 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41472624-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41472624-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-41472624-octreotide-v1
- Content SHA-256: `e1cdd0e8a7e857a67922321eb0183c2df85d6f80c6932734440b5531efd3d005`

### Claims and source pins

#### Headline

Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury. ([`pubmed-observation-pmid-41472624-2026-08-13-f7e7c2c507f6`](#source-pubmed-observation-pmid-41472624-2026-08-13-f7e7c2c507f6))

#### Summary

PubMed lists PMID 41472624 in Clinical and translational gastroenterology as Journal Article, Comparative Study, with publication-date metadata of 2026-02-01 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41472624-2026-08-13-f7e7c2c507f6`](#source-pubmed-observation-pmid-41472624-2026-08-13-f7e7c2c507f6))

#### Paragraph 1

PubMed lists PMID 41472624 in Clinical and translational gastroenterology as Journal Article, Comparative Study, with publication-date metadata of 2026-02-01 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41472624-2026-08-13-f7e7c2c507f6`](#source-pubmed-observation-pmid-41472624-2026-08-13-f7e7c2c507f6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41472624-2026-08-13-f7e7c2c507f6`](#source-pubmed-observation-pmid-41472624-2026-08-13-f7e7c2c507f6))

### Sources

<a id="source-pubmed-observation-pmid-41472624-2026-08-13-f7e7c2c507f6"></a>
- **Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury. · retained source version 1:2026-08-13:current:f7e7c2c507f6c4281c06579da10a83cf8aefd9e160f323eb207325cdcc10934d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41472624/) (`pubmed-observation-pmid-41472624-2026-08-13-f7e7c2c507f6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-41472624-octreotide-v1 SHA-256: e1cdd0e8a7e857a67922321eb0183c2df85d6f80c6932734440b5531efd3d005.

---

<a id="pubmed-pmid-41647114-octreotide-v1"></a>

## Octreotide long-acting release in the treatment of autosomal dominant polycystic kidney disease: a meta-analysis.

> PubMed lists PMID 41647114 in Frontiers in endocrinology as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2026-01-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41647114-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-13
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41647114-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-41647114-octreotide-v1
- Content SHA-256: `85f7376c1b480bbbc6151835f43c63b7390ca66db2616327893136076246f48b`

### Claims and source pins

#### Headline

Octreotide long-acting release in the treatment of autosomal dominant polycystic kidney disease: a meta-analysis. ([`pubmed-observation-pmid-41647114-2026-07-13-bf553f1ffa0c`](#source-pubmed-observation-pmid-41647114-2026-07-13-bf553f1ffa0c))

#### Summary

PubMed lists PMID 41647114 in Frontiers in endocrinology as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2026-01-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41647114-2026-07-13-bf553f1ffa0c`](#source-pubmed-observation-pmid-41647114-2026-07-13-bf553f1ffa0c))

#### Paragraph 1

PubMed lists PMID 41647114 in Frontiers in endocrinology as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2026-01-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41647114-2026-07-13-bf553f1ffa0c`](#source-pubmed-observation-pmid-41647114-2026-07-13-bf553f1ffa0c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41647114-2026-07-13-bf553f1ffa0c`](#source-pubmed-observation-pmid-41647114-2026-07-13-bf553f1ffa0c))

### Sources

<a id="source-pubmed-observation-pmid-41647114-2026-07-13-bf553f1ffa0c"></a>
- **Octreotide long-acting release in the treatment of autosomal dominant polycystic kidney disease: a meta-analysis. · retained source version 1:2026-07-13:current:bf553f1ffa0c8c84c4129b5d97ae42898b5397326628612409b90aa142616489** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41647114/) (`pubmed-observation-pmid-41647114-2026-07-13-bf553f1ffa0c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Octreotide long-acting release in the treatment of autosomal dominant polycystic kidney disease: a meta-analysis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-41647114-octreotide-v1 SHA-256: 85f7376c1b480bbbc6151835f43c63b7390ca66db2616327893136076246f48b.

---

<a id="pubmed-pmid-41719493-octreotide-v1"></a>

## PubMed record PMID 41719493

> PeptideScanner retained PubMed bibliographic metadata for PMID 41719493 at 2026-08-10T18:13:42.706Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-02-20. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41719493-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41719493-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-41719493-octreotide-v1
- Content SHA-256: `3c9ef98b0512083dd39dd1b9dead2fb6737ae5f2431e4558563212f597bc2b4b`

### Claims and source pins

#### Headline

PubMed record PMID 41719493 ([`pubmed-observation-pmid-41719493-2026-07-29-18e839888a11`](#source-pubmed-observation-pmid-41719493-2026-07-29-18e839888a11))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41719493 at 2026-08-10T18:13:42.706Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-02-20. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41719493-2026-07-29-18e839888a11`](#source-pubmed-observation-pmid-41719493-2026-07-29-18e839888a11))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41719493 at 2026-08-10T18:13:42.706Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-02-20. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41719493-2026-07-29-18e839888a11`](#source-pubmed-observation-pmid-41719493-2026-07-29-18e839888a11))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41719493-2026-07-29-18e839888a11`](#source-pubmed-observation-pmid-41719493-2026-07-29-18e839888a11))

### Sources

<a id="source-pubmed-observation-pmid-41719493-2026-07-29-18e839888a11"></a>
- **PubMed record PMID 41719493 · retained source version 1:2026-07-29:current:18e839888a1199a62703df29df284ddfaafcf5cfd4eb8eff27c5f624cfb67974** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41719493/) (`pubmed-observation-pmid-41719493-2026-07-29-18e839888a11`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41719493." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-41719493-octreotide-v1 SHA-256: 3c9ef98b0512083dd39dd1b9dead2fb6737ae5f2431e4558563212f597bc2b4b.

---

<a id="pubmed-pmid-41831704-octreotide-v1"></a>

## Comprehensive design and characterization of pH-gradient-loaded donkey-milk exosomes for oral octreotide delivery: A bench-to-in silico roadmap.

> PubMed lists PMID 41831704 in International journal of pharmaceutics as Journal Article, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41831704-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-11
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41831704-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-41831704-octreotide-v1
- Content SHA-256: `1304868d2348d648acfa0886d6a2d3bc7b2b551ccd88d004bf509b291206c646`

### Claims and source pins

#### Headline

Comprehensive design and characterization of pH-gradient-loaded donkey-milk exosomes for oral octreotide delivery: A bench-to-in silico roadmap. ([`pubmed-observation-pmid-41831704-2026-07-11-78a249745834`](#source-pubmed-observation-pmid-41831704-2026-07-11-78a249745834))

#### Summary

PubMed lists PMID 41831704 in International journal of pharmaceutics as Journal Article, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41831704-2026-07-11-78a249745834`](#source-pubmed-observation-pmid-41831704-2026-07-11-78a249745834))

#### Paragraph 1

PubMed lists PMID 41831704 in International journal of pharmaceutics as Journal Article, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41831704-2026-07-11-78a249745834`](#source-pubmed-observation-pmid-41831704-2026-07-11-78a249745834))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41831704-2026-07-11-78a249745834`](#source-pubmed-observation-pmid-41831704-2026-07-11-78a249745834))

### Sources

<a id="source-pubmed-observation-pmid-41831704-2026-07-11-78a249745834"></a>
- **Comprehensive design and characterization of pH-gradient-loaded donkey-milk exosomes for oral octreotide delivery: A bench-to-in silico roadmap. · retained source version 1:2026-07-11:current:78a24974583407a5a1719915af7add679e9f4cefba746f019dafa8053bba2730** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41831704/) (`pubmed-observation-pmid-41831704-2026-07-11-78a249745834`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comprehensive design and characterization of pH-gradient-loaded donkey-milk exosomes for oral octreotide delivery: A bench-to-in silico roadmap." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-41831704-octreotide-v1 SHA-256: 1304868d2348d648acfa0886d6a2d3bc7b2b551ccd88d004bf509b291206c646.

---

<a id="pubmed-pmid-41840662-octreotide-v1"></a>

## Recurrent ventricular asystole during octreotide infusion in a patient with pancreatic neuroendocrine tumor: a case report.

> PubMed lists PMID 41840662 in Journal of medical case reports as Journal Article, Case Reports, with publication-date metadata of 2026-03-16 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41840662-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-11
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41840662-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-41840662-octreotide-v1
- Content SHA-256: `e90e36726914ccb391003a867a296baad88f2673328b472a6c5b15b8e7d5cfdb`

### Claims and source pins

#### Headline

Recurrent ventricular asystole during octreotide infusion in a patient with pancreatic neuroendocrine tumor: a case report. ([`pubmed-observation-pmid-41840662-2026-07-11-89d37d681eb0`](#source-pubmed-observation-pmid-41840662-2026-07-11-89d37d681eb0))

#### Summary

PubMed lists PMID 41840662 in Journal of medical case reports as Journal Article, Case Reports, with publication-date metadata of 2026-03-16 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41840662-2026-07-11-89d37d681eb0`](#source-pubmed-observation-pmid-41840662-2026-07-11-89d37d681eb0))

#### Paragraph 1

PubMed lists PMID 41840662 in Journal of medical case reports as Journal Article, Case Reports, with publication-date metadata of 2026-03-16 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41840662-2026-07-11-89d37d681eb0`](#source-pubmed-observation-pmid-41840662-2026-07-11-89d37d681eb0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41840662-2026-07-11-89d37d681eb0`](#source-pubmed-observation-pmid-41840662-2026-07-11-89d37d681eb0))

### Sources

<a id="source-pubmed-observation-pmid-41840662-2026-07-11-89d37d681eb0"></a>
- **Recurrent ventricular asystole during octreotide infusion in a patient with pancreatic neuroendocrine tumor: a case report. · retained source version 1:2026-07-11:current:89d37d681eb0f90e7a6e9da78dc1c6b2a91172d75fd9888cb397a61a432cf632** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41840662/) (`pubmed-observation-pmid-41840662-2026-07-11-89d37d681eb0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Recurrent ventricular asystole during octreotide infusion in a patient with pancreatic neuroendocrine tumor: a case report." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-41840662-octreotide-v1 SHA-256: e90e36726914ccb391003a867a296baad88f2673328b472a6c5b15b8e7d5cfdb.

---

<a id="pubmed-pmid-42014536-octreotide-v1"></a>

## Optimization of automated radiosynthesis method for \[18F\]AlF-NOTA-Octreotide and PET/CT imaging in neuroendocrine neoplasms.

> PubMed lists PMID 42014536 in EJNMMI radiopharmacy and chemistry as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42014536-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42014536-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42014536-octreotide-v1
- Content SHA-256: `effcaa34e4b2a9d1a3325b6704363bcd6773c4265a40d31e0d02213077667702`

### Claims and source pins

#### Headline

Optimization of automated radiosynthesis method for \[18F\]AlF-NOTA-Octreotide and PET/CT imaging in neuroendocrine neoplasms. ([`pubmed-observation-pmid-42014536-2026-07-26-e43eb8f17c18`](#source-pubmed-observation-pmid-42014536-2026-07-26-e43eb8f17c18))

#### Summary

PubMed lists PMID 42014536 in EJNMMI radiopharmacy and chemistry as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42014536-2026-07-26-e43eb8f17c18`](#source-pubmed-observation-pmid-42014536-2026-07-26-e43eb8f17c18))

#### Paragraph 1

PubMed lists PMID 42014536 in EJNMMI radiopharmacy and chemistry as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42014536-2026-07-26-e43eb8f17c18`](#source-pubmed-observation-pmid-42014536-2026-07-26-e43eb8f17c18))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42014536-2026-07-26-e43eb8f17c18`](#source-pubmed-observation-pmid-42014536-2026-07-26-e43eb8f17c18))

### Sources

<a id="source-pubmed-observation-pmid-42014536-2026-07-26-e43eb8f17c18"></a>
- **Optimization of automated radiosynthesis method for \[18F\]AlF-NOTA-Octreotide and PET/CT imaging in neuroendocrine neoplasms. · retained source version 1:2026-07-26:current:e43eb8f17c1859d0436c40570dd69daf25a449321adaf733fb9ec067d18ceebf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42014536/) (`pubmed-observation-pmid-42014536-2026-07-26-e43eb8f17c18`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Optimization of automated radiosynthesis method for \[18F\]AlF-NOTA-Octreotide and PET/CT imaging in neuroendocrine neoplasms." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42014536-octreotide-v1 SHA-256: effcaa34e4b2a9d1a3325b6704363bcd6773c4265a40d31e0d02213077667702.

---

<a id="pubmed-pmid-42026400-octreotide-v1"></a>

## Uptake of 18F-AlF-NOTA-octreotide PET/CT in gastrointestinal stromal tumors.

> PubMed lists PMID 42026400 in EJNMMI reports as Journal Article, with publication-date metadata of 2026-04-24 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42026400-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42026400-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42026400-octreotide-v1
- Content SHA-256: `b830f9aae75318f5775d4fe07c5e79d9aaecb3f00525d8e69bed839e6832ad9f`

### Claims and source pins

#### Headline

Uptake of 18F-AlF-NOTA-octreotide PET/CT in gastrointestinal stromal tumors. ([`pubmed-observation-pmid-42026400-2026-08-13-3921f3ad0451`](#source-pubmed-observation-pmid-42026400-2026-08-13-3921f3ad0451))

#### Summary

PubMed lists PMID 42026400 in EJNMMI reports as Journal Article, with publication-date metadata of 2026-04-24 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42026400-2026-08-13-3921f3ad0451`](#source-pubmed-observation-pmid-42026400-2026-08-13-3921f3ad0451))

#### Paragraph 1

PubMed lists PMID 42026400 in EJNMMI reports as Journal Article, with publication-date metadata of 2026-04-24 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42026400-2026-08-13-3921f3ad0451`](#source-pubmed-observation-pmid-42026400-2026-08-13-3921f3ad0451))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42026400-2026-08-13-3921f3ad0451`](#source-pubmed-observation-pmid-42026400-2026-08-13-3921f3ad0451))

### Sources

<a id="source-pubmed-observation-pmid-42026400-2026-08-13-3921f3ad0451"></a>
- **Uptake of 18F-AlF-NOTA-octreotide PET/CT in gastrointestinal stromal tumors. · retained source version 1:2026-08-13:current:3921f3ad04512f95397a601d413a1aa222210c0bb1a95642b464f8b136854e8e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42026400/) (`pubmed-observation-pmid-42026400-2026-08-13-3921f3ad0451`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Uptake of 18F-AlF-NOTA-octreotide PET/CT in gastrointestinal stromal tumors." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42026400-octreotide-v1 SHA-256: b830f9aae75318f5775d4fe07c5e79d9aaecb3f00525d8e69bed839e6832ad9f.

---

<a id="pubmed-pmid-42029102-octreotide-v1"></a>

## PubMed record PMID 42029102

> PeptideScanner retained PubMed bibliographic metadata for PMID 42029102 at 2026-08-10T10:49:08.854Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-04-24. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42029102-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42029102-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42029102-octreotide-v1
- Content SHA-256: `42fc9c134df14ebafb991ced96c3814dcbe9f21995a79f1040dafb12a599e197`

### Claims and source pins

#### Headline

PubMed record PMID 42029102 ([`pubmed-observation-pmid-42029102-2026-08-03-f262a6a7e4e8`](#source-pubmed-observation-pmid-42029102-2026-08-03-f262a6a7e4e8))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42029102 at 2026-08-10T10:49:08.854Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-04-24. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42029102-2026-08-03-f262a6a7e4e8`](#source-pubmed-observation-pmid-42029102-2026-08-03-f262a6a7e4e8))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42029102 at 2026-08-10T10:49:08.854Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-04-24. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42029102-2026-08-03-f262a6a7e4e8`](#source-pubmed-observation-pmid-42029102-2026-08-03-f262a6a7e4e8))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42029102-2026-08-03-f262a6a7e4e8`](#source-pubmed-observation-pmid-42029102-2026-08-03-f262a6a7e4e8))

### Sources

<a id="source-pubmed-observation-pmid-42029102-2026-08-03-f262a6a7e4e8"></a>
- **PubMed record PMID 42029102 · retained source version 1:2026-08-03:current:f262a6a7e4e8caf65eb3fe1037d968252a7318ef0de4d8099efa9fe013a2ece8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42029102/) (`pubmed-observation-pmid-42029102-2026-08-03-f262a6a7e4e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42029102." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42029102-octreotide-v1 SHA-256: 42fc9c134df14ebafb991ced96c3814dcbe9f21995a79f1040dafb12a599e197.

---

<a id="pubmed-pmid-42169939-octreotide-v1"></a>

## Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience.

> PubMed lists PMID 42169939 in Journal of gastrointestinal oncology as Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42169939-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42169939-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42169939-octreotide-v1
- Content SHA-256: `3238a771ae04533c68d2fe81e940a2dace6ca3f116ecc3277a91e267e5ba91ef`

### Claims and source pins

#### Headline

Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience. ([`pubmed-observation-pmid-42169939-2026-08-13-06e297b8cda2`](#source-pubmed-observation-pmid-42169939-2026-08-13-06e297b8cda2))

#### Summary

PubMed lists PMID 42169939 in Journal of gastrointestinal oncology as Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42169939-2026-08-13-06e297b8cda2`](#source-pubmed-observation-pmid-42169939-2026-08-13-06e297b8cda2))

#### Paragraph 1

PubMed lists PMID 42169939 in Journal of gastrointestinal oncology as Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42169939-2026-08-13-06e297b8cda2`](#source-pubmed-observation-pmid-42169939-2026-08-13-06e297b8cda2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42169939-2026-08-13-06e297b8cda2`](#source-pubmed-observation-pmid-42169939-2026-08-13-06e297b8cda2))

### Sources

<a id="source-pubmed-observation-pmid-42169939-2026-08-13-06e297b8cda2"></a>
- **Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience. · retained source version 1:2026-08-13:current:06e297b8cda201ad477b5c8afbca6205fdf9a8379d0960360c74858ae263890b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42169939/) (`pubmed-observation-pmid-42169939-2026-08-13-06e297b8cda2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42169939-octreotide-v1 SHA-256: 3238a771ae04533c68d2fe81e940a2dace6ca3f116ecc3277a91e267e5ba91ef.

---

<a id="pubmed-pmid-42333429-octreotide-v1"></a>

## PubMed record PMID 42333429

> PeptideScanner retained PubMed bibliographic metadata for PMID 42333429 at 2026-08-10T10:49:10.713Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-23. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42333429-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42333429-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42333429-octreotide-v1
- Content SHA-256: `4e48e2c1fd976a600441013a99433470278bfe5a88189192deb38992f16079b5`

### Claims and source pins

#### Headline

PubMed record PMID 42333429 ([`pubmed-observation-pmid-42333429-2026-08-03-e5ad96752d31`](#source-pubmed-observation-pmid-42333429-2026-08-03-e5ad96752d31))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42333429 at 2026-08-10T10:49:10.713Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-23. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42333429-2026-08-03-e5ad96752d31`](#source-pubmed-observation-pmid-42333429-2026-08-03-e5ad96752d31))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42333429 at 2026-08-10T10:49:10.713Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-23. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42333429-2026-08-03-e5ad96752d31`](#source-pubmed-observation-pmid-42333429-2026-08-03-e5ad96752d31))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42333429-2026-08-03-e5ad96752d31`](#source-pubmed-observation-pmid-42333429-2026-08-03-e5ad96752d31))

### Sources

<a id="source-pubmed-observation-pmid-42333429-2026-08-03-e5ad96752d31"></a>
- **PubMed record PMID 42333429 · retained source version 1:2026-08-03:current:e5ad96752d3137944824af34ddff8d04644cc26a1ffefa24ce83770a0e4b7c9f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42333429/) (`pubmed-observation-pmid-42333429-2026-08-03-e5ad96752d31`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42333429." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42333429-octreotide-v1 SHA-256: 4e48e2c1fd976a600441013a99433470278bfe5a88189192deb38992f16079b5.

---

<a id="pubmed-pmid-42370133-octreotide-v1"></a>

## Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report.

> PubMed lists PMID 42370133 in Frontiers in oncology as Case Reports, Journal Article, with publication-date metadata of 2026-06-11 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42370133-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42370133-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42370133-octreotide-v1
- Content SHA-256: `90aba33f74b60037ffbda3136be0a86161e7072f607e1aaaedaebfa1f03ae5ca`

### Claims and source pins

#### Headline

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report. ([`pubmed-observation-pmid-42370133-2026-08-13-0b1ac7241d1d`](#source-pubmed-observation-pmid-42370133-2026-08-13-0b1ac7241d1d))

#### Summary

PubMed lists PMID 42370133 in Frontiers in oncology as Case Reports, Journal Article, with publication-date metadata of 2026-06-11 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42370133-2026-08-13-0b1ac7241d1d`](#source-pubmed-observation-pmid-42370133-2026-08-13-0b1ac7241d1d))

#### Paragraph 1

PubMed lists PMID 42370133 in Frontiers in oncology as Case Reports, Journal Article, with publication-date metadata of 2026-06-11 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42370133-2026-08-13-0b1ac7241d1d`](#source-pubmed-observation-pmid-42370133-2026-08-13-0b1ac7241d1d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42370133-2026-08-13-0b1ac7241d1d`](#source-pubmed-observation-pmid-42370133-2026-08-13-0b1ac7241d1d))

### Sources

<a id="source-pubmed-observation-pmid-42370133-2026-08-13-0b1ac7241d1d"></a>
- **Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report. · retained source version 1:2026-08-13:current:0b1ac7241d1d46305d86af9e0e1d9807ea95012cc191d40d7d443846db416946** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42370133/) (`pubmed-observation-pmid-42370133-2026-08-13-0b1ac7241d1d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42370133-octreotide-v1 SHA-256: 90aba33f74b60037ffbda3136be0a86161e7072f607e1aaaedaebfa1f03ae5ca.

---

<a id="pubmed-pmid-42478204-octreotide-v1"></a>

## Octreotide in the Management of Chyle Leaks After Head and Neck Surgery: A Systematic Review of Cohort Studies.

> PubMed lists PMID 42478204 in The Journal of laryngology and otology as Journal Article, Review, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42478204-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-21
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42478204-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42478204-octreotide-v1
- Content SHA-256: `dd5d5c41ac4350ef06d53b80fd859b0cec00799c54078048f44699286e207542`

### Claims and source pins

#### Headline

Octreotide in the Management of Chyle Leaks After Head and Neck Surgery: A Systematic Review of Cohort Studies. ([`pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8`](#source-pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8))

#### Summary

PubMed lists PMID 42478204 in The Journal of laryngology and otology as Journal Article, Review, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8`](#source-pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8))

#### Paragraph 1

PubMed lists PMID 42478204 in The Journal of laryngology and otology as Journal Article, Review, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8`](#source-pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8`](#source-pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8))

### Sources

<a id="source-pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8"></a>
- **Octreotide in the Management of Chyle Leaks After Head and Neck Surgery: A Systematic Review of Cohort Studies. · retained source version 1:2026-07-21:current:1c4af7971ca871e2db6dbd7c52c76ef4827c4dd27f3de67197d22a1664a1c0fc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42478204/) (`pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Octreotide in the Management of Chyle Leaks After Head and Neck Surgery: A Systematic Review of Cohort Studies." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42478204-octreotide-v1 SHA-256: dd5d5c41ac4350ef06d53b80fd859b0cec00799c54078048f44699286e207542.

---

<a id="pubmed-pmid-42478204-octreotide-v2"></a>

## Octreotide in the management of chyle leaks after head and neck surgery: a systematic review of cohort studies.

> PubMed lists PMID 42478204 in The Journal of laryngology and otology as Journal Article, Review, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42478204-octreotide:v2`
- Evidence domain: Literature metadata
- Date in source: 2026-09-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42478204-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42478204-octreotide-v2
- Content SHA-256: `ccf3c4689558a50c1c1c659e236995b191843c9abb1d9934c3111a8efbb87583`

### Claims and source pins

#### Headline

Octreotide in the management of chyle leaks after head and neck surgery: a systematic review of cohort studies. ([`pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2`](#source-pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2))

#### Summary

PubMed lists PMID 42478204 in The Journal of laryngology and otology as Journal Article, Review, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2`](#source-pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2))

#### Paragraph 1

PubMed lists PMID 42478204 in The Journal of laryngology and otology as Journal Article, Review, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2`](#source-pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2`](#source-pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2))

### Sources

<a id="source-pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2"></a>
- **Octreotide in the management of chyle leaks after head and neck surgery: a systematic review of cohort studies. · retained source version 1:2026-09-28:current:831a576d689d07dfbb681a0a42f4b9b3104320f2a7922da8b288bd1367d086c3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42478204/) (`pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2`)

### Correction lineage

updated on 2026-11-16: PubMed revised the bibliographic metadata of PMID 42478204, with a metadata revision date of 2026-09-28. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2`](#source-pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2)

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Octreotide in the management of chyle leaks after head and neck surgery: a systematic review of cohort studies." Version 2, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42478204-octreotide-v2 SHA-256: ccf3c4689558a50c1c1c659e236995b191843c9abb1d9934c3111a8efbb87583.

---

<a id="pubmed-pmid-42503373-octreotide-v1"></a>

## PubMed record PMID 42503373

> PeptideScanner retained PubMed bibliographic metadata for PMID 42503373 at 2026-08-10T18:13:56.753Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-26. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42503373-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42503373-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42503373-octreotide-v1
- Content SHA-256: `43141cf4c5224fb0aa7056acd36651642ff4dea426070b1fc3e5159f74e1ddef`

### Claims and source pins

#### Headline

PubMed record PMID 42503373 ([`pubmed-observation-pmid-42503373-2026-07-26-4e51aeee41c7`](#source-pubmed-observation-pmid-42503373-2026-07-26-4e51aeee41c7))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42503373 at 2026-08-10T18:13:56.753Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-26. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42503373-2026-07-26-4e51aeee41c7`](#source-pubmed-observation-pmid-42503373-2026-07-26-4e51aeee41c7))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42503373 at 2026-08-10T18:13:56.753Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-26. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42503373-2026-07-26-4e51aeee41c7`](#source-pubmed-observation-pmid-42503373-2026-07-26-4e51aeee41c7))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42503373-2026-07-26-4e51aeee41c7`](#source-pubmed-observation-pmid-42503373-2026-07-26-4e51aeee41c7))

### Sources

<a id="source-pubmed-observation-pmid-42503373-2026-07-26-4e51aeee41c7"></a>
- **PubMed record PMID 42503373 · retained source version 1:2026-07-26:current:4e51aeee41c7aeec01feeadacd9c44eb4d5947499558fe0f4e860ff562797682** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42503373/) (`pubmed-observation-pmid-42503373-2026-07-26-4e51aeee41c7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42503373." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42503373-octreotide-v1 SHA-256: 43141cf4c5224fb0aa7056acd36651642ff4dea426070b1fc3e5159f74e1ddef.

---

<a id="pubmed-pmid-42515664-octreotide-v1"></a>

## PubMed record PMID 42515664

> PeptideScanner retained PubMed bibliographic metadata for PMID 42515664 at 2026-08-10T10:49:12.892Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42515664-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-31
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42515664-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42515664-octreotide-v1
- Content SHA-256: `e8651b96b772b5b5c20b8a3886b6d5d72a6c3d92d7f8b55bdb6624040155e777`

### Claims and source pins

#### Headline

PubMed record PMID 42515664 ([`pubmed-observation-pmid-42515664-2026-07-31-daf03be0f37a`](#source-pubmed-observation-pmid-42515664-2026-07-31-daf03be0f37a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42515664 at 2026-08-10T10:49:12.892Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42515664-2026-07-31-daf03be0f37a`](#source-pubmed-observation-pmid-42515664-2026-07-31-daf03be0f37a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42515664 at 2026-08-10T10:49:12.892Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42515664-2026-07-31-daf03be0f37a`](#source-pubmed-observation-pmid-42515664-2026-07-31-daf03be0f37a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42515664-2026-07-31-daf03be0f37a`](#source-pubmed-observation-pmid-42515664-2026-07-31-daf03be0f37a))

### Sources

<a id="source-pubmed-observation-pmid-42515664-2026-07-31-daf03be0f37a"></a>
- **PubMed record PMID 42515664 · retained source version 1:2026-07-31:current:daf03be0f37acdec193228b5772b9b505bffc76110508b17f6f0c9f1cb8d2f9e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42515664/) (`pubmed-observation-pmid-42515664-2026-07-31-daf03be0f37a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42515664." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42515664-octreotide-v1 SHA-256: e8651b96b772b5b5c20b8a3886b6d5d72a6c3d92d7f8b55bdb6624040155e777.

---

<a id="pubmed-pmid-42712757-octreotide-v1"></a>

## A long-acting octreotide analog formed by conjugation with a peptide linker modified with two fatty acids.

> PubMed lists PMID 42712757 in Frontiers in endocrinology as Journal Article, Randomized Controlled Trial, Clinical Trial, with publication-date metadata of 2026-08-25 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42712757-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-09
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42712757-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42712757-octreotide-v1
- Content SHA-256: `52fe3cf256eb791a875dcf04769a85b532dd68bab8604f208121d4a41b0fd78e`

### Claims and source pins

#### Headline

A long-acting octreotide analog formed by conjugation with a peptide linker modified with two fatty acids. ([`pubmed-observation-pmid-42712757-2026-09-09-36f27a718dd5`](#source-pubmed-observation-pmid-42712757-2026-09-09-36f27a718dd5))

#### Summary

PubMed lists PMID 42712757 in Frontiers in endocrinology as Journal Article, Randomized Controlled Trial, Clinical Trial, with publication-date metadata of 2026-08-25 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42712757-2026-09-09-36f27a718dd5`](#source-pubmed-observation-pmid-42712757-2026-09-09-36f27a718dd5))

#### Paragraph 1

PubMed lists PMID 42712757 in Frontiers in endocrinology as Journal Article, Randomized Controlled Trial, Clinical Trial, with publication-date metadata of 2026-08-25 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42712757-2026-09-09-36f27a718dd5`](#source-pubmed-observation-pmid-42712757-2026-09-09-36f27a718dd5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42712757-2026-09-09-36f27a718dd5`](#source-pubmed-observation-pmid-42712757-2026-09-09-36f27a718dd5))

### Sources

<a id="source-pubmed-observation-pmid-42712757-2026-09-09-36f27a718dd5"></a>
- **A long-acting octreotide analog formed by conjugation with a peptide linker modified with two fatty acids. · retained source version 1:2026-09-09:current:36f27a718dd53f76368cf564f08cae7a41857334e4c3d6f76a1390a1b9d98c68** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42712757/) (`pubmed-observation-pmid-42712757-2026-09-09-36f27a718dd5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A long-acting octreotide analog formed by conjugation with a peptide linker modified with two fatty acids." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42712757-octreotide-v1 SHA-256: 52fe3cf256eb791a875dcf04769a85b532dd68bab8604f208121d4a41b0fd78e.

---

<a id="pubmed-pmid-42931878-octreotide-v1"></a>

## Oxalate Nephropathy in a patient with Neuroendocrine tumor receiving Long-acting Octreotide.

> PubMed lists PMID 42931878 in CEN case reports as Journal Article, Case Reports, with publication-date metadata of 2026-10-26 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42931878-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-29
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42931878-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42931878-octreotide-v1
- Content SHA-256: `19983fd0472e76de9a2c04d7948be851d3bc144c753161ca17e3cdf9de464fa3`

### Claims and source pins

#### Headline

Oxalate Nephropathy in a patient with Neuroendocrine tumor receiving Long-acting Octreotide. ([`pubmed-observation-pmid-42931878-2026-10-29-52acb08cdc3a`](#source-pubmed-observation-pmid-42931878-2026-10-29-52acb08cdc3a))

#### Summary

PubMed lists PMID 42931878 in CEN case reports as Journal Article, Case Reports, with publication-date metadata of 2026-10-26 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42931878-2026-10-29-52acb08cdc3a`](#source-pubmed-observation-pmid-42931878-2026-10-29-52acb08cdc3a))

#### Paragraph 1

PubMed lists PMID 42931878 in CEN case reports as Journal Article, Case Reports, with publication-date metadata of 2026-10-26 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42931878-2026-10-29-52acb08cdc3a`](#source-pubmed-observation-pmid-42931878-2026-10-29-52acb08cdc3a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42931878-2026-10-29-52acb08cdc3a`](#source-pubmed-observation-pmid-42931878-2026-10-29-52acb08cdc3a))

### Sources

<a id="source-pubmed-observation-pmid-42931878-2026-10-29-52acb08cdc3a"></a>
- **Oxalate Nephropathy in a patient with Neuroendocrine tumor receiving Long-acting Octreotide. · retained source version 1:2026-10-29:current:52acb08cdc3acc59c4cff354e1013e8607580f8bab0ff74e1362f5aef91549b6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42931878/) (`pubmed-observation-pmid-42931878-2026-10-29-52acb08cdc3a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Oxalate Nephropathy in a patient with Neuroendocrine tumor receiving Long-acting Octreotide." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42931878-octreotide-v1 SHA-256: 19983fd0472e76de9a2c04d7948be851d3bc144c753161ca17e3cdf9de464fa3.

---

<a id="pubmed-pmid-42940741-octreotide-v1"></a>

## Mechanistic Basis of Octreotide Therapy in Neonatal Postoperative Chylothorax: A Translational Case Report.

> PubMed lists PMID 42940741 in Children (Basel, Switzerland) as Case Reports, Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42940741-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-28
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42940741-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42940741-octreotide-v1
- Content SHA-256: `6612d7d6a92295618f932db9bf22063cedd6389e6c7e2a636492f1dcaa4d9593`

### Claims and source pins

#### Headline

Mechanistic Basis of Octreotide Therapy in Neonatal Postoperative Chylothorax: A Translational Case Report. ([`pubmed-observation-pmid-42940741-2026-10-28-3d358a18b56f`](#source-pubmed-observation-pmid-42940741-2026-10-28-3d358a18b56f))

#### Summary

PubMed lists PMID 42940741 in Children (Basel, Switzerland) as Case Reports, Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42940741-2026-10-28-3d358a18b56f`](#source-pubmed-observation-pmid-42940741-2026-10-28-3d358a18b56f))

#### Paragraph 1

PubMed lists PMID 42940741 in Children (Basel, Switzerland) as Case Reports, Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42940741-2026-10-28-3d358a18b56f`](#source-pubmed-observation-pmid-42940741-2026-10-28-3d358a18b56f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42940741-2026-10-28-3d358a18b56f`](#source-pubmed-observation-pmid-42940741-2026-10-28-3d358a18b56f))

### Sources

<a id="source-pubmed-observation-pmid-42940741-2026-10-28-3d358a18b56f"></a>
- **Mechanistic Basis of Octreotide Therapy in Neonatal Postoperative Chylothorax: A Translational Case Report. · retained source version 1:2026-10-28:current:3d358a18b56fbda1e352269beb792cb7d919131777b5f3e2f0a016b593b86ca4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42940741/) (`pubmed-observation-pmid-42940741-2026-10-28-3d358a18b56f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Mechanistic Basis of Octreotide Therapy in Neonatal Postoperative Chylothorax: A Translational Case Report." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42940741-octreotide-v1 SHA-256: 6612d7d6a92295618f932db9bf22063cedd6389e6c7e2a636492f1dcaa4d9593.

---

<a id="pubmed-pmid-42944769-octreotide-v1"></a>

## Octreotide-modified pH-responsive nanocomposites for ultrasound imaging-guided chemo-photothermal therapy of prostate cancer.

> PubMed lists PMID 42944769 in Nanoscale as Journal Article, with publication-date metadata of 2026-11-12 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42944769-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42944769-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42944769-octreotide-v1
- Content SHA-256: `5fd6a1f357684b8789ad7692f145d65838cba66f13bd44aae200e350d5fd662b`

### Claims and source pins

#### Headline

Octreotide-modified pH-responsive nanocomposites for ultrasound imaging-guided chemo-photothermal therapy of prostate cancer. ([`pubmed-observation-pmid-42944769-2026-11-12-f9047d3489ae`](#source-pubmed-observation-pmid-42944769-2026-11-12-f9047d3489ae))

#### Summary

PubMed lists PMID 42944769 in Nanoscale as Journal Article, with publication-date metadata of 2026-11-12 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42944769-2026-11-12-f9047d3489ae`](#source-pubmed-observation-pmid-42944769-2026-11-12-f9047d3489ae))

#### Paragraph 1

PubMed lists PMID 42944769 in Nanoscale as Journal Article, with publication-date metadata of 2026-11-12 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42944769-2026-11-12-f9047d3489ae`](#source-pubmed-observation-pmid-42944769-2026-11-12-f9047d3489ae))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42944769-2026-11-12-f9047d3489ae`](#source-pubmed-observation-pmid-42944769-2026-11-12-f9047d3489ae))

### Sources

<a id="source-pubmed-observation-pmid-42944769-2026-11-12-f9047d3489ae"></a>
- **Octreotide-modified pH-responsive nanocomposites for ultrasound imaging-guided chemo-photothermal therapy of prostate cancer. · retained source version 1:2026-11-12:current:f9047d3489ae478071d004b4a6984f250b4d21054c20eba349c4b1afce901f4f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42944769/) (`pubmed-observation-pmid-42944769-2026-11-12-f9047d3489ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Octreotide-modified pH-responsive nanocomposites for ultrasound imaging-guided chemo-photothermal therapy of prostate cancer." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42944769-octreotide-v1 SHA-256: 5fd6a1f357684b8789ad7692f145d65838cba66f13bd44aae200e350d5fd662b.

---

<a id="pubmed-pmid-42964248-octreotide-v1"></a>

## Cascaded deep learning for synthesis of 18F-FDG PET from 18F-octreotide: model parameter optimization and performance evaluation.

> PubMed lists PMID 42964248 in Frontiers in nuclear medicine as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42964248-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-01
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42964248-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42964248-octreotide-v1
- Content SHA-256: `d189ce7cc6c1231ea2e5449302eb1cfa3effa396cad3f70cfdf06d359669faa8`

### Claims and source pins

#### Headline

Cascaded deep learning for synthesis of 18F-FDG PET from 18F-octreotide: model parameter optimization and performance evaluation. ([`pubmed-observation-pmid-42964248-2026-11-01-edeace7d5447`](#source-pubmed-observation-pmid-42964248-2026-11-01-edeace7d5447))

#### Summary

PubMed lists PMID 42964248 in Frontiers in nuclear medicine as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42964248-2026-11-01-edeace7d5447`](#source-pubmed-observation-pmid-42964248-2026-11-01-edeace7d5447))

#### Paragraph 1

PubMed lists PMID 42964248 in Frontiers in nuclear medicine as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42964248-2026-11-01-edeace7d5447`](#source-pubmed-observation-pmid-42964248-2026-11-01-edeace7d5447))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42964248-2026-11-01-edeace7d5447`](#source-pubmed-observation-pmid-42964248-2026-11-01-edeace7d5447))

### Sources

<a id="source-pubmed-observation-pmid-42964248-2026-11-01-edeace7d5447"></a>
- **Cascaded deep learning for synthesis of 18F-FDG PET from 18F-octreotide: model parameter optimization and performance evaluation. · retained source version 1:2026-11-01:current:edeace7d544770cb07d25ff048f160cd7bf1d03e0924fbd56b603fccb427b2c0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42964248/) (`pubmed-observation-pmid-42964248-2026-11-01-edeace7d5447`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Cascaded deep learning for synthesis of 18F-FDG PET from 18F-octreotide: model parameter optimization and performance evaluation." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42964248-octreotide-v1 SHA-256: d189ce7cc6c1231ea2e5449302eb1cfa3effa396cad3f70cfdf06d359669faa8.

---

<a id="pubmed-pmid-42978565-octreotide-v1"></a>

## Case Report: Neurosurgery, octreotide, cabergoline, radiotherapy, pasireotide and pegvisomant - a multimodal strategy for adolescent acrogigantism.

> PubMed lists PMID 42978565 in Frontiers in endocrinology as Case Reports, Journal Article, with publication-date metadata of 2026-10-20 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42978565-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-05
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42978565-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42978565-octreotide-v1
- Content SHA-256: `bb6ec1807ff8880b8108c7dae9fdb6eea83a10d745e7cca0b42013fdec26fe97`

### Claims and source pins

#### Headline

Case Report: Neurosurgery, octreotide, cabergoline, radiotherapy, pasireotide and pegvisomant - a multimodal strategy for adolescent acrogigantism. ([`pubmed-observation-pmid-42978565-2026-11-05-b12052a1fd1b`](#source-pubmed-observation-pmid-42978565-2026-11-05-b12052a1fd1b))

#### Summary

PubMed lists PMID 42978565 in Frontiers in endocrinology as Case Reports, Journal Article, with publication-date metadata of 2026-10-20 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42978565-2026-11-05-b12052a1fd1b`](#source-pubmed-observation-pmid-42978565-2026-11-05-b12052a1fd1b))

#### Paragraph 1

PubMed lists PMID 42978565 in Frontiers in endocrinology as Case Reports, Journal Article, with publication-date metadata of 2026-10-20 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42978565-2026-11-05-b12052a1fd1b`](#source-pubmed-observation-pmid-42978565-2026-11-05-b12052a1fd1b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42978565-2026-11-05-b12052a1fd1b`](#source-pubmed-observation-pmid-42978565-2026-11-05-b12052a1fd1b))

### Sources

<a id="source-pubmed-observation-pmid-42978565-2026-11-05-b12052a1fd1b"></a>
- **Case Report: Neurosurgery, octreotide, cabergoline, radiotherapy, pasireotide and pegvisomant - a multimodal strategy for adolescent acrogigantism. · retained source version 1:2026-11-05:current:b12052a1fd1b399aa5de50fa14c0ca9ca06df1b14bfe5b75b567c68209390011** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42978565/) (`pubmed-observation-pmid-42978565-2026-11-05-b12052a1fd1b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Case Report: Neurosurgery, octreotide, cabergoline, radiotherapy, pasireotide and pegvisomant - a multimodal strategy for adolescent acrogigantism." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-42978565-octreotide-v1 SHA-256: bb6ec1807ff8880b8108c7dae9fdb6eea83a10d745e7cca0b42013fdec26fe97.

---

<a id="pubmed-pmid-8302723-octreotide-v1"></a>

## PubMed record PMID 8302723

> PeptideScanner retained PubMed bibliographic metadata for PMID 8302723 at 2026-07-30T23:02:28.626Z. PubMed recorded a metadata revision date of 2004-11-17 and an Entrez history date of 1993-11-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-8302723-octreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2004-11-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8302723-octreotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-8302723-octreotide-v1
- Content SHA-256: `a52fa658f4577efa20a4ad9552ef9e43c2b4cf4ac21f307013effa04029664b8`

### Claims and source pins

#### Headline

PubMed record PMID 8302723 ([`pubmed-observation-pmid-8302723-2004-11-17-12bd579dc845`](#source-pubmed-observation-pmid-8302723-2004-11-17-12bd579dc845))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 8302723 at 2026-07-30T23:02:28.626Z. PubMed recorded a metadata revision date of 2004-11-17 and an Entrez history date of 1993-11-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8302723-2004-11-17-12bd579dc845`](#source-pubmed-observation-pmid-8302723-2004-11-17-12bd579dc845))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 8302723 at 2026-07-30T23:02:28.626Z. PubMed recorded a metadata revision date of 2004-11-17 and an Entrez history date of 1993-11-01. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-8302723-2004-11-17-12bd579dc845`](#source-pubmed-observation-pmid-8302723-2004-11-17-12bd579dc845))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8302723-2004-11-17-12bd579dc845`](#source-pubmed-observation-pmid-8302723-2004-11-17-12bd579dc845))

### Sources

<a id="source-pubmed-observation-pmid-8302723-2004-11-17-12bd579dc845"></a>
- **PubMed record PMID 8302723 · retained source version 1:2004-11-17:current:12bd579dc845ad817a3fc92f203e17ed2180e50e6273e1a74fd9327d65568d97** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8302723/) (`pubmed-observation-pmid-8302723-2004-11-17-12bd579dc845`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 8302723." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/octreotide.json#pubmed-pmid-8302723-octreotide-v1 SHA-256: a52fa658f4577efa20a4ad9552ef9e43c2b4cf4ac21f307013effa04029664b8.

